



(51) International Patent Classification:

C12N 15/82 (2006.01) *C12N 15/40* (2006.01)
A01H 5/00 (2018.01) *C12N 15/62* (2006.01)
A61K 39/12 (2006.01) *C12N 15/63* (2006.01)
A61P 31/14 (2006.01) *C12N 5/10* (2006.01)
A61P 37/04 (2006.01) *C12N 7/01* (2006.01)
C07K 14/08 (2006.01) *C12N 7/04* (2006.01)
C07K 16/20 (2006.01) *C12P 21/02* (2006.01)

(21) International Application Number:

PCT/CA2018/050352

(22) International Filing Date:

23 March 2018 (23.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/475,660 23 March 2017 (23.03.2017) US

(71) Applicant: **MEDICAGO INC.** [CA/CA]; Suite 600 - 1020
Route de l'Eglise, Quebec, Québec G1V 3V9 (CA).

(72) Inventors: **LAVOIE, Pierre-Olivier**; 621 Franklin, Que-
bec, Québec G1N 2L7 (CA). **D'AOUST, Marc-Andre**;
3925 rue Louise-Fiset, Quebec, Québec G1X 4N4 (CA).

(74) Agent: **SECHLEY, Konrad** et al.; Gowling WLG (Can-
ada) LLP., 2300 - 550 Burrard Street, Vancouver, British Co-
lumbia V6C 2B5 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOROVIRUS FUSION PROTEINS AND VLPs COMPRISING NOROVIRUS FUSION PROTEINS




Figure 1A

(57) **Abstract:** Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.



Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

Norovirus fusion proteins and VLPs comprising norovirus fusion proteins

FIELD OF INVENTION

[0001] The present invention relates to norovirus fusion proteins, VLPs comprising norovirus fusion proteins, and methods of producing the same.

BACKGROUND OF THE INVENTION

[0002] The global disease burden attributed to norovirus infection is high, being associated with an estimated 20% of all worldwide diarrheal cases and causing over 200,000 deaths annually. Noroviruses are the primary cause of foodborne disease outbreaks in North America and are the causative agent for the majority of healthcare-associated outbreaks amongst the elderly. Norovirus strains are also recognized as being the leading cause of pediatric gastrointestinal illness worldwide.

[0003] Noroviruses comprise one of a number of genera of the family *Caliciviridae*. The human norovirus genome is a single-stranded, positive-sense RNA molecule encoding three open reading frames (ORFs) and capped on its 5' end by a VPg protein. ORF1 encodes six non-structural viral proteins, including VPg, an RNA-dependent RNA polymerase, and a viral protease. ORF2 encodes the major structural capsid protein (VP1). ORF3 encodes a minor capsid protein (VP2).

[0004] VP1 is comprised of 2 domains: a shell (S) domain, and a protruding (P) domain. The P domain is further comprised of a P1 sub-domain and a P2 sub-domain. The P2 sub-domain is referred to as the hypervariable domain and is thought to play an important role in receptor binding and immune reactivity.

[0005] VP1 proteins form dimers via P domain-mediated protein interactions. Dimerization increases the stability of the virion capsid and results in formation of the protrusions extending from the base core of the norovirus particle formed by S domains. When expressed, norovirus VP1 proteins can automatically assemble to form 2 virion structures: a 180-mer capsid structure with T=3 icosahedral symmetry having a 38-40 nm diameter; and a 60-mer capsid structure with T=1 icosahedral symmetry having a 23 nm diameter.

[0006] VP2, the minor structural protein, has a molecular weight (MW) of approximately 21-24 kDa. Studies suggest that VP2 is highly basic and located inside the capsid. The function of VP2 has not yet been fully understood but it is generally believed to play a role in capsid stability by protecting the virions from disassembly and degradation (Bertolotti-Ciarlet A., Crawford S.E., Hutson A.M., Estes M.K. 2003, J. Virol. 77:11603-11615). VP2 may also have a function during RNA genome packaging. The amount of VP2 minor structural protein in virions is relatively low with 1.5 to 8 copies incorporated into the mature virion. Bertolotti-Ciarlet et. al. (2003) report that in insect and mammalian cells, VLPs composed of VP1/VP2 are more resistant to protease cleavage than those with only VP1, and that expression of VP2 in *cis*, results in an increase in VP1 protein production. In addition, the presence of the 3'UTR downstream of the ORF2 gene increases the steady-state levels of NV ORF2 mRNA. The greatest increase in VP1 expression was observed when ORF2 + ORF3 + 3'UTR, residing on the same construct and under regulation of one promoter, was expressed. Expression of VP2 in *trans* did not result in any increase in VP1 expression, indicating that the subgenomic organization of ORF2-ORF2-3'UTR was required for the observed increase in VP1 production.

[0007] Noroviruses are classified according to their phylogenetic clustering of the VP1 amino acid sequence. Seven genogroups have been classified to date (GI through GVII) with only genogroups GI, GII, and GIV known to infect humans. Of the 32 specific genotypes currently associated with human infections, GII.4 noroviruses have been responsible for the majority of recent norovirus outbreaks. New strains of GII.4 emerge every two to three years, evolving by a process driven by mutations in epitope determining regions of the hypervariable P2 domain of VP1. This process allows the norovirus to escape humoral immune responses acquired by previous exposure to earlier strains.

[0008] While faced with the difficulty of rapidly evolving and genetically diverse norovirus strains, the development of effective norovirus vaccines has been exacerbated by additional challenges. For instance, until recently, human norovirus could not be grown in cell culture and even now, robust cell culture systems for both VLPs and live attenuated noroviruses are lacking.

[0009] An additional challenge in vaccine development is that immunity to norovirus infection is strain and genotype specific with minimal cross-immunity conferred against other genogroups. Furthermore, immunity to a norovirus strain is not life-long and is estimated to persist from anywhere between six months and nine years.

[0010] Various approaches have been undertaken to develop a suitable vaccine against norovirus infection including the production of recombinant norovirus proteins in plants and recombinant generation of fusion/chimeric VP1 proteins.

[0011] Mason *et al.* (*Proc Natl Acad Sci U.S.A.*, 1996, 93(11):5335-40) teach the use of genetically engineered tobacco plants and potato tubers to express GI.1 norovirus VLPs from native VP1 protein. The plant produced norovirus VLPs are morphologically and physically similar to the 38 nm Norwalk VLPs produced in insect cells. Oral administration of purified tobacco-produced Norwalk VLPs from native capsid protein, or potato tubers expressing GI.1 capsid protein induced a humoral immune response in mice and humans (Tacket *et al.*, *J. Infect. Dis.*, 2000, 182(1):302-5).

[0012] Huang *et al.* (*Biotechnol. Bioeng.*, 2009, 103(4):706-14) describe a geminivirus-derived DNA replicon vector for production of GI.1 norovirus VLP in plants. Co-delivery of bean yellow dwarf virus-derived vector and Rep/RepA-supplying vector in *Nicotiana benthamiana* resulted in rapid and robust protein production.

[0013] Coit *et al.* (WO 2007/081447; US 7,527,801; US 8,119,145; US 8,124,104; US 8,142,793; US 9,428,739) teach polynucleotides encoding capsid proteins and other immunogenic proteins from norovirus. The production of norovirus-derived multiple epitope fusion antigens comprising a norovirus NTPase-polymerase fusion protein is also described. The fusion protein may comprise a linker sequence. Methods to produce norovirus fusion proteins comprising VP1 are also disclosed.

[0014] Steadman *et al.* (U.S. 8,980,275) describe a chimeric protein comprising a Calicivirus capsid protein and at least one heterologous antigen, and the formation of VLPs when the chimeric protein is expressed in a host cell. A chimeric protein

comprising a heterologous antigen, or fragment thereof, inserted into a P2 domain of the Calicivirus protein is also disclosed.

[0015] Lin *et al.* (WO 2016/019890) teach a fusion protein in which an antigen is fused, with or without a linker sequence, on both its N-terminal and C-terminal ends, to viral structural proteins, or fragments thereof, and wherein fusion improves the folding and antigenicity of the antigen. The viral structural protein may be any protein that contributes to the structure of the capsid or protein core of the virus, and the norovirus S domain or P domain are mentioned as examples.

[0016] Settembre *et al.* (U.S. 14/946,324) disclose immunogenic compositions comprising chimeric norovirus VP1 proteins capable of forming VLPs produced in insect cells, mammalian cells, avian cells, bacterial cells, yeast cells, or *Tetrahymena* cells. The chimeric VP1 proteins have all, or a portion, of a VP1 P domain from one strain of norovirus replaced with all, or a portion, of a P domain from a non-homologous norovirus strain.

[0017] Noroviruses are known to bind specific histo-blood group antigens (HBGA). Huo *et al.* (*Virus Res.*, 2016, 224:1-5) teach the production of chimeric VP1 capsid proteins where the P2 domain of a GII.4 Sydney 2012-like variant norovirus is exchanged for the P2 domain of a GII.3 strain norovirus. Results from *in vitro* HBGA-binding blockade assays indicate that although GII.3 norovirus VLPs do not bind to any synthetic or salivary HBGAs tested, the chimeric VLPs are capable of binding synthetic blood type A (trimer) and Le(x) HBGAs and blood type A, B and O salivary HBGAs. Furthermore, Huo *et al.* demonstrate that this binding can be competitively inhibited by anti-GII.3 serum but not anti-GI.2 or anti GII.4 serum.

SUMMARY OF THE INVENTION

[0018] The present invention relates to norovirus fusion proteins, virus like particles (VLPs) comprising norovirus fusion proteins, and methods of producing the same.

[0019] It is an object of the invention to produce norovirus fusion proteins, VLPs comprising norovirus fusion proteins, and to producing VLPs comprising norovirus fusion proteins in plants.

[0020] As described herein there is provided a nucleic acid encoding a norovirus VP1 fusion protein comprising, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain, the first and second sequence are selected from norovirus genogroups GI, GII, and GIV.

[0021] Also provided is the nucleic acid encoding the norovirus VP1 fusion protein as described above, wherein the first and second norovirus strains are independently selected from norovirus genotypes GI.1, GI.2, GI.3, GI.4, GI.5, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.12, GII.13, GII.14, GII.17 and GII.21 is also provided. For example, which is not to be considered limiting, the first norovirus strain and the second norovirus strain may be independently selected from norovirus subtypes:

[0022] GI.1/US/1968,

[0023] GI.2/Leuven/2003/Bel,

[0024] GI.3/S29/2008/Lilla Edet/Sweden,

[0025] GI.5/AlbertaEI390/2013/CA,

[0026] GII.1/Ascension208/2010/USA,

[0027] GII.12/HS206/2010/USA,

[0028] GII.13/VA173/2010/USA,

[0029] GII.14/8610/Saga/2008/JPN,

[0030] GII.17/Kawazaki/2014/A0A077KVU6, and

[0031] GII.21/Salisbury150/2011/USA.

[0032] The nucleic acid as described above may also comprise a fifth sequence encoding a CPMV enhancer, the CPMV enhancer operatively linked with the first, second, third, and fourth sequences. The nucleic acid as described above may also be optimized for human codon usage, increased GC content, or a combination thereof.

[0033] A norovirus VP1 fusion protein encoded by the nucleic acid as described above is also described herein. Furthermore, a virus like particle (VLP) comprising the norovirus VP1 fusion protein encoded by the nucleic acid is also disclosed.

[0034] Methods to produce an antibody or antibody fragment using the norovirus fusion VP1 fusion protein or the VLP encoded by the nucleic acid, or the VLP comprising the norovirus VP1 fusion protein and norovirus VP2 protein encoded by the nucleic acid complex, are described herein. An antibody, an antibody fragment, or a combination thereof, produced using these methods is also provided.

[0035] The present disclosure also describes a method of producing a norovirus VP1 fusion protein in a plant host cell, for example the plant, the portion of a plant, or the plant cell. The method comprises introducing the nucleic acid, or nucleic acid complex, as described above into the plant host cell, and incubating the plant host cell under conditions that permit expression of the norovirus VP1 fusion protein. The method may further comprises a step of harvesting the plant host cell, for example the plant, the portion of a plant, or the plant cell, and purifying the norovirus VP1 fusion protein.

[0036] As described herein, there is a method of producing a VLP comprising a norovirus VP1 fusion protein in a plant, portion of the plant, or a plant cell. The method comprises introducing the nucleic acid as described herein into the plant, portion of the plant, or the plant cell, and incubating the plant, portion of the plant, or the plant cell under conditions that permit expression of the nucleic acid and the formation of the VLP. The method of producing the VLP may further comprise a step of harvesting the plant, portion of the plant, or the plant cell, producing a plant extract, and purifying the VLP, wherein the VLP has a diameter of about 15 nm to 50 nm, for example, about 23 nm (for T=1 icosahedral symmetry) or about 38 to about 40 nm (for T=3 icosahedral symmetry). Furthermore, in the step of introducing, a second nucleic acid sequence encoding a norovirus VP2 protein may be introduced in the plant, portion of the plant, or the plant cell, and in the step of incubating, the conditions permit co-expression and co-production, of both the VP1 fusion protein and the VP2 protein in the plant, the portion of a plant, or the plant cell

[0037] A plant, portion of a plant, or a plant cell comprising the VLP produced by the method described above is also provided herein. A plant extract comprising the VLP produced by this method is also described.

[0038] Also provided is a composition for inducing an immune response. The composition comprises, an effective dose of the norovirus VP1 fusion protein encoded by the nucleic acid as described herein; and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient. Alternatively, the composition may comprise, an effective dose of the VLP produced by the method described herein, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.

[0039] A method of producing an antibody or an antibody fragment is also described. The method comprises, administering the norovirus fusion VP1 fusion protein as described above to a subject in need thereof, or a host animal, thereby producing the antibody or the antibody fragment.

[0040] Additionally there is provided a vaccine for inducing an immune response in a subject in need thereof, the vaccine comprising an effective dose of the norovirus VP1 fusion protein encoded by the nucleic acid described herein. Alternatively, the vaccine may comprise an effective dose of VLP produced by the method described herein.

[0041] The present disclosure also provides a method of inducing immunity to a norovirus infection in a subject comprising administering the norovirus VP1 fusion protein encoded by the nucleic acid described herein. The norovirus VP1 fusion protein may be administered orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously. Also provided is a method of inducing immunity to a norovirus infection in a subject comprising of administering the VLP produced by the method described herein. The VLP may be administered orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

[0042] Also described herein is a nucleic acid complex comprising, a VP1 sequence encoding a norovirus VP1 fusion protein, and a VP2 sequence encoding a norovirus VP2 protein, the VP1 sequence comprising a first and a second nucleic acid sequence, the first nucleic acid sequence encoding an S domain derived from a first

norovirus strain, the second nucleic acid sequence encoding a P domain derived from a second norovirus strain, the VP2 sequence comprising a third nucleic acid sequence derived from the first norovirus strain and encoding the norovirus VP2 protein, wherein the VP1 sequence is operatively linked to a first regulatory region, and the VP2 sequence is operatively linked to a second regulatory region, and the VP1 sequence and the VP2 sequence are located on one nucleic acid segment, or the VP1 sequence and the VP2 sequence are located on separate nucleic acid segments. The first regulatory region, the second regulatory region, or the first and second regulatory region of the nucleic acid complex may comprise a CPMV enhancer element that is operatively linked with a promoter active in the plant. For example, the first and the second regulatory region may comprise the CPMV enhancer element, and the first and the second regulatory region may comprise the same promoter. Furthermore, the first and the second regulatory region may comprise a CPMV enhancer element, and the CPMV enhancer sequence of the first and the second regulatory region may be the same CPMV enhancer sequence. The first, the second, the third nucleic acid sequence, or all of the first, second and third nucleic acid sequence, may be optimized for human codon usage, increased GC content, or a combination thereof.

[0043] Also provided herein is a VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein encoded by the nucleic acid complex as defined above. The VLP may have a diameter of about 15 nm to 50 nm, for example, from about 23 nm or about 38nm.

[0044] A method of producing a virus like particle (VLP) in a plant, portion of a plant, or a plant cell is also described. The method comprises introducing the nucleic acid complex as defined above into the plant, the portion of a plant, or the plant cell, and incubating the plant, the portion of a plant, or the plant cell under conditions that permit the production of the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein. The method may further comprises a step of harvesting the plant, the portion of a plant, or the plant cell. Furthermore, the method may comprises a step of extracting, purifying, or both extracting and purifying, the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein, from the plant, the portion of a plant, or the plant cell.

[0045] Also included herein is a plant, portion of the plant, or the plant cell comprising the nucleic acid complex as described above. Furthermore, a plant extract comprising the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein, produced by the method described above is provided

5 [0046] Also described herein is the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein produced by the method described above. The VLP may have a diameter of about 15 nm to 50 nm, for example about 23 nm or about 38nm. Furthermore, a plant, portion of the plant, or the plant cell comprising the VLP comprising the VP1 fusion protein and the norovirus VP2 protein as
10 described above is also provided.

[0047] A composition for inducing an immune response comprising, an effective dose of the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein described above, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient is also presented herein. Also provided, is a method for inducing
15 immunity to a norovirus infection in a subject, comprising, administering the composition as just described to the subject. Furthermore, the composition may be administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

[0048] Also described is a method for inducing immunity to a norovirus infection
20 in a subject, the method comprising administering the VLP comprising, an effective dose of the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein as described above, to the subject. The VLP may be administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

25 [0049] A vaccine is also described herein. The vaccine comprising an effective dose of the VLP of claim 66 for inducing an immune response. Also presented is a method for inducing immunity to a norovirus infection in a subject, comprising administering the vaccine as just described to the subject. The vaccine may be administered to the subject orally, intranasally, intramuscularly, intraperitoneally,
30 intravenously, or subcutaneously.

[0050] The present disclosure also describes a method of producing an antibody or an antibody fragment comprising, administering the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein, described above, to a subject in need thereof, or a host animal, thereby producing the antibody or the antibody fragment, is also provided. For example, the antibody or antibody fragment may recognize an epitope of the P domain.

[0051] This summary of the invention does not necessarily describe all features of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0052] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

[0053] **FIGURE 1A** shows a schematic representation of the linear structure of the norovirus genome and the polyprotein and proteins translated therefrom. **FIGURE 1B** shows a ribbon diagram representation of the 3-dimensional structure of the norovirus VP1 protein comprising a shell (S) domain, a P1 subdomain (P1), and a P2 subdomain (P2). **FIGURE 1C** shows a ribbon diagram representation of the 3-dimensional structure of a norovirus VP1 protein dimer comprising of two S domains (S), two P1 subdomains (P1), and two P2 subdomains (P2).

[0054] **FIGURE 2A** shows Uniprot and NCBI references for several norovirus VP1 (upper panel) and VP2 (lower panel) proteins. **FIGURE 2B** shows NCBI references for several norovirus VP1 and VP2 nucleic acid sequences. **FIGURE 2C** shows the amino acid sequence identity between norovirus VP1 (upper panel) and VP2 (lower panel) proteins. G1.1 (SEQ ID NO:1), G1.2 (SEQ ID NO:2), G1.3 (SEQ ID NO:3), G1.4 (SEQ ID NO:4), G1.6 (SEQ ID NO:5), G1.13 (SEQ ID NO:6), G1.17 (SEQ ID NO:7). **FIGURE 2D** shows the amino acid sequence identity between several strains of norovirus G1.4 VP1 proteins (upper panel), the amino acid sequence identity between several strains of norovirus G1.4 VP1 P domain (middle panel), and the amino acid sequence identity between several strains of norovirus G1.4 P2 domain (lower panel). **US96:** G1.4/Dresden174/1997/DE (G1.4 variant: US

1995/96; SEQ ID NO:8); **FH02**: GII.4/FarmingtonHills/2002/US (SEQ ID NO:9);
Hnt04: GII.4/Hunter-NSW504D/2004/AU (SEQ ID NO:10); **2006b**:
 GII.4/Shellharbour-NSW696T/2006/AU (SEQ ID NO:11); **NO09**: GII.4/Orange-
 NSW001P/2008/AU (GII.4 variant New Orleans 2009; SEQ ID NO:12); **Syd12**:
 Hu/GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:4).

[0055] **FIGURE 3A** shows norovirus protein production. Crude protein extracts prepared from *N. benthamiana* leaves, six and nine days post infiltration (DPI) of native (wildtype; wt) GI.1/United States/Norwalk/1968 ORF2 alone (VP1) (SEQ ID NO's: 1 (aa) and 13 (na); construct # 2720) and ORF 3 alone (VP2) (SEQ ID NO's: 14 (aa) and 15 (na); construct # 2721), ORF2/ORF3 (VP1/VP2; SEQ ID NO:16 (na); construct # 2722) and ORF2/ORF3/3'UTR (VP1/VP2/3'UTR; SEQ ID NO:17 (na); construct # 2723), and human codon-optimized (hCod) GI.1/United States/Norwalk/1968 ORF2 alone (VP1) (SEQ ID NO:18; construct # 2724), ORF3 alone (hCod VP2) (SEQ ID NO:19 (na); construct # 2725), ORF2/ORF3 (hCod VP1/VP2; in *cis*, on the same construct; SEQ ID NO:20 (na); construct # 2726) and ORF2/ORF3/3'UTR (hCod VP1/PV2/3'UTR; SEQ ID NO:21; construct # 2727), expression constructs. VP1+VP2: ORF2 (SEQ ID NO's: 1 (aa) and 13 (na); construct # 2720) and ORF 3 (SEQ ID NO's: 14 (aa) and 15 (na); construct # 2721) expressed on separated constructs, in *trans*. Proteins were analyzed by Coomassie-stained SDS-PAGE. **FIGURE 3B** upper panel shows norovirus protein expression and VLP assembly using Coomassie-stained SDS-PAGE analysis of fractions from an iodixanol density gradient separation of crude protein extracts prepared from *N. benthamiana* leaves expressing human codon-optimized GI.1/United States/Norwalk/1968 VP1 (construct #2724), or human codon-optimized VP1 (construct #2724) and co-expressed with human codon-optimized VP2 (construct #2725). Lower panel shows electron micrographs of norovirus VLPs purified from 33% iodixanol gradient fractions of VP1 or co-expression of VP1 and VP2 proteins. An electron micrograph of native norovirus VLP is shown for comparison. **FIGURE 3C** shows norovirus protein expression and VLP assembly using Coomassie-stained SDS-PAGE analysis of fractions from an iodixanol density gradient separation of crude protein extracts prepared from *N. benthamiana* leaves expressing: upper panel – human codon optimized GI.1/United States/Norwalk/1968 native VP1 (construct

#2724); lower panel (left hand side) - human codon optimized GI.2 Leu03 native VP1 (construct #3300); lower panel (right hand side) human codon optimized VP1 S(GI.1)+P (GI.2) fusion protein (construct 3360).

[0056] **FIGURE 4A** shows the alignment of several amino acid sequences of norovirus S domain-P domain boundary for GI.1 (VP1 Norwalk 1968 GI.1 Q83884 Rf; SEQ ID NO:88), GI.2 (VP1 Leuven 2003 Gi.1 D2DEL3; SEQ ID NO:89), GI.3 (VP1 LillaEdet 2008 Gi.3 H2DG70; SEQ ID NO:90), GII.4 (VP1 Sydney 2012 GII.3 K4LM89; SEQ ID NO:91), GII.6 (VP1 Ohio 2012 GII.6 M9T020; SEQ ID NO:92), GII.13 (VP1 VA173 2010 GII.13 H9AWU4; SEQ ID NO:93), GII.17 (VP1 awasaki 2014 GII.17 A0A077KVU6; SEQ ID NO:94), and the consensus sequence (SEQ ID NO:95). **FIGURE 4B** shows amino acid sequence identity between a GI.1 native norovirus VP1 protein (SEQ ID NO:1) and several VP1 fusion proteins as described herein (S(GI.1)+P(GI.2), SEQ ID NO:22; S(GI.1)+P(GI.3), SEQ ID NO:23; S(GI.1)+P(GII.4), SEQ ID NO:24; S(GI.1)+P(GII.6), SEQ ID NO:25; S(GI.1)+P(GII.12), SEQ ID NO:71; S(GI.1)+P(GII.13), SEQ ID NO:26; and S(GI.1)+P(GII.17), SEQ ID NO:27). **FIGURE 4C** shows amino acid sequence identity between a GII.12 norovirus native VP1 protein (SEQ ID NO:28) and several VP1 fusion proteins demonstrating that GII-S domain may be used for VP1 fusions as described herein (S(GII.12)+P(GI.1), SEQ ID NO: 29; S(GII.12)+P(GI.2), SEQ ID NO: 30; S(GII.12)+P(GI.3), SEQ ID NO: 31; S(GII.12)+P(GI.5), SEQ ID NO: 32; S(GII.12)+P(GII.1), SEQ ID NO: 33; S(GII.12)+P(GII.2), SEQ ID NO: 34; S(GII.12)+P(GII.3), SEQ ID NO: 35; S(GII.12)+P(GII.4), SEQ ID NO: 36; S(GII.12)+P(GII.5), SEQ ID NO: 37; S(GII.12)+P(GII.6), SEQ ID NO: 38; S(GII.12)+P(GII.7), SEQ ID NO: 39; S(GII.12)+P(GII.13), SEQ ID NO: 40; S(GII.12)+P(GII.14), SEQ ID NO: 41; S(GII.12)+P(GII.17), SEQ ID NO: 42; S(GII.12)+P(GII.21), SEQ ID NO: 43). **FIGURE 4D** shows amino acid sequence identity between a GI.5 native VP1 protein (SEQ ID NO: 44), a GII.1 norovirus native VP1 protein (SEQ ID NO: 45), a GII.14 norovirus native VP1 protein (SEQ ID NO: 46), a GII.21 norovirus native VP1 protein (SEQ ID NO: 47) and several VP1 fusion proteins as described herein (S(GI.5)+P(GII.4), SEQ ID NO: 48; S(GII.1)+P(GI.3), SEQ ID NO: 49; S(GII.1)+P(GII.4), SEQ ID NO: 50;

S(GII.1)+P(GII.17), SEQ ID NO: 51; S(GII.14)+P(GII.4), SEQ ID NO: 52;
S(GII.21)+P(GII.4), SEQ ID NO: 53). S: shell domain; P: P domain.

[0057] **FIGURE 5A** shows Coomassie-stained SDS-PAGE analysis of crude protein extracts prepared from *N. benthamiana* leaves producing native norovirus VP1 and VP1 fusion proteins, six and nine days post infiltration (DPI) with expression vectors encoding human codon optimized (hCod) norovirus native VP1 (GI.1, construct #2724, SEQ ID NO's:1 (aa) and 18 (na); GI.2, construct #3300, SEQ ID NO's:2 (aa) and 54(na); GI.3, construct #3302, SEQ ID NO's:3(aa) and 55(na); GII.4, construct #3304, SEQ ID NO's:4(aa) and 56(na)) or norovirus VP1 fusion proteins (GI.1+GI.2, construct #3360, SEQ ID NO's:22(aa) and 57(na); GI.1+GI.3, construct #3361, SEQ ID NO's:23(aa) and 58(na); GI.1+GII.4, construct #3362, SEQ ID NO's:24(aa) and 59(na)). **FIGURE 5B** shows Coomassie-stained SDS-PAGE analysis of crude protein extracts prepared from *N. benthamiana* leaves, producing native norovirus VP1 and VP1 fusion proteins, six and nine days post infiltration (DPI) with expression vectors encoding native (wildtype) norovirus VP1 (GI.1, construct #2724, SEQ ID NO's:1(aa) and 18(na); GII.6, construct #3306, SEQ ID NO's:5(aa) and 60(na); GII.13, construct #3308, SEQ ID NO's:6(aa) and 61(na); GII.17, construct #3310, SEQ ID NO's:7(aa) and 62(na)) or norovirus VP1 fusion proteins (GI.1+GII.6, construct #3363, SEQ ID NO's:25(aa) and 63(na); GI.1+GII.13, construct #3364, SEQ ID NO's:26(aa) and 64(na); GI.1+GII.17, construct #3365, SEQ ID NO's:27(aa) and 65(na)). **FIGURE 5C** shows electron micrographs of human codon optimized native norovirus VLPs from iodixanol gradient fractions. GI.3 S29/2008/Lilla Edet/Sweedden (SEQ ID NO:3 (aa);55 (na); Figure 15B); GI.5 Siklos/HUN5407/2013/HUN (SEQ ID NO:44; Figure 16A); GII.1 Ascension208/2010/USA SEQ ID NO:45; Figures 16B); GII.7 Musashimurayama/2010/JP (SEQ I NO:69; Figure 16F). **FIGURE 5D** shows electron micrographs of human codon optimized native norovirus VLPs from iodixanol gradient fractions. GII.12 HS206/2010/USA (SEQ ID NO:28 , Figure 22A); GII.13 VA173/2010/USA (SEQ ID NO:61 , Figure 19B); GII.14 8610/Saga/2008/JPN (SEQ ID NO:46 , Figure 22B); GII.21 Salisbury150/2011/USA (SEQ ID NO:47 , Figure 22B). **FIGURE 5E** shows norovirus protein expression and VLP assembly using Coomassie-stained SDS-PAGE analysis of fractions from an

iodixanol density gradient separation of crude protein extracts prepared from *N. benthamiana* leaves expressing: Panel A (left hand side) - human codon optimized GII.4/Sydney/NSW0514/2012/AU native VP1 (construct #3304); Panel A (right hand side) - human codon optimized GII.4/Sydney/NSW0514/2012/AU (construct #3304; SEQ ID NO:56; Figure 17B) native VP1 co-expressed with GII.4/Sydney/NSW0514/2012/AU native VP2 (construct #3305; SEQ ID NO:120; Figure 23D); Panel B (left hand side) - human codon optimized VP1 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B); Panel B (right hand side) - human codon optimized VP1 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B) co-expressed with human codon optimized GI.1/Norwalk native VP2 (construct #2725; SEQ ID NO:19; Figure 23C); Panel C (left hand side) - human codon optimized VP1 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B) co-expressed with human codon optimized GI.1/Norwalk native VP2 (construct #2725; SEQ ID NO:19; Figure 23C); Panel C (right hand side) - human codon optimized VP1 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B) co-expressed with human codon optimized GII.4/Sydney native VP2 (construct #3305; SEQ ID NO:120; Figure 23D).

[0058] **FIGURE 6A** upper panel shows production of native norovirus VP1, native norovirus VLPs, VP1 fusion proteins and VLPs comprising VP1 fusion proteins using Coomassie-stained SDS-PAGE analysis of fractions from density gradients using crude protein extracts prepared from *N. benthamiana* leaves, nine days post infiltration (DPI) with expression vectors encoding human codon optimized norovirus VP1 (GI.2, construct #3300, SEQ ID NO's:2(aa) and 54(na)) or norovirus human codon optimized VP1 fusion (GI.1+GI.2, construct #3360, SEQ ID NO's:22(aa) and 57(na)). Lower panel shows electron micrographs of wildtype norovirus GI.2 VLPs and VLPs comprising norovirus GI.1+GI.2 VP1 fusions proteins from iodixanol gradient fractions. **FIGURE 6B** upper panel shows production of native norovirus VP1, native norovirus VLPs, VP1 fusion proteins and VLPs comprising VP1 fusion proteins using Coomassie-stained SDS-PAGE analysis of fractions from density gradients using crude protein extracts prepared from *N. benthamiana* leaves, nine days post infiltration (DPI) with expression vectors encoding norovirus human codon optimized VP1 (GI.3, construct #3302, SEQ ID

NO's:3(aa) and 55(na)) or norovirus VP1 fusion (GI.1+GI.3, construct #3361, SEQ ID NO's:23(aa) and 58(na)). Lower panel shows electron micrographs of wildtype norovirus GI.3 VLPs and VLPs comprising norovirus GI.1+GI.3 VP1 fusions proteins from iodixanol gradient fractions. **FIGURE 6C** upper panel shows production of VP1 fusion proteins and VLPs comprising VP1 fusion proteins using Coomassie-stained SDS-PAGE analysis of fractions from density gradients using crude protein extracts prepared from *N. benthamiana* leaves, nine days post infiltration (DPI) with expression vectors encoding norovirus human codon optimized VP1 fusion (GI.1+GII.13, construct #3364, SEQ ID NO's: 26(aa) and 64(na) GI.1+GII.17, construct #3365, SEQ ID NO's:27(aa) and 65(na)). Lower panel shows electron micrographs of VLPs comprising norovirus GI.1+GII.13 or GI.1+GII.17 VP1 fusions proteins from iodixanol gradient fractions. **FIGURE 6D** shows an electron micrographs of a human codon optimized norovirus VLP from iodixanol gradient fractions, the VLP comprising the VP1 fusion S(GI.1) +P(GII.4) (S(GI.1 Nor/68) +P(GII.4/Sydney/NSW0514/12; SEQ ID NO:59, Figure 27B). **FIGURE 6E** shows GI.1 VLP-specific total IgG titers measured in serum samples from animals after IM immunization with one dose (Day 21) and two doses (Day 42) of 1 µg or 10 µg of each formulation. Total IgG titers were measured by ELISA using GI.1 VLP-coated plates (LOQ = 100). Total IgG titers per treatment group (n=8 animals/group) are represented by geometric mean titer (GMT) with a 95 % confidence interval. Same letter (A, B, C, D): no significant difference detected between treatment groups (p > 0.05).

[0059] **FIGURE 7A** shows the nucleotide sequence of primer IF-NoV(US68)VP1(ORF2).c (SEQ ID NO: 72); **FIGURE 7B** shows the nucleotide sequence of primer IF-NoV(US68)VP1(ORF2).r (SEQ ID NO: 73); **FIGURE 7C** shows the nucleotide sequence of construct 1190 from left to right t-DNA borders (underlined). 2X35S/CPMV-160/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette (SEQ ID NO: 74); **FIGURE 7D** shows a schematic representation of construct 1190.

[0060] **FIGURE 8A** shows the nucleotide sequence of construct 2720 from 2X35S promoter to NOS terminator. Wild-type VP1 from Norovirus GI.1/Norwalk/1968/US

strain is underlined. (SEQ ID NO: 75); **FIGURE 8B** shows a schematic representation of construct 2720.

[0061] **FIGURE 9A** shows the nucleotide sequence of primer IF-NoV(US68)VP1(ORF2)(hCod).c (SEQ ID NO: 76); **FIGURE 9B** shows the nucleotide sequence of primer IF-NoV(US68)VP1(ORF2)(hCod).r (SEQ ID NO: 77); **FIGURE 9C** shows the nucleotide sequence of construct 2724 from 2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.1/Norwalk/1968/US strain is underlined. (SEQ ID NO: 78); **FIGURE 9D** shows a schematic representation of construct 2724.

[0062] **FIGURE 10A** shows the nucleotide sequence of primer IF-NoV(US68)VP2(ORF3)(hCod).c (SEQ ID NO: 79); **FIGURE 10B** shows the nucleotide sequence of primer IF-NoV(US68)VP2(ORF3)(hCod).r (SEQ ID NO: 80); **FIGURE 10C** shows the nucleotide sequence of construct 2725 from 2X35S promoter to NOS terminator. Human codon-optimized VP2 from Norovirus GI.1/Norwalk/1968/US strain is underlined. (SEQ ID NO: 81); **FIGURE 10D** shows a schematic representation of construct 2725.

[0063] **FIGURE 11A** shows the nucleotide sequence of primer IF-GI2Leu03VP1.c (SEQ ID NO: 82); **FIGURE 11B** shows the nucleotide sequence of primer IF-GI2Leu03VP1.r (SEQ ID NO: 83); **FIGURE 11C** shows the nucleotide sequence of construct 3300 from 2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.2/Leuven/2003/Bel strain is underlined. (SEQ ID NO: 84); **FIGURE 11D** shows a schematic representation of construct 3300.

[0064] **FIGURE 12A** shows the nucleotide sequence of primer GI2Leu+GI1VP1.r (SEQ ID NO: 85); **FIGURE 12B** shows the nucleotide sequence of primer GI1VP1+GI2Leu.c (SEQ ID NO: 86); **FIGURE 12C** shows the nucleotide sequence of construct 3360 from 2X35S promoter to NOS terminator. Human codon-optimized fusion VP1 S(GI.1)+P(GI.2) protein gene sequence is underlined. (SEQ ID NO: 87); **FIGURE 12D** shows a schematic representation of construct 3360.

[0065] **FIGURE 13A** shows the amino acid sequence of VP1 GI.1 United States Norwalk 1968 (SEQ ID NO:1); **FIGURE 13B** shows the nucleic acid sequence of

wild type VP1 GI.1 United States Norwalk 1968 (SEQ ID NO:13); **FIGURE 13C** shows the nucleic acid sequence of human codon optimized VP1 GI.1 United States Norwalk 1968 (SEQ ID NO:18).

[0066] **FIGURE 14A** shows the amino acid sequence of VP1 GI.2 Leuven 2003 D2DEL3 (SEQ ID NO:2); **FIGURE 14B** shows the nucleic acid sequence of human codon optimized VP1 GI.2 Leuven 2003 D2DEL3 (SEQ ID NO:54).

[0067] **FIGURE 15A** shows the amino acid sequence of VP1 GI.3 LillaEdet 2008 H2DG70 (SEQ ID NO:3); **FIGURE 15B** shows the nucleic acid sequence of human codon optimized GI.3 LillaEdet 2008 H2DG70 (SEQ ID NO:55).

[0068] **FIGURE 16A** shows the amino acid sequence of VP1 GI.5 Siklos HUN5407 2013 HUN AHW99832 (SEQ ID NO:44); **FIGURE 16B** shows the amino acids sequence of VP1 GII.1 Ascension208 2010 USA AFA55174 (SEQ ID NO: 45); **FIGURE 16C** shows the amino acid sequence of VP1 GII.2 CGMH47 2011 TW AGT39206 (SEQ ID NO: 66); **FIGURE 16D** shows the amino acid sequence of VP1 GII.3 Jingzhou 2013402 CHN AGX01095 (SEQ ID NO: 67); **FIGURE 16E** shows the amino acid sequence of VP1 GII.5 Alberta 2013 CA ALT54485 (SEQ ID NO: 68); **FIGURE 16F** shows the amino acid sequence of VP1 GII.7 Musa 2010 AII73774 (SEQ ID NO: 69); **FIGURE 16G** shows the amino acid sequence of VP1 consensus sequence from genotypes GI.1, GI.2, GI.3, GII.4, GII.6, GII.13 and GII.17 (SEQ ID NO: 70) the S-P domain boundary sequence is underlined, and the boundary indicated with a “||”.

[0069] **FIGURE 17A** shows the amino acid sequence of VP1 GII.4 Sydney 2012 K4LM89 (SEQ ID NO:4); **FIGURE 17B** shows the nucleic acid sequence of human codon optimized VP1 GII.4 Sydney 2012 K4LM89 (SEQ ID NO:56).

[0070] **FIGURE 18A** shows the amino acid sequence of VP1 GII.6 Ohio 2012 M9T020 (SEQ ID NO: 5); **FIGURE 18B** shows the nucleic acid sequence of human codon optimized VP1 GII.6 Ohio 2012 M9T020 (SEQ ID NO: 60).

[0071] **FIGURE 19A** shows the amino acid sequence of VP1 GII.13 VA173 2010 H9AWU4 (SEQ ID NO: 6); **FIGURE 19B** shows the nucleic acid sequence of human codon optimized VP1 GII.13 VA173 2010 H9AWU4 (SEQ ID NO: 61).

[0072] **FIGURE 20A** shows the amino acid sequence of VP1 GII.17 Kawa 2014 A0A077KVU6 (SEQ ID NO: 7); **FIGURE 20B** shows the nucleic acid sequence of human codon optimized VP1 GII.17 Kawa 2014 A0A077KVU6 (SEQ ID NO: 62).

[0073] **FIGURE 21A** shows the amino acid sequence of VP1 US96: GII.4/Dresden174/1997/DE AY741811 (SEQ ID NO: 8); **FIGURE 21B** shows the Amino acid sequence of VP1 FH02: GII.4/FarmingtonHills/2002/US AY502023 (SEQ ID NO: 9); **FIGURE 21C** shows the amino acid sequence of VP1 Hnt04: GII.4/Hunter-NSW504D/2004/AU DQ078814 (SEQ ID NO: 10); **FIGURE 21D** shows the amino acid sequence of VP1 2006b: GII.4/Shellharbour-NSW696T/2006/AU EF684915 (SEQ ID NO: 11); **FIGURE 21E** shows the amino acid sequence of VP1 NO09: GII.4/Orange-NSW001P/2008/AU GQ845367 (SEQ ID NO: 12);

[0074] **FIGURE 22A** shows the amino acid sequence of VP1 GII.12 HS206 2010 USA AEI29586 (SEQ ID NO: 28); **FIGURE 22B** shows the amino acid sequence of VP1 GII.14 Saga 2008 JPN ADE28701 (SEQ ID NO: 46); **FIGURE 22C** shows the amino acid sequence of VP1 GII.21 Sali 2011 USA AFC89665 (SEQ ID NO: 47).

[0075] **FIGURE 23A** shows the amino acid sequence of native VP2 G1.1 (SEQ ID NO: 14); **FIGURE 23B** shows the nucleic acid sequence of wild-type VP2 G1.1 (SEQ ID NO: 15); **FIGURE 23C** shows the nucleic acid sequence of human codon-optimized VP2 G1.1 (SEQ ID NO: 19). **FIGURE 23D** shows the nucleic acid sequence of human codon-optimized VP2 GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO: 120). **FIGURE 23E** shows the amino acid sequence of VP2 GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO: 121).

[0076] **FIGURE 24A** shows the nucleic acid sequence of wild-type VP1/VP2 G1.1 (SEQ ID NO: 16); **FIGURE 24B** shows the nucleic acid sequence of wild-type VP1/VP2/3'UTR G1.1 (SEQ ID NO: 17); **FIGURE 24C** shows the nucleic acid sequence of human codon-optimized VP1/VP2 G1.1 (SEQ ID NO: 20); **FIGURE**

24D shows the nucleic acid sequence of human codon-optimized VP1/VP2/3'UTR G1.1 (SEQ ID NO: 21).

[0077] **FIGURE 25A** shows the amino acid sequence of S(GI.1)+P(GI.2) fusion VP1 (SEQ ID NO: 22); **FIGURE 25B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GI.2) fusion VP1 (SEQ ID NO: 57).

[0078] **FIGURE 26A** shows the amino acid sequence of S(GI.1)+P(GI.3) fusion VP1 (SEQ ID NO: 23); **FIGURE 26B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GI.3) fusion VP1 (SEQ ID NO: 58).

[0079] **FIGURE 27A** shows the amino acid sequence of S(GI.1)+P(GII.4) fusion VP1 (SEQ ID NO: 24); **FIGURE 27B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GII.4) fusion VP1 (SEQ ID NO: 59).

[0080] **FIGURE 28A** shows the amino acid sequence of S(GI.1)+P(GII.6) fusion VP1 (SEQ ID NO: 25); **FIGURE 28B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GII.6) fusion VP1 (SEQ ID NO: 63).

[0081] **FIGURE 29A** shows the amino acid sequence of S(GI.1)+P(GII.13) fusion VP1 (SEQ ID NO: 26); **FIGURE 29B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GII.13) fusion VP1 (SEQ ID NO: 64).

[0082] **FIGURE 30A** shows the amino acid sequence of S(GI.1)+P(GII.17) fusion VP1 (SEQ ID NO: 27); **FIGURE 30B** shows the nucleic acid sequence of human codon optimized S(GI.1)+P(GII.17) fusion VP1 (SEQ ID NO: 65).

[0083] **FIGURE 31A** shows the amino acid sequence of S(GI.1)+P(GII.12) fusion VP1 (SEQ ID NO: 71); **FIGURE 31B** shows the amino acid sequence of S(GI.5)+P(GII.4) fusion VP1 (SEQ ID NO: 48).

[0084] **FIGURE 32A** shows the amino acid sequence of S(GII.1)+P(GI.3) fusion VP1 (SEQ ID NO: 49); **FIGURE 32B** shows the amino acid sequence of S(GII.1)+P(GII.4) fusion VP1 (SEQ ID NO: 50); **FIGURE 32C** shows the amino acid sequence of S(GII.1)+P(GII.17) fusion VP1 (SEQ ID NO: 51).

[0085] **FIGURE 33A** shows the amino acid sequence of S(GII.12)+P(GI.1) fusion VP1 (SEQ ID NO: 29); **FIGURE 33B** shows the amino acid sequence of S(GII.12)+P(GI.2) fusion VP1 (SEQ ID NO: 30); **FIGURE 33C** shows the amino acid sequence of S(GII.12)+P(GI.3) fusion VP1 (SEQ ID NO: 31); **FIGURE 33D** shows the amino acid sequence of S(GII.12)+P(GI.5) fusion VP1 (SEQ ID NO: 32); **FIGURE 33E** shows the amino acid sequence of S(GII.12)+P(GII.1) fusion VP1 (SEQ ID NO: 33); **FIGURE 33F** shows the amino acid sequence of S(GII.12)+P(GII.2) fusion VP1 (SEQ ID NO: 34); **FIGURE 33G** shows the amino acid sequence of S(GII.12)+P(GII.3) fusion VP1 (SEQ ID NO: 35); **FIGURE 33H** shows the amino acid sequence of S(GII.12)+P(GII.4) fusion VP1 (SEQ ID NO: 36); **FIGURE 33I** shows the amino acid sequence of S(GII.12)+P(GII.5) fusion VP1 (SEQ ID NO: 37); **FIGURE 33J** shows the amino acid sequence of S(GII.12)+P(GII.6) fusion VP1 (SEQ ID NO: 38); **FIGURE 33K** shows the amino acid sequence of S(GII.12)+P(GII.7) fusion VP1 (SEQ ID NO: 39); **FIGURE 33L** shows the amino acid sequence of S(GII.12)+P(GII.13) fusion VP1 (SEQ ID NO: 40); **FIGURE 33M** shows the amino acid sequence of S(GII.12)+P(GII.14) fusion VP1 (SEQ ID NO: 41); **FIGURE 33N** shows the amino acid sequence of S(GII.12)+P(GII.17) fusion VP1 (SEQ ID NO: 42); **FIGURE 33O** shows the amino acid sequence of S(GII.12)+P(GII.21) fusion VP1 (SEQ ID NO: 43).

[0086] **FIGURE 34A** shows the amino acid sequence of S(GII.14)+P(GII.4) fusion VP1 (SEQ ID NO: 52); **FIGURE 34B** shows the amino acid sequence of S(GII.21)+P(GII.4) fusion VP1 (SEQ ID NO: 53).

DETAILED DESCRIPTION

[0087] The following description is of a preferred embodiment.

[0088] As used herein, the terms “comprising,” “having,” “including” and “containing,” and grammatical variations thereof, are inclusive or open-ended and do not exclude additional, un-recited elements and/or method steps. The term “consisting essentially of” when used herein in connection with a use or method, denotes that additional elements and/or method steps may be present, but that these

additions do not materially affect the manner in which the recited method or use functions. The term “consisting of” when used herein in connection with a use or method, excludes the presence of additional elements and/or method steps. A use or method described herein as comprising certain elements and/or steps may also, in certain embodiments, consist essentially of those elements and/or steps, and in other embodiments consist of those elements and/or steps, whether or not these embodiments are specifically referred to. In addition, the use of the singular includes the plural, and “or” means “and/or” unless otherwise stated. The term “plurality” as used herein means more than one, for example, two or more, three or more, four or more, and the like. Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. As used herein, the term “about” refers to an approximately +/-10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to. The use of the word “a” or “an” when used herein in conjunction with the term “comprising” may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one” and “one or more than one.”

[0089] The term “plant”, “portion of a plant”, “plant portion”, “plant matter”, “plant biomass”, “plant material”, “plant extract”, or “plant leaves”, as used herein, may comprise an entire plant, tissue, cells, or any fraction thereof, intracellular plant components, extracellular plant components, liquid or solid extracts of plants, or a combination thereof, that are capable of providing the transcriptional, translational, and post-translational machinery for expression of one or more than one nucleic acids described herein, and/or from which an expressed protein or VLP may be extracted and purified. Plants may include, but are not limited to, agricultural crops including for example canola, Brassica spp., maize, Nicotiana spp., (tobacco) for example, *Nicotiana benthamiana*, *Nicotiana rustica*, *Nicotiana tabacum*, *Nicotiana glauca*, *Arabidopsis thaliana*, alfalfa, potato, sweet potato (*Ipomoea batatas*), ginseng, pea, oat, rice, soybean, wheat, barley, sunflower, cotton, corn, rye (*Secale cereale*), sorghum (*Sorghum bicolor*, *Sorghum vulgare*), safflower (*Carthamus tinctorius*).

[0090] The term “plant portion”, as used herein, refers to any part of the plant including but not limited to leaves, stem, root, flowers, fruits, a plant cell obtained

from leaves, stem, root, flowers, fruits, a plant extract obtained from leaves, stem, root, flowers, fruits, or a combination thereof. The term “plant extract”, as used herein, refers to a plant-derived product that is obtained following treating a plant, a portion of a plant, a plant cell, or a combination thereof, physically (for example by freezing followed by extraction in a suitable buffer), mechanically (for example by grinding or homogenizing the plant or portion of the plant followed by extraction in a suitable buffer), enzymatically (for example using cell wall degrading enzymes), chemically (for example using one or more chelators or buffers), or a combination thereof. A plant extract may be further processed to remove undesired plant components for example cell wall debris. A plant extract may be obtained to assist in the recovery of one or more components from the plant, portion of the plant or plant cell, for example a protein (including protein complexes, protein suprastructures and/or VLPs), a nucleic acid, a lipid, a carbohydrate, or a combination thereof from the plant, portion of the plant, or plant cell. If the plant extract comprises proteins, then it may be referred to as a protein extract. A protein extract may be a crude plant extract, a partially purified plant or protein extract, or a purified product, that comprises one or more proteins, protein complexes, protein suprastructures, and/or VLPs, from the plant tissue. If desired a protein extract, or a plant extract, may be partially purified using techniques known to one of skill in the art, for example, the extract may be subjected to salt or pH precipitation, centrifugation, gradient density centrifugation, filtration, chromatography, for example, size exclusion chromatography, ion exchange chromatography, affinity chromatography, or a combination thereof. A protein extract may also be purified, using techniques that are known to one of skill in the art.

[0091] The term nucleic acid segment as used herein refers to a sequence of nucleic acids that encodes a protein of interest. In addition to the sequence of nucleic acids, the nucleic acid segment comprise a regulatory region and a terminator that are operatively linked to the sequence of nucleic acids. The regulatory region may for example comprise a promoter, and optionally, an enhancer element operatively linked to the promoter.

[0092] The term “nucleic acid complex” as used herein refers to a combination of two or more than two nucleic acid segments. The two or more than two nucleic acid

segments may be present in a single nucleic acid, so that the nucleic acid complex comprises two, or more than two nucleic acid segments, with each nucleic acid segment under the control of a regulatory region and a terminator. Alternatively, the nucleic acid complex may comprise two or more separate nucleic acids, each of the nucleic acids comprising one or more than one nucleic acid segment, where each nucleic acid segment is under the control of a regulatory region and a terminator. For example a nucleic acid complex may comprise one nucleic acid that comprises two nucleic acid segments, a nucleic acid complex may comprise two nucleic acids, each nucleic acid comprising one nucleic acid segment, or a nucleic acid complex may comprise two or more than two nucleic acids, with each nucleic acid comprising one or more than one nucleic acid segment.

[0093] The term “vector” or “expression vector”, as used herein, refers to a recombinant nucleic acid for transferring exogenous nucleic acid sequences into host cells (e.g. plant cells) and directing expression of the exogenous nucleic acid sequences in the host cells. “Expression cassette” refers to a nucleotide sequence comprising a nucleic acid of interest under the control of, and operably (or operatively) linked to, an appropriate promoter or other regulatory elements for transcription of the nucleic acid of interest in a host cell. As one of skill in the art would appreciate, the expression cassette may comprise a termination (terminator) sequence that is any sequence that is active the plant host. For example the termination sequence may be derived from the RNA-2 genome segment of a bipartite RNA virus, e.g. a comovirus, the termination sequence may be a NOS terminator, or terminator sequence may be obtained from the 3'UTR of the alfalfa plastocyanin gene.

[0094] The constructs of the present disclosure may further comprise a 3' untranslated region (UTR). A 3' untranslated region contains a polyadenylation signal and any other regulatory signals capable of effecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by effecting the addition of polyadenylic acid tracks to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognized by the presence of homology to the canonical form 5' AATAAA-3' although variations are not uncommon. Non-limiting examples of suitable 3' regions are the 3' transcribed non-translated regions

containing a polyadenylation signal of *Agrobacterium* tumor inducing (Ti) plasmid genes, such as the nopaline synthase (Nos gene) and plant genes such as the soybean storage protein genes, the small subunit of the ribulose-1, 5-bisphosphate carboxylase gene (ssRUBISCO; US 4,962,028; which is incorporated herein by reference), the promoter used in regulating plastocyanin expression.

[0095] By “regulatory region” “regulatory element” or “promoter” it is meant a portion of nucleic acid typically, but not always, upstream of the protein coding region of a gene, which may be comprised of either DNA or RNA, or both DNA and RNA. When a regulatory region is active, and in operative association, or operatively linked, with a nucleotide sequence of interest, this may result in expression of the nucleotide sequence of interest. A regulatory element may be capable of mediating organ specificity, or controlling developmental or temporal gene activation. A “regulatory region” includes promoter elements, core promoter elements exhibiting a basal promoter activity, elements that are inducible in response to an external stimulus, elements that mediate promoter activity such as negative regulatory elements or transcriptional enhancers. “Regulatory region”, as used herein, also includes elements that are active following transcription, for example, regulatory elements that modulate gene expression such as translational and transcriptional enhancers, translational and transcriptional repressors, upstream activating sequences, and mRNA instability determinants. Several of these latter elements may be located proximal to the coding region.

[0096] In the context of this disclosure, the term “regulatory element” or “regulatory region” typically refers to a sequence of DNA, usually, but not always, upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at a particular site. However, it is to be understood that other nucleotide sequences, located within introns, or 3' of the sequence may also contribute to the regulation of expression of a coding region of interest. An example of a regulatory element that provides for the recognition for RNA polymerase or other transcriptional factors to ensure initiation at a particular site is a promoter element. Most, but not all, eukaryotic promoter elements contain a TATA box, a conserved nucleic acid sequence comprised of adenosine and thymidine nucleotide base pairs

usually situated approximately 25 base pairs upstream of a transcriptional start site. A promoter element may comprise a basal promoter element, responsible for the initiation of transcription, as well as other regulatory elements that modify gene expression.

5 [0097] There are several types of regulatory regions, including those that are developmentally regulated, inducible or constitutive. A regulatory region that is developmentally regulated, or controls the differential expression of a gene under its control, is activated within certain organs or tissues of an organ at specific times during the development of that organ or tissue. However, some regulatory regions
10 that are developmentally regulated may preferentially be active within certain organs or tissues at specific developmental stages, they may also be active in a developmentally regulated manner, or at a basal level in other organs or tissues within the plant as well. Examples of tissue-specific regulatory regions, for example see-specific a regulatory region, include the napin promoter, and the cruciferin promoter
15 (Rask et al., 1998, J. Plant Physiol. 152: 595-599; Bilodeau et al., 1994, Plant Cell 14: 125-130). An example of a leaf-specific promoter includes the plastocyanin promoter (see US 7,125,978, which is incorporated herein by reference).

[0098] An inducible regulatory region is one that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an
20 inducer. In the absence of an inducer the DNA sequences or genes will not be transcribed. Typically the protein factor that binds specifically to an inducible regulatory region to activate transcription may be present in an inactive form, which is then directly or indirectly converted to the active form by the inducer. However, the protein factor may also be absent. The inducer can be a chemical agent such as a
25 protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus. A plant cell containing an inducible regulatory region may be exposed to an inducer by externally applying the inducer to the cell or plant such as by spraying, watering,
30 heating or similar methods. Inducible regulatory elements may be derived from either plant or non-plant genes (e.g. Gatz, C. and Lenk, I.R.P., 1998, Trends Plant Sci. 3, 352-358). Examples, of potential inducible promoters include, but not limited to,

tetracycline-inducible promoter (Gatz, C., 1997, *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 48, 89-108), steroid inducible promoter (Aoyama, T. and Chua, N.H., 1997, *Plant J.* 2, 397-404) and ethanol-inducible promoter (Salter, M.G., et al, 1998, *Plant Journal* 16, 127-132; Caddick, M.X., et al, 1998, *Nature Biotech.* 16, 177-180)
 5 cytokinin inducible IB6 and CKII genes (Brandstatter, I. and Kieber, J.J., 1998, *Plant Cell* 10, 1009-1019; Kakimoto, T., 1996, *Science* 274, 982-985) and the auxin inducible element, DR5 (Ulmasov, T., et al., 1997, *Plant Cell* 9, 1963-1971).

[0099] A constitutive regulatory region directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development.

10 Examples of known constitutive regulatory elements include promoters associated with the CaMV 35S transcript. (p35S; Odell et al., 1985, *Nature*, 313: 810-812; which is incorporated herein by reference), the rice actin 1 (Zhang et al, 1991, *Plant Cell*, 3: 1155-1165), actin 2 (An *et al.*, 1996, *Plant J.*, 10: 107-121), or tms 2 (U.S. 5,428,147), and triosephosphate isomerase 1 (Xu et. al., 1994, *Plant Physiol.* 106: 459-467) genes, the maize ubiquitin 1 gene (Cornejo et al, 1993, *Plant Mol. Biol.* 29: 637-646), the *Arabidopsis* ubiquitin 1 and 6 genes (Holtorf et al, 1995, *Plant Mol. Biol.* 29: 637-646), the tobacco translational initiation factor 4A gene (Mandel et al, 1995 *Plant Mol. Biol.* 29: 995-1004). the Cassava Vein Mosaic Virus promoter, pCAS, (Verdaguer et al., 1996); the promoter of the small subunit of ribulose
 15 biphosphate carboxylase, pRbcS; (Outchkourov et al., 2003), the pUbi (for monocots and dicots).
 20

[00100] The term "constitutive" as used herein does not necessarily indicate that a nucleotide sequence under control of the constitutive regulatory region is expressed at the same level in all cell types, but that the sequence is expressed in a
 25 wide range of cell types even though variation in abundance is often observed.

[00101] The expression constructs as described above may be present in a vector. The vector may comprise border sequences which permit the transfer and integration of the expression cassette into the genome of the organism or host. The construct may be a plant binary vector, for example a binary transformation vector
 30 based on pPZP (Hajdukiewicz, et al. 1994). Other example constructs include pBin19

(see Frisch, D. A., L. W. Harris-Haller, et al. 1995, *Plant Molecular Biology* 27: 405-409).

[00102] The term “native”, “native protein” or “native domain”, as used herein, refers to a protein or domain having a primary amino acid sequence identical to wildtype. Native proteins or domains may be encoded by nucleotide sequences having 100% sequence similarity to the wildtype sequence. A native amino acid sequence may also be encoded by a human codon (hCod) optimized nucleotide sequence or a nucleotide sequence comprising an increased GC content when compared to the wild type nucleotide sequence provided that the amino acid sequence encoded by the hCod-nucleotide sequence exhibits 100% sequence identity with the native amino acid sequence.

[00103] By a nucleotide sequence that is “human codon optimized” or a “hCod” nucleotide sequence, it is meant the selection of appropriate DNA nucleotides for the synthesis of an oligonucleotide sequence or fragment thereof that approaches the codon usage generally found within an oligonucleotide sequence of a human nucleotide sequence. By “increased GC content” it is meant the selection of appropriate DNA nucleotides for the synthesis of an oligonucleotide sequence or fragment thereof in order to approach codon usage that, when compared to the corresponding native oligonucleotide sequence, comprises an increase of GC content, for example, from about 1 to about 30%, or any amount therebetween, over the length of the coding portion of the oligonucleotide sequence. For example, from about 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30%, or any amount therebetween, over the length of the coding portion of the oligonucleotide sequence. As described below, a human codon optimized nucleotide sequence, or a nucleotide sequence comprising an increased GC content (when compared to the wild type nucleotide sequence) exhibits increased expression within a plant, portion of a plant, or a plant cell, when compared to expression of the non-human optimized (or lower GC content) nucleotide sequence.

[00104] Norovirus VP1 fusion proteins and methods of producing norovirus VP1 fusion proteins in plants are described herein. The norovirus VP1 fusion protein, comprises an S domain derived from a first norovirus strain fused to a P domain, or a

portion of the P domain, derived from a second norovirus strain. It has been observed that expression of the VP1 fusion protein increases the yield of the P domain, or a portion of the P domain, derived from the second norovirus strain in plants, when compared to the yield of the P domain, or a portion of the P domain, of the second norovirus strain, when expressed in the same plant and under the same conditions, as a native VP1 protein comprising both an S domain and the P domain (or comprising the P domain that comprises a portion of the P domain), from the same second norovirus strain.

[00105] For example, the norovirus VP1 fusion protein, and methods of producing the norovirus VP1 fusion protein, may include a VP1 fusion protein comprising an S domain derived from a first norovirus strain fused to the P1 and P2 subdomains derived from a second norovirus strain:

$S_{1st\ strain}-P1a_{2nd\ strain}-P2_{2nd\ strain}-P1b_{2nd\ strain}$.

also referred to as: “ $S_1-P1a_2-P2_2-P1b_2$ ”, or “ S_1-P_2 ”.

The VP1 fusion protein, S_1-P_2 , was observed to maintain or increase the yield of the P1 and P2 subdomains (P domain) derived from the second norovirus strain, as compared to the yield of the P subdomain of the second strain, when expressed in the same plant and under the same conditions as a native VP1 protein comprising both an S domain and the P domain, that comprises the P1 and P2 subdomains, from the same second norovirus strain. The sequence encoding the VP1 fusion protein may be optimized for human codon usage, for having an increased GC content, or a combination thereof.

[00106] Also provided herein are methods of increasing production of VLPs comprising norovirus VP1 fusion proteins in plants, wherein a nucleic acid encoding a norovirus VP1 fusion protein as described herein, for example $S_{1st\ strain}-P1a_{2nd\ strain}-P2_{2nd\ strain}-P1b_{2nd\ strain}$ ($S_1-P1a_2-P2_2-P1b_2$; S_1-P_2) is introduced into the plant or a portion of the plant. One or more than one type of norovirus fusion protein may be expressed in a plant or portion of the plant in order to produce a VLP comprising one or more than one type of norovirus fusion protein.

[00107] The methods of producing a VLP comprising a VP1 fusion protein may also comprise a step of co-expressing a nucleic acid sequence encoding a VP2 protein in the plant or portion of the plant.

[00108] The term “single construct” or “single constructs”, as used herein, refers to nucleic acid vectors comprising a single nucleic acid sequence. The term “dual construct” or “dual constructs”, as used herein, refers to a nucleic acid vector comprising two nucleic acid sequences.

[00109] By co-expression it is meant the introduction and expression of two or more nucleotide sequences, each of the two or more nucleotide sequences encoding a protein of interest, or a fragment of a protein of interest within a plant, portion of a plant or a plant cell. The two or more nucleotide sequences may be introduced into the plant, portion of the plant or the plant cell within one vector, so that each of the two or more nucleotide sequences is under the control of a separate regulatory region (e.g. comprising a dual construct). Alternatively, the two or more nucleotide sequences may be introduced into the plant, portion of the plant or the plant cell within separate vectors (e.g. comprising single constructs), and each vector comprising appropriate regulatory regions for the expression of the corresponding nucleic acid. For example, two nucleotide sequences, each on a separate vector and introduced into separate *A. tumefaciens* hosts, may be co-expressed by mixing suspensions of each *A. tumefaciens* host in a desired volume (for example, an equal volume, or the ratios of each *A. tumefaciens* host may be altered) before vacuum infiltration. In this manner, co-infiltration of multiple *Agrobacterium* suspensions permits co-expression of multiple transgenes.

[00110] The nucleic acid comprising encoding a norovirus VP1 fusion protein as described herein, for example, S₁- P₂, may further comprise sequences that enhance expression of the norovirus VP1 fusion protein in the plant, or in a portion of the plant. Sequences that enhance expression may include, a CPMV enhancer element in operative association with the nucleic acid encoding the norovirus VP1 fusion protein. The sequence encoding the VP1 fusion protein may also be optimized for human codon usage, for having an increased GC content, or a combination thereof. Furthermore, a nucleic acid encoding VP2 may be co-expressed along with the

sequence encoding the VP1 fusion protein. The co-expression of a nucleic acid encoding VP2 may lead to increased stability, an increased yield, or both an increase in stability and yield, of VLPs that comprise the one or more than one type of VP1 fusion protein.

[00111] The term “CPMV enhancer element”, as used herein, refers to a nucleotide sequence encoding the 5'UTR regulating the Cowpea Mosaic Virus (CPMV) RNA2 polypeptide or a modified CPMV sequence as is known in the art. For example, a CPMV enhancer element or a CPMV expression enhancer, includes a nucleotide sequence as described in WO2015/14367; WO2015/103704; WO2007/135480; WO2009/087391; Sainsbury F., and Lomonossoff G.P., (2008, Plant Physiol. 148: pp. 1212-1218), each of which is incorporated herein by reference. A CPMV enhancer sequence can enhance expression of a downstream heterologous open reading frame (ORF) to which they are attached. The CPMV expression enhancer may include CPMV HT, CPMVX, CPMVX+, CPMV-HT+, CPMV HT+[WT115], or CPMV HT+[511] (WO2015/14367; WO2015/103704 which are incorporated herein by reference). The CPMV expression enhancer may be used within a plant expression system comprising a regulatory region that is operatively linked with the CPMV expression enhancer sequence and a nucleotide sequence of interest. The term “5'UTR” or “5' untranslated region” or “5' leader sequence” refers to regions of an mRNA that are not translated. The 5'UTR typically begins at the transcription start site and ends just before the translation initiation site or start codon of the coding region. The 5' UTR may modulate the stability and/or translation of an mRNA transcript.

[00112] By "operatively linked" it is meant that the particular sequences interact either directly or indirectly to carry out an intended function, such as mediation or modulation of expression of a nucleic acid sequence. The interaction of operatively linked sequences may, for example, be mediated by proteins that interact with the operatively linked sequences.

[00113] When one or more than one type of the norovirus VP1 fusion protein is expressed in the plant, portion of the plant or the plant cell, the one or more than one type of VP1 fusion proteins auto-assemble into VLPs. The plant or portion of the

plant may be harvested under suitable extraction and purification conditions to maintain the integrity of the VLP, and the VLP comprising the one or more than one type of VP1 fusion protein may be purified. The one or more than one VP1 fusion protein may also be co-expressed with nucleotide sequence encoding VP2, so that the VLP may comprise both VP1 fusion protein and VP2 protein. The present disclosure also provides for the production of one or more than one type of VP1 fusion protein as described herein within a plant, portion of a plant, or plant cell, and the extraction and purification of the one or more than one type of VP1 fusion protein from the plant, the portion of the plant, or the plant cell to produce plant matter, a plant extract, or a protein extract, comprising the VP1 fusion protein.

[00114] Plant matter, a plant extract, or a protein extract comprising the norovirus VP1 fusion protein, for example S₁- P₂, or VLPs comprising the norovirus a VP1 fusion protein as described herein, for example S₁- P₂ is also provided. The plant matter, plant extract, or protein extract may be used to induce immunity to norovirus infection in a subject. Alternatively, the VP1 fusion protein, or the VLP comprising the VP1 fusion protein (and optionally VP2), may be purified or partially purified, and the purified or partially purified preparation may be used in inducing immunity to norovirus infection in a subject.

[00115] The present disclosure also provides a composition comprising an effective dose of one or more than one type of norovirus VP1 fusion protein, for example, S₁- P₂, a combination thereof, or VLPs comprising one or more than one type of norovirus VP1 fusion protein, and optionally VP2, for example S₁- P₂, for inducing an immune response, and a pharmaceutically acceptable carrier, adjuvant, vehicle, or excipient.

[00116] Also provided herein are methods of inducing immunity to a norovirus infection in a subject comprising of administering one or more than one type of norovirus VP1 fusion protein or VLPs comprising one or more than one types of norovirus VP1 fusion proteins to a subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

[00117] The term “norovirus”, as used herein, refers to a non-enveloped viral strain of the genus *norovirus* of the family *Caliciviridae* that is characterized as having a

single-stranded, positive-sense RNA. The norovirus genome is 7,654 nucleotides in length. The ORF1 encodes a nonstructural polyprotein that is cleaved by viral 3C-like protease into 6 proteins, including an RNA-dependent RNA polymerase. ORF2 and ORF3 encode a major (VP1) and a minor (VP2) capsid proteins, respectively (see Figure 1A).

[00118] Norovirus strains as disclosed herein include, any known norovirus strain, but also modifications to known norovirus strains that are known to develop on a regular basis over time (See for example Parra G.I. et. al. PLoS Pathog 13(1): e1006136. doi:10.1371/journal.ppat.1006136). For example norovirus strains may include, but are not limited to GI.1/Norwalk/1968/US (GI.1; SEQ ID NO:1; Figure 13A), GI.2/Leuven/2003/Bel (GI.2; SEQ ID NO:2; Figure 14A), GI.3/S29/2008/Lilla Edet/Sweden (GI.3; SEQ ID NO:3; Figure 15A), GI.5/Siklos/Hun5407/2013/HUN (GI.5; SEQ ID NO:44; Figure 16A), GII.1/Ascension208/2010/USA (GII.1; SEQ ID NO:45; Figure 16B), GII.2/CGMH47/2011/TW (GII.2; SEQ ID NO:66; Figure 16C), GII.3/Jingzhou/2013402/CHN (GII.3; SEQ ID NO:67; Figure 16D), GII.4/Sydney/NSW0514/2012/AU (GII.4; SEQ ID NO:4; Figure 17A), GII.5/AlbertaEI390/2013/CA (GII.5; SEQ ID NO:68; Figure 16E), GII.7/Musahimurayama/2010/JP (GII.7; SEQ ID NO:69; Figure 16F), GII.12/HS206/2010/USA (GII.12; SEQ ID NO:28; Figure 22A), GII.13/VA173/2010/USA (GII.13; SEQ ID NO:6; Figure 19A), GII.14/8610/Saga/2008/JP (GII.14; SEQ ID NO:46; Figure 46B), GII.17/Kawasaki323/2014/JP (GII.17; SEQ ID NO:7; Figure 20A), and GII.21/Salisbury150/2011/USA (GII.21; SEQ ID NO:47; Figure 22C). Norovirus strains also include strains having from about 30-100%, or any amount therebetween, amino acid sequence identity to the VP1 protein, the VP2 protein, or both the VP1 and the VP2 proteins, with any of the above norovirus strains of the strains listed in Figures 2A and 2B, provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject. For example, norovirus strains also include strains having 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100%, or any amount therebetween, amino acid sequence identity (sequence similarity; percent identity; percent similarity) to the VP1 protein, the VP2 protein, or both the

VP1 and the VP2 proteins, with any of the above norovirus strains of the strains listed in Figures 2A and 2B, provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject. An amino acid sequence identity comparison between the VP1 and the VP2 proteins of several norovirus strains, which are not to be considered limiting, is shown in Figure 2C (VP1, upper panel; VP2, lower panel).

[00119] The terms “percent similarity”, “sequence similarity”, “percent identity”, or “sequence identity”, when referring to a particular sequence, are used for example as set forth in the University of Wisconsin GCG software program, or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds. 1995 supplement). Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, using for example the algorithm of Smith & Waterman, (1981, Adv. Appl. Math. 2:482), by the alignment algorithm of Needleman & Wunsch, (1970, J. Mol. Biol. 48:443), by the search for similarity method of Pearson & Lipman, (1988, Proc. Natl. Acad. Sci. USA 85:2444), by computerized implementations of these algorithms (for example: GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.).

[00120] An example of an algorithm suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977, Nuc. Acids Res. 25:3389-3402) and Altschul et al., (1990, J. Mol. Biol. 215:403-410), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. For example the BLASTN program (for nucleotide sequences) may use as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program may use as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1989, Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. Software for performing BLAST

analyses is publicly available through the National Center for Biotechnology Information (see URL: ncbi.nlm.nih.gov/).

[00121] The term “VP1”, as used herein, refers to the norovirus major capsid protein or polypeptide comprising an amino acid sequence similar to the protein or polypeptide encoded by ORF2 of one or more strains of norovirus as described herein. The major capsid protein folds into two principal domains, a shell (S) domain and a protruding (P) domain, which contains two subdomains, P1 and P2 (see Figure 1B). The VP1 protein forms a dimer (Figure 1C) when incorporated into a virion particle, or a VLP. The nucleotide sequence encoding the VP1 protein is comprised, in series, of: a first sequence, encoding the S domain; a second sequence, encoding a first portion of the P1 domain; a third sequence, encoding the P2 domain; and a fourth sequence, encoding a second portion of the P1 domain. When translated, the resulting polypeptide folds into the VP1 protein as depicted in FIGURE 1B, comprising of a globular S domain (bottom of ribbon structure), a P1 subdomain (middle of ribbon structure), and a P2 subdomain (top of ribbon structure).

[00122] As shown in Figure 1C, the VP1 protein dimerizes via P-domain interactions. These interactions stabilize the spontaneous assembly of norovirus capsid molecules.

Norovirus VP1 Protein Production in Plants

[00123] The VP1 protein as disclosed herein includes any VP1 protein comprising an amino acid sequence having from about 40 to about 100%, from about 50 to about 100%, from about 60 to about 100%, from about 70 to about 100%, from about 80 to about 100%, from about 85 to about 100% from about 90 to about 100%, or from about 95 to about 100% or any amount therebetween, sequence identity (which may be also termed sequence similarity) with a VP1 amino acid sequenced from a norovirus GI.1 (SEQ ID NO:1; Figure 13A), GI.2 (SEQ ID NO:2; Figure 14A), GI.3 (SEQ ID NO:3; Figure 15A), GII.4 (SEQ ID NO:4; Figure 17A), GII.6 (SEQ ID NO:5; Figure 18A), GII.13 (SEQ ID NO:6; Figure 19A), GII.17 (SEQ ID NO:7; Figure 20A), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject. For example, the VP1 protein may comprise an amino acid sequence exhibiting from about 40, 42, 44, 46,

48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween sequence identity with a VP1 amino acid sequence from a norovirus GI.1 (SEQ ID NO:1), GI.2 (SEQ ID NO:2), GI.3 (SEQ ID NO:3), GII.4 (SEQ ID NO:4), GII.6 (SEQ ID NO:5), GII.13 (SEQ ID NO:6; GII.17 (SEQ ID NO:7; see Figure 2C, upper panel), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00124] It is well known in the art that the sequence of the P domain of the norovirus VP1 protein is hypervariable and readily mutates. For example as shown in Figure 2D, the amino acid identity of six known GII.4 strains is compared. In this example, the full length amino acid sequence of the GII.4 VP1 protein exhibits from 93.1% to 97.4% sequence identity (upper panel Figure 2D). However, the P domain of these same six GII.4 strains exhibits an amino acid sequence identity from 88.7% to 96.9%, and the P2 subdomain of these same six GII.4 strains exhibits an amino acid sequence identity from 81.3% to 94.4%. The P domain of VP1 proteins obtained from other norovirus strains exhibits a similar range of amino acid sequence identity. An example of the consensus amino acid sequence for VP1 is shown in Figure 16G (SEQ ID NO:70).

[00125] The present disclosure therefore includes nucleic acid sequences that exhibit from about 60% to about 100%, or any amount therebetween, sequence identity with any of the nucleic acid sequences encoding VP1, including the S, P or both the S and P domains, between the strains identified above, and as listed in Figures 2A and 2B. For example, nucleic acid sequences may exhibit from about 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100%, or any amount therebetween, sequence identity with any of the nucleic acid sequences encoding a norovirus VP1, including the S domain, P domain or both the S and P domains, from GI.1 (SEQ ID NO:1), GI.2 (SEQ ID NO:2), GI.3 (SEQ ID NO:3), GII.4 (SEQ ID NO:4), GII.6 (SEQ ID NO:5), GII.13 (SEQ ID NO:6), GII.17 (SEQ ID NO:7), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00126] Similarly, the present invention includes amino acid sequences that exhibit from about 40% to about 100% or any amount therebetween, sequence similarity with any of the VP1 sequences, including the S, P or both the S and P domains, from GI.1 (SEQ ID NO:1), GI.2 (SEQ ID NO:2), GI.3 (SEQ ID NO:3), GII.4 (SEQ ID NO:4), GII.6 (SEQ ID NO:5), GII.13 (SEQ ID NO:6), GII.17 (SEQ ID NO:7). For example, from about 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100% or any amount therebetween, sequence similarity with any of the VP1 amino acid sequences, including the S domain, the P domain, or both the S and P domains. For example, as shown in Figure 2C (upper panel), amino acid sequences of VP1 sequences between several norovirus strains, including but not limited to, GI.1, GI.2, GI.3, GII.4, GII.6, GII.13), exhibit a sequence identity from about 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100% or any amount therebetween, provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00127] Figure 2C (lower panel) also shows that these same norovirus strains (from GI.1 (SEQ ID NO:1), GI.2 (SEQ ID NO:2), GI.3 (SEQ ID NO:3), GII.4 (SEQ ID NO:4), GII.6 (SEQ ID NO:5), GII.13 (SEQ ID NO:6), GII.17 (SEQ ID NO:7), exhibit from about 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100% or any amount therebetween, amino acid sequence similarity of the VP2 protein.

[00128] Figure 16G shows the consensus amino acid sequence (SEQ ID NO:70) of GI.1 (SEQ ID NO:1), GI.2 (SEQ ID NO:2), GI.3 (SEQ ID NO:3), GII.4 (SEQ ID NO:4), GII.6 (SEQ ID NO:5), GII.13 (SEQ ID NO:6), GII.17 (SEQ ID NO:7). Any of these VP1 proteins, or the VP1 consensus amino acid sequence may be used to prepare the VP1 fusion proteins described herein.

[00129] By “VP1 fusion protein” or “chimeric VP1 protein” it is meant, a protein comprising an S domain derived from a first norovirus strain fused to the P1 and P2 subdomains derived from a second norovirus strain:

S_{1st strain}-P1a_{2nd strain}-P2_{2nd strain}-P1b_{2nd strain} (S₁-P1a₂-P2₂-P1b₂; S₁-P₂).

The boundary between the S domain and the P domain of the norovirus VP1 amino acid sequence is well conserved (see Figure 4A) and comprise of the following consensus sequence:

...LVPPtvE||sKTkpFs... (SEQ ID NO:88),

5 where “||” indicates the boundary between the S and P domains.

[00130] Examples of VP1 fusion protein of the form: S₁-P1a₂-P2₂-P1b₂ include, but are not limited to:

- S(GI.1 Nor/68) +P (GI.2/Leuven/03) (SEQ ID NO:22, Figure 25A;
S(GI.1)+P(GI.2)): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P
10 domain from GI.2/Leuven/03 (SEQ ID NO:2), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 25A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
15 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject;

- S(GI.1 Nor/68) +P (GI.3/S29/08/Lilla Edet) (SEQ ID NO:23, Figure 26A;
20 S(GI.1)+P(GI.3)): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GI.3/S29/08/Lilla Edet (SEQ ID NO:3), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 26A, for example from about 59, 60, 62, 64, 66,
25 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject;

- S(GI.1 Nor/68) +P (GII.4/Sydney/NSW0514/12) (SEQ ID NO:24, Figure 27A; S(GI.1)+P(GII.4)): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.4/Sydney/NSW0514/12 (SEQ ID NO:4), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 27A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject;

- S(GI.1 Nor/68) +P (GII.6/Ohio/490/12) (SEQ ID NO:25, Figure 28A; S(GI.1)+P(GII.6)): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.6/Ohio/490/12 (SEQ ID NO:5), or a sequence that exhibits from about 59-100% or any amount therebetween, sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion shown in Figure 28A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions, provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject;

- S(GI.1 Nor/68) +P (GII.12/HS206/2010/USA) (SEQ ID NO:71, Figure 31A; S(GI.1)+P(GII.12)): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.12/HS206/2010/USA (SEQ ID NO:28), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 31A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject;

- (GI.1 Nor/68) +P (GII.13/VA173/10) (SEQ ID NO:26, Figure 29A;

S(GI.1)+P(GII.13): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.13/VA173/10 (SEQ ID NO:6), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 29A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject; or

- (GI.1 Nor/68) +P (GII.17/Kawasaki323/14) (SEQ ID NO:27, Figure 30A;

S(GI.1)+P(GII.17): comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.17/Kawasaki323/14 (SEQ ID NO: 7), or a sequence that exhibits from about 59-100% or any amount therebetween (see Figure 4B), sequence similarity with the amino acid sequence of the GI.1 VP1 protein, or the S₁-P1a₂-P2₂-P1b₂ fusion amino acid sequence shown in Figure 30A, for example from about 59, 60, 62, 64, 66, 68, 70, 72, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount therebetween, sequence similarity with the amino acid sequence of the S₁-P1a₂-P2₂-P1b₂ fusions (see Figure 4B), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00131] The VP1 fusion protein is heterologous (or chimeric) in that the fusion protein comprises an S domain from a first VP1 protein and a P domain from a second VP1 protein. The heterologous VP1 fusion protein may comprise an amino acid sequence that falls within, or the amino acid sequence is found within (or maps against) the consensus sequence of the VP1 sequence shown in Figure 16G (S-P boundary underlined and indicated by “||”; SEQ ID NO:70), provided that the S and P domains of the VP1 fusion protein is heterologous, and that the VP1 fusion protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00132] Additional non-limiting examples of VP1 fusion proteins include those that comprise an S domain from: GI.1, for example but not limited to, the VP1 fusion shown in Figures 32A-32C (SEQ ID NO's:49-51); GI.5, for example but not limited to, the VP1 fusion shown in Figure 31B (SEQ ID NO:48); GII.12, for example but not limited to, the VP1 fusion as shown in Figures 33A – 33O (SEQ ID NO's:29-43), GII.14 for example, but not limited to, the VP1 fusion shown in Figure 34A (SEQ ID NO:52), GII.21 for example but not limited to, the VP1 fusion shown in Figure 34B (SEQ ID NO:53), or a sequence that exhibits from about 40-100% or any amount therebetween, sequence similarity with the amino acid sequence of the S domain provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject. Furthermore, the VP1 fusion protein may comprise an S domain that comprises an amino acid sequence that falls within (i.e. the amino acid sequence is found within, or maps against) the consensus sequence of the S domain as shown in Figure 16G (i.e. the N terminal portion of the consensus sequence; S-P boundary underlined and indicated by “||”; SEQ ID NO:70), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00133] VP1 fusion proteins may also comprise a P domain obtained from GI.1/Norwalk/1968/US (SEQ ID NO:1); GI.5 Siklos/Hun5407/2013/HUN (SEQ ID NO:44); GII.1 Ascension 208/2010/USA (SEQ ID NO:45); GII.2 CGMH47/2011/TW (SEQ ID NO:66); GII.3 Jingzhou/2013402/CHN (SEQ ID NO:67); GII.4/Dresden174/1997/DE(variant:US1995/96); GII.4/FarmingtonHills/2002/US (SEQ ID NO:9); GII.4/Hunter-NSW504D/2004/AU (SEQ ID NO:10); GII.4/Shellharbour-NSW696T/2006/AU (11) ; GII.4/Orange-NSW001P/2008/AU (variant New Orleans 2009) (SEQ ID NO:12); GII.5 AlbertaEI390/2013/CA (SEQ ID NO:68); GII.7 Musashimurayama/2010/JP (SEQ ID NO:69); GII.14 8610/Saga/2008/JPN (SEQ ID NO:46); GII.21 Salisbury150/2011/USA (SEQ ID NO:47), or a sequence that exhibits from about 40-100% or any amount therebetween, sequence similarity with the amino acid sequence of the P domain from any one of GI.1/Norwalk/1968/US; GI.5 Siklos/Hun5407/2013/HUN; GII.1 Ascension 208/2010/USA; GII.2 CGMH47/2011/TW; GII.3 Jingzhou/2013402/CHN; GII.4/Dresden174/1997/DE(variant:US1995/96); GII.4/FarmingtonHills/2002/US;

GII.4/Hunter-NSW504D/2004/AU; GII.4/Shellharbour-NSW696T/2006/AU (11) ;
 GII.4/Orange-NSW001P/2008/AU (variant New Orleans 2009); GII.5
 AlbertaEI390/2013/CA; GII.7 Musashimurayama/2010/JP; GII.14
 8610/Saga/2008/JPN; GII.21 Salisbury150/2011/USA, for example from about 40,
 5 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 81, 82, 83,
 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount
 therebetween sequence similarity with the amino acid sequence of the P or the P2
 domain from any one of GI.1/Norwalk/1968/US; GI.5 Siklos/Hun5407/2013/HUN;
 GII.1 Ascension 208/2010/USA; GII.2 CGMH47/2011/TW; GII.3
 10 Jingzhou/2013402/CHN; GII.4/Dresden174/1997/DE(variant:US1995/96);
 GII.4/FarmingtonHills/2002/US; GII.4/Hunter-NSW504D/2004/AU;
 GII.4/Shellharbour-NSW696T/2006/AU (11) ; GII.4/Orange-NSW001P/2008/AU
 (variant New Orleans 2009); GII.5 AlbertaEI390/2013/CA; GII.7
 Musashimurayama/2010/JP; GII.14 8610/Saga/2008/JPN; GII.21
 15 Salisbury150/2011/USA, provided that the VP1 protein induces immunity to
 norovirus in a subject, when the VP1 protein is administered to the subject.
 Furthermore, the VP1 fusion protein may comprise a P domain that comprises an
 amino acid sequence that falls within (i.e. the amino acid sequence maps against, or is
 found within) the consensus sequence of the P domain as shown in Figure 16G (i.e.
 20 the C terminal portion of the consensus sequence; S-P boundary underlined and
 indicated by “||”; SEQ ID NO:70), provided that the VP1 protein induces immunity
 to norovirus in a subject, when the VP1 protein is administered to the subject.

[00134] In the VP1 fusion protein examples provided above, the S domain may
 comprise an amino acid sequence that exhibits from about 80-100%, or any amount
 25 therebetween, sequence similarity with the amino acid sequence of the S domain from
 any norovirus, for example but not limited to, the S domain from GI.1 Nor/68 (SEQ
 ID NO:1; see Figures13A, and 4B), GII.12/HS206/2010/USA (SEQ ID NO:28 ; see
 Figure 22A and 4C), or GI.5 Siklos/Hun5407/2013/HUN (SEQ ID NO:44 ; see Figure
 16A and 4D). For example the S domain may comprise an amino acid sequence that
 30 exhibits from about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
 97, 98, 99, 100% or any amount therebetween sequence similarity with the amino
 acid sequence of the S domain from GI.1 Nor/68 (SEQ ID NO:1),

GII.12/HS206/2010/USA (SEQ ID NO:28), or GI.5 Siklos/Hun5407/2013/HUN (SEQ ID NO:44), provided that the VP1 protein induces immunity to norovirus in a subject, when the VP1 protein is administered to the subject.

[00135] As shown in Figures 5A, 5B, 6A, 6B and 6C, VP1 fusion proteins comprising S(GI.1)+P(GI.2), S(GI.1)+P(GI.3), S(GI.1)+P(GII.4), S(GI.1)+P(GII.13), S(GI.1)+P(GII.17) resulted in VP1 fusion protein production in plants (as determined using a SDS-Comassie stained gel, or Western analysis) that was similar to or greater than the yield of the native VP1 protein that comprised the corresponding P domain (as determined using a SDS-Comassie stained gel, or Western analysis).

[00136] Expression of native GII.6/Ohio/490/12 VP1 protein has proven to be challenging (e.g. Figure 5B) and VP1 protein production varies from below detectable levels to detectable levels (see Example 4 below). Additionally expression of a VP1 fusion protein comprising an S domain from GI.1 Nor/68 (SEQ ID NO: 1) and a P domain from GII.6/Ohio/490/12 (SEQ ID NO: 5), was also bellow detection levels (Figure 5B).

[00137] The term “virus-like particle”, VLP, “virus-like particles”, or “VLPs”, as used herein, refers to a norovirus virus like particles that comprise one or more than one type of norovirus VP1 protein, one or more than one type of VP1 fusion protein, or a combination thereof, and that self-assemble into non-replicating, non-enveloped, non-infectious viral capsid structures lacking all parts of the norovirus genome. For example, the VLP may comprise one type of VP1 fusion protein, or the VLP may comprise two or more different VP1 fusion proteins. Furthermore the VLP may comprise a VP2 protein. VLPs comprising VP1 protein, VP1+VP2 protein, VP1 fusion protein, or VP1 fusion protein +VP2 protein are of the size from about 15nm to 50nm or any amount therebetween, for example 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50nm, or any amount therebetween. For example, for T=1 icosahedral symmetry, VLPs may about 23 nm, or for T=3 icosahedral symmetry, VLPs may be from about 38 to about 40 nm.

[00138] As shown in Figures 6A, 6B, 6C, VLPS may be produced in plants from expressing human codon optimized nucleotide sequences encoding VP1 fusion

proteins described herein. For example, VLPs were produced comprising an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GI.2/Leuven/03 (SEQ ID NO:2; Figure 6A), an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GI.3/S29/08/Lilla Edet (SEQ ID NO:3 ; Figure 6B), an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.13/VA173/10 (SEQ ID NO:6; Figure 6C), and an S domain from GI.1 Nor/68 (SEQ ID NO:1) and a P domain from GII.17/Kawasaki323/14 (SEQ ID NO:7 ; Figure 6C).

[00139] An aspect of the present disclosure provides for the production of norovirus VP1 protein in plants. As shown in Figure 3A, leaves (from *N. benthamiana*) were vacuum infiltrated with *Agrobacterium tumefaciens* comprising expression vectors encoding GI.1 VP1 as a single nucleic acid construct, GI.1 VP2 as a single nucleic acid construct, both GI.1 VP1 and VP2, with VP1 and VP2 nucleic acid sequences introduced in separate vectors ("VP1+VP2"; dual constructs), or on the same vector ("VP1/VP2" or "VP1/VP2/3'UTR"; single nucleic acid constructs) to permit co-expression of the VP1 and/or VP2 sequences and the leaves examined for VP1 and VP2 production. After 6 or 9 days post infiltration (6 DPI and 9 DPI, respectively), total crude protein extracts were prepared from leaf homogenates, separated by SDS-PAGE, and stained with Coomassie Brilliant Blue dye. As seen in lanes 3-4, 7-10 and 19-20, leaves infiltrated with expression vectors comprising nucleotide sequences that correspond to wildtype GI.1 ORF2, encoding the VP1 protein, produced low or non-detectable levels of GI.1 VP1 as determined using Coomassie stained gels (VP1 expression was observed when expression was assayed by Western analysis, data not provided). In contrast, leaves infiltrated with expression vectors comprising GI.1 VP1 nucleotide sequences that were codon optimized for human expression (hCod), or enriched for GC content when compared to the GC content of the wildtype VP1 nucleic acid sequence, produced increased amounts of GI.1 VP1 protein (see lanes 11, 12, 21, 22; "VP1", 55-70 kDa band) in Coomassie stained gels. These results show that hCod VP1 may be produced in plants when VP1 is expressed on its own.

[00140] Furthermore, as seen in lanes 7-10 and 15-18 of Figure 3A, leaves infiltrated with vectors comprising either wildtype GI.1 VP1 and VP2 (lanes 7-10) or human codon optimized GI.1 VP1 and VP2 (lanes 15-18; dual nucleic acid

constructs) produced low or non-detectable levels of GI.1 VP1 protein in Coomassie stained gels, suggesting that expression of VP1 is not enhanced by the presence of VP2 when co-expressed in *cis* on the same vector, using the same organization as found in the viral genome (using one promoter to control expression). However, when VP1 or human codon optimized VP1 was co-expressed in *trans* (on a separate construct) along with VP2 or hCod VP2 (hCod VP1+VP2), respectively, an increase in VP1 protein (approx. 55-60kDa band) was observed (see lanes 15, 16, and 21, 22; Figure 3A). In this example, VP1 and VP2 nucleic acid segments, with each nucleic acid segment comprising a regulatory region and a terminator, were introduced into the plants as a nucleic acid complex, and this resulted in a corresponding increase in VP1 protein yield.

[00141] This observation is in contrast to that observed in insect and mammalian cells (Bertolotti-Ciarlet A., Crawford S.E., Hutson A.M., Estes M.K. 2003, J. Virol. 77:11603-11615), who reported that an increase in VP1 expression was only observed when VP1 and VP2 (or VP1+VP2+3'UTR) resided in *cis*, and were co-expressed using the same organization as that found in the viral genome, under the control of one promoter and terminator. No increase in VP1 expression was observed by Bertolotti-Ciarlet (2003) in insect or mammalian cells, when VP1 and VP2 were co-expressed in *trans*.

[00142] As described in more detail below (see "Norovirus VP1 Fusion Proteins"; reference to Figure 5E), when VP1 fusion proteins are expressed in plants, it is preferred that the ORF3 sequence encoding VP2 is obtained from the same norovirus genotype and strain as that used to obtain the S domain of fusion VP1 sequence.

[00143] The data presented in Figure 3A show that in plants, hCod VP1 may be expressed on its own, and that if hCod VP1 is co-expressed along with VP2, then both VP1 and VP2 should be expressed using separate expression systems, for example, on separate plasmids, or VP1 and VP2 may be expressed on the same vector but each of the sequences encoding VP1 and VP2 should be under the control of separate promoter and terminator sequences, so that they have a separate expression system.

Assembly of Plant-produced Norovirus VP1 into VLPs

[00144] FIGURE 3B (upper panel) shows a Coomassie-stained SDS-PAGE analysis of fractions from an iodixanol density gradient separation of crude protein extracts prepared from *N. benthamiana* leaves expressing GI.1 VP1 (single nucleic acid human codon optimized constructs), or VP1 and VP2 (dual nucleic acid human codon optimized constructs). Norovirus VP1 proteins (approx. 55-60kDa band) in high density fractions were analyzed by scanning electron microscopy. As seen in FIGURE 3B (lower panel), norovirus VP1 proteins and norovirus VP1+VP2 proteins self-assemble into VLPs in plants. The isolated VLPs exhibit a structural conformation similar to that of wildtype norovirus GI.1 virion particles (insert, Figure 3B).

[00145] Differential Expression of Norovirus VP1 in Plants

[00146] The expression levels of norovirus VP1 protein derived from six norovirus strains having the highest occurrence of outbreaks between September 1, 2013 and August 31, 2015 (as reported by the Centers for Disease Control and Prevention, see URL: www.cdc.gov/norovirus/reporting/calicinet/data.html) were compared in *N. benthamiana*.

[00147] VP1 protein production was determined using Coomassie-stained SDS-PAGE analysis (approx. 55-60kDa band) of extracts obtained from plant leaves vacuum infiltrated with expression vectors comprising human codon optimized sequences of VP1 derived from GI.1/Norwalk/1968/US (SEQ ID NO:18), GI.2/Leuven/2003/Bel (SEQ ID NO:54), GI.3/S29/2008/Lilla Edet/Sweden (SEQ ID NO:55), GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:56), GII.6/Ohio/490/12 (SEQ ID NO:60), GII.13/VA173/2010/USA (SEQ ID NO:61), GII.17/Kawasaki323/2014/JP (SEQ ID NO:62), strains. As shown in Figures 5A and 5B, VP1 protein production was observed in plant leaves expressing GI.1/Norwalk/1968/US (SEQ ID NO:1), GI.2/Leuven/2003/Bel (SEQ ID NO:2), GI.3/S29/2008/Lilla Edet/Sweden (SEQ ID NO:3), and GII.13/VA173/2010/USA (SEQ ID NO:6). A low or non-detectable amount of VP1 protein production was observed in plant leaves expressing GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:4), GII.6/Ohio/490/12 (SEQ ID NO:5), and GII.17/Kawasaki323/2014/JP (SEQ ID NO:7).

[00148] VP1 protein expression was also observed when GI.3 (/S29/2008/Lilla Edet/Sweden; SEQ ID NO:3, Figure 15A), GI.5 (Siklos/Hun5407/2013/HUN; SEQ ID NO: 44, Figure 16A), GII.1 (Ascension208/2010/USA; SEQ ID NO: 45, Figure 16B), GII.2 (CGMH47/2011/TW; SEQ ID NO: 66, Figure 16C), GII.3 (Jingzhou/2013402/CHN; SEQ ID NO:67, Figure 16D), GII.5 (AlbertaEI390/2013/CA; SEQ ID NO: 68, Figure 16E), GII.6 (Ohio/490/12; SEQ ID NO: 60, Figure 18B), GII.7 (Musahimurayama/2010/JP; SEQ ID NO: 69, Figure 16F), GII.12 (HS206/2010/USA; SEQ ID NO:28, Figure 22A), GII.14 (8610/Saga/2008/JP; SEQ ID NO: 46, Figure 22B), and GII.21 (Salisbury 150/2011/USA; SEQ ID NO: 47, Figure 22C), were expressed in plants (see Example 4 below).

[00149] As shown in the electron micrographs of Figures 3B, 5C, 5D, 6A and 6B, plant produced VP1 proteins derived from several norovirus strains self-assembled into VLPs. VLPs were observed in plant extracts following expression of strains GI.2/Leuven/2003/Bel (SEQ ID NO:54, Figure 14B), GI.3 S29/2008/Lilla Edet/Sweedeen (SEQ ID NO's:3 (aa); 55 (na); Figure 15B), GI.5 Siklos/HUN5407/2013/HUN (SEQ ID NO:44: Figure 16A), GII.1 Ascension208/2010/USA SEQ ID NO:45; Figures 16B); GII.7 Musashimurayama/2010/JP (SEQ I NO:69; Figure 16F), GII.12 HS206/2010/USA (SEQ ID NO:28 , Figure 22A), GII.13 VA173/2010/USA (SEQ ID NO:61, Figure 19B), GII.14 8610/Saga/2008/JPN (SEQ ID NO:46 , Figure 22B), and GII.21 Salisbury 150/2011/USA (SEQ ID NO:47 , Figure 22B). The VLPs have a structural conformation and diameter of about 15 nm to 50 nm, for example, of either about 23 nm, for T=1 icosahedral symmetry; or about 38 to 40 nm, for T=3 icosahedral symmetry, similar to that of wildtype norovirus.

[00150] Even though expression levels of VP1 protein in leaves infiltrated with vectors expressing GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:4), GII.6/Ohio/490/12 (SEQ ID NO:5), GII.17/Kawasaki323/2014/JP (SEQ ID NO:7), was either low or undetectable using Coomassie-stained SDS-PAGE analysis (see Figures 5A and 5B), expression of these VP1 proteins was observed at low levels (see Example 4, below).

[00151] Norovirus VP1 Fusion Proteins

[00152] Expression vectors were constructed which encoded norovirus VP1 fusion proteins wherein the S domain of GI.1 was fused to the following P domains:

GI.2 (S(GI.1)+P(GI.2); S(GI.1 Nor/68) +P (GI.2/Leuven/03); SEQ ID NO's:22(aa), 57(na), Figures 25A, 25B; construct 3360; SEQ ID NO:87; Figure 12C,

GI.3 (S(GI.1)+P(GI.3); GI.3 S(GI.1 Nor/68) +P (GI.3/S29/08/Lilla Edet) SEQ ID NO:23(aa), 58(na), Figures 26A, 26B; construct 3361),

GII.4 (S(GI.1)+P(GII.4); S(GI.1 Nor/68) +P (GII.4/Sydney/NSW0514/12) SEQ ID NO:24(aa), 59na), Figures 27A, 27B; construct 3362),

GII.6 (S(GI.1)+P(GII.6); S(GI.1 Nor/68) +P(GII.6/Ohio/490/12) SEQ ID NO:25(aa), 63(na), Figures 28A, 28B; construct 3363),

GII.13 (S(GI.1)+P(GII.13); S(GI.1 Nor/68) +P (GII.13/VA173/10) SEQ ID NO:26(aa); 64(na), Figures 29A, 29B; construct 3364), and

GII.17 (S(GI.1)+P(GII.17); S(GI.1 Nor/68) +P (GII.17/Kawasaki323/14) SEQ ID NO:27(aa), 65(na), Figures 30A, 30B; construct 3365)

[00153] VP1 fusion protein production was determined using Coomassie-stained SDS-PAGE analysis (approx. 55-60kDa band) of extracts obtained from plant leaves vacuum infiltrated with expression vectors comprising the above nucleotide sequences encoding the various VP1 fusion proteins, and VP2. As shown in Figures 5A and 5B, the fusion of the GI.1 Norwalk S domain to the P domain of GI.2 (GI.1S-GI.2P), GI.3 (GI.1S-GI.3P), or GII.13 (GI.1S-GII.13P), resulted in similar levels of expression of norovirus VP1 fusion proteins as compared to their native non-fusion counterparts. Demonstrating that VP1 fusion proteins may be expressed in a plant, portion of a plant, or a plant cell.

[00154] Even though protein product was not observed using SDS-PAGE analysis for the VP1 fusion S(GI.1) +P(GII.4) (S(GI.1 Nor/68)+P (GII.4/Sydney/NSW0514/12; SEQ ID NO:59, Figure 27B), and S(GI.1)+P(GII.17) (S(GI.1 Nor/68) +P (GII.17/Kawasaki323/14; SEQ ID NO:65, Figure 30B), electron

micrograph analysis of S(GI.1) +P(GII.4) and GII.17 (GI.1S-GII.17P), revealed that VLPs were produced (see Figures 6C and 6D).

[00155] The fusion of the GI.1 Norwalk S domain to the P domains of low-expressing GII.6 (GI.1S-GII.6P) did not result in enhanced expression of norovirus VP1 fusion protein as compared to their native non-fusion counterparts. Without wishing to be bound by theory, these results suggest that the S domain may not be responsible for the low-level of expression in plants for these particular norovirus strains.

[00156] When VP1 fusion proteins are expressed in plants, it is preferred that the ORF3 sequence encoding VP2 is obtained from the same norovirus strain as used to obtain the S domain of fusion VP1 sequence. Support for this observation may be found with reference to Panels B and C of Figure 5E, which show that, in this example, the level of expression of a VP1 fusion protein, when co-expressed with VP2 obtained from the same genotype and strain as the S domain of the VP1 fusion, results in greater VLP yield (Panel B; Figure 5E, right hand side), then co-expression of the same VP1 fusion protein with a VP2 obtained from a different genotype and strain (Figure 5E; Panel C, right hand side). Rather, the VLP yield observed following co-expression of the VP1 fusion along with a heterologous VP2 (i.e. the S domain of the VP1 fusion and VP2 are from different genotypes and strains) decreased and approximated the VLP yield observed when VP1 was expressed alone (Figure 5E, Panel A, left hand side).

[00157] It is also of interest to note that the VLP yield obtained from co-expressing a VP1 fusion along with a VP2, where the S domain and the VP2 area obtained from the same genotype and strain (Panel B; Figure 5E, right hand side), is greater than the VLP yield observed following expression of the VP1 fusion when expressed alone (Panel B; Figure 5E, left hand side).

[00158] As shown in the electron micrographs of Figures 6A and 6B, VP1 fusion proteins derived from several of the strains including GI.1 Nor68+ GI.2/Leuven/2003/Bel (Figure 6A, right hand side); GI.1 Nor68+GI.3/S29/2008/Lilla Edet/Sweden (Figure 6B, right hand side), GI.1+GII.13Vas10 (Figure 6C left hand side), GI.1+GII.17Kaw14 (Figure 6C right hand side), self-assembled into VLPs

having a structural conformation and diameter of about 15 nm to 50 nm, for example, for T=1 icosahedral symmetry, about 23 nm, or for T=3 icosahedral symmetry, about 38 to about 40 nm, similar to that of wildtype norovirus. Of note is that the VP1 fusion product encoded by GI.1+GII.17Kaw14 resulted in a low yield (Figure 5B), however, VLPs comprising this VP1 protein could be purified from plant extracts.

[00159] However, no VLPs were obtained from plant extracts expressing the VP1 fusion protein GI.1+GII.6/Ohio/490/12 (also see Example 5), consistent with the low or undetectable expression levels of this VP1 fusion protein as shown in Figure 5B.

[00160] Additional human codon optimized VP1 fusion proteins were prepared and co-expressed with VP2 in *N. benthamiana* leaves, as described in Example 5 below. The VP1 fusion proteins included:

S(GI.1)+P(X), where X= GI.2, GI.3, GII.4, GII.6, GII.12, GII.13, GII.17;

S(GI.5)+P(Y), where Y= GII.4;

S(GII.1)+P(Z), where Z= GI.3, GII.4, GII.17;

S(GII.12)+P(W), where W= GI.1, GI.2, GI.3, GI.5, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.13, GII.14, GII.17, GII.21;

S(GII.14)+P(T), where T= GII.4;

S(GII.21)+P(Q), where Q= GII.4

Expression of VP1 fusion proteins in a plant, a portion of a plant or a plant cell was observed (see Example 5) with the following VP1 fusion constructs:

S(GI.1)+P(GI.2), S(GI.1)+P(GI.3), S(GI.1)+P(GII.4), S(GI.1)+P(GII.6), S(GI.1)+P(GII.12), S(GI.1)+P(GII.13), S(GI.1)+P(GII.17),

S(GI.5)+P(GII.4),

S(GII.1)+P(GI.3), S(GII.1)+P(GII.4),

S(GII.12)+P(GI.1), S(GII.12)+P(GI.2), S(GII.12)+P(GI.3), S(GII.12)+P(GI.5), S(GII.12)+P(GII.1), S(GII.12)+P(GII.2), S(GII.12)+P(GII.4), S(GII.12)+P(GII.7),

S(GII.12)+P(GII.13), S(GII.12)+P(GII.14), S(GII.12)+P(GII.17),
S(GII.12)+P(GII.21).

[00161] Enhanced Stability of VLPs Comprising Norovirus VP1 Fusion Proteins

[00162] As shown in Figure 3C (upper panel), the levels of VLPs comprising of high-expressing native GI.1 VP1 protein (encoded by construct 2724) peaked in fractions four through eight following iodixanol gradient centrifugation. In contrast, VLPs comprising of native GI.2 VP1 protein (encoded by construct 3300) Figure 3C lower panel, left hand side) peaked in lower-density fractions six through nine. These results indicate that the assembly of native GI.2 VLPs may be less stable than GI.1 VLPs and may be more susceptible to malformed capsid particles and the generation of fragmentation products.

[00163] However, VLPs comprising S(GI.1 Nor68) +P(GI.2 Leu03) norovirus VP1 fusion proteins (encoded by construct 3360; Figure 3C, lower panel, right hand side), peaked in fractions four through eight, indicating that VLPs comprising norovirus VP1 fusion proteins having a GI.1 S domain core maybe more stable than their native VLP counterparts where the S domain is not derived from GI.1.

[00164] A similar shift in density was also observed in VLPs comprising of S(GI.1)+P(GI.3P) norovirus VP1 fusion proteins (Figure 6B; GI.1 Nor68+GI.3 Lil08, encoded by construct 3360).

[00165] Additionally, as shown with reference to Figure 5E, when a VP1 fusion protein is co-expressed with a VP2 minor structural protein that is obtained from the same genotype and strain as the S domain of the VP1 fusion, then the VP2 protein is incorporated on the VLPs (see high-molecular weight fractions of the density gradient that contain Norovirus VLPs, band of 21-24 kDa, indicated by a square; Figure 5E; Panel B right hand side, and Panel C left hand side). The VP2 band is absent when the VP2 protein is obtained from a different genotype and strain as the S domain of the VP1 fusion (Figure 5E, Panel C, right hand side). Without wishing to be bound by theory, these results are consistent with the proposal that VP2 is located on the inside of the viral particle and that VP2 may play a role in particle stability.

[00166] Induction of Immunity Against Norovirus Infection

[00167] An “immune response” generally refers to a response of the adaptive immune system of a subject. The adaptive immune system generally comprises a humoral response, and a cell-mediated response. The humoral response is the aspect of immunity that is mediated by secreted antibodies, produced in the cells of the B lymphocyte lineage (B cell). Secreted antibodies bind to antigens on the surfaces of invading microbes (such as viruses or bacteria), which flags them for destruction. Humoral immunity is used generally to refer to antibody production and the processes that accompany it, as well as the effector functions of antibodies, including Th2 cell activation and cytokine production, memory cell generation, opsonin promotion of phagocytosis, pathogen elimination and the like. The terms “modulate” or “modulation” or the like refer to an increase or decrease in a particular response or parameter, as determined by any of several assays generally known or used, some of which are exemplified herein.

[00168] A cell-mediated response is an immune response that does not involve antibodies but rather involves the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. Cell-mediated immunity is used generally to refer to some Th cell activation, Tc cell activation and T-cell mediated responses. Cell mediated immunity may be of particular importance in responding to viral infections.

[00169] For example, the induction of antigen specific CD8 positive T lymphocytes may be measured using an ELISPOT assay; stimulation of CD4 positive T-lymphocytes may be measured using a proliferation assay. Anti-norovirus antibody titres may be quantified using an ELISA assay; isotypes of antigen-specific or cross reactive antibodies may also be measured using anti-isotype antibodies (e.g. anti -IgG, IgA, IgE or IgM). Methods and techniques for performing such assays are well-known in the art.

[00170] Cytokine presence or levels may also be quantified. For example a T-helper cell response (Th1/Th2) will be characterized by the measurement of IFN- γ and IL-4 secreting cells using by ELISA (e.g. BD Biosciences OptEIA kits). Peripheral blood mononuclear cells (PBMC) or splenocytes obtained from a subject may be cultured,

and the supernatant analyzed. T lymphocytes may also be quantified by fluorescence-activated cell sorting (FACS), using marker specific fluorescent labels and methods as are known in the art.

[00171] A microneutralization assay may also be conducted to characterize an immune response in a subject, see for example the methods of Rowe *et al.*, 1973.

Virus neutralization titers may be quantified in a number of ways, including: enumeration of lysis plaques (plaque assay) following crystal violet fixation/coloration of cells; microscopic observation of cell lysis in *in vitro* culture; and 2) ELISA and spectrophotometric detection of norovirus.

[00172] The term “epitope” or “epitopes”, as used herein, refers to a structural part of an antigen to which an antibody specifically binds.

[00173] With reference to Figure 6E, an immune response is observed following the administration of GI.1 VP1 VLPs, produced as described herein, to mice. Mice immunized with plant-made Norovirus native VP1 VLPs from GI.1 genotype exhibited GI.1 VLP-specific IgG antibody titers in sera on Days 21 and 42. IgG titer levels induced by each treatment on Days 21 and 42 were statistically higher than the titers quantified for the placebo group ($p < 0.05$). IgG titer level increased in a dose-dependent manner with a significant difference observed between the 1 μ g and 10 μ g treatments. The addition of Alhydrogel to the Norovirus VLP vaccine enhanced the immune response. These results demonstrate the ability of plant produced Norovirus native VP1 VLPs to elicit a robust immune response in mice. Similar results are observed with the administration of VP1 fusion proteins produced as described herein.

[00174] Plant expression

[00175] The constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, etc. For reviews of such techniques see for example Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academy Press, New York VIII, pp. 421-463 (1988); Geierman and Corey, *Plant Molecular Biology*, 2d Ed. (1988); and Miki and Iyer, Fundamentals of Gene Transfer in Plants. In *Plant*

Metabolism, 2d Ed. DT. Dennis, DH Turpin, DD Lefebvre, DB Layzell (eds), Addison Wesley, Langmans Ltd. London, pp. 561-579 (1997). Other methods include direct DNA uptake, the use of liposomes, electroporation, for example using protoplasts, micro-injection, microprojectiles or whiskers, and vacuum infiltration. See, for example, Bilang, et al. (1991, *Gene* 100: 247-250), Scheid et al. (1991, *Mol. Gen. Genet.* 228: 104-112), Guerche et al. (1987, *Plant Science* 52: 111-116), Neuhauser et al. (1987, *Theor. Appl Genet.* 75: 30-36), Klein et al. (1987, *Nature* 327: 70-73); Freeman et al. (1984, *Plant Cell Physiol.* 29: 1353), Howell et al. (1980, *Science* 208: 1265), Horsch et al. (1985, *Science* 227: 1229-1231), DeBlock et al. (1989, *Plant Physiology* 91: 694-701), *Methods for Plant Molecular Biology* (Weissbach and Weissbach, eds., Academic Press Inc., 1988), *Methods in Plant Molecular Biology* (Schuler and Zielinski, eds., Academic Press Inc., 1989), WO 92/09696, WO 94/00583, EP 331083, EP 175966, Liu and Lomonosoff (2002, *J Virol Meth.* 105:343-348), EP 290395; WO 8706614; U.S. Pat. Nos. 4,945,050; 5,036,006; and 5,100,792, U.S. patent application Ser. Nos. 08/438,666, filed May 10, 1995, and 07/951,715, filed Sep. 25, 1992, (all of which are hereby incorporated by reference).

[00176] Transient expression methods may be used to express the constructs of the present invention (see D' Aoust et al., 2009, *Methods in molecular biology*, Vol 483, pages41-50; Liu and Lomonosoff, 2002, *Journal of Virological Methods*, 105:343-348; which is incorporated herein by reference). Alternatively, a vacuum-based transient expression method, as described by Kapila et al. (1997, *Plant Sci.* **122**, 101-108; which is incorporated herein by reference), or WO 00/063400, WO 00/037663 (which are incorporated herein by reference) may be used. These methods may include, for example, but are not limited to, a method of Agro-inoculation or Agro-infiltration, syringe infiltration, however, other transient methods may also be used as noted above. With Agro-inoculation, Agro-infiltration, or syringe infiltration, a mixture of *Agrobacteria* comprising the desired nucleic acid enter the intercellular spaces of a tissue, for example the leaves, aerial portion of the plant (including stem, leaves and flower), other portion of the plant (stem, root, flower), or the whole plant. After crossing the epidermis the *Agrobacteria* infect and transfer t-DNA copies into the cells. The t-DNA is episomally transcribed and the mRNA translated, leading to

the production of the protein of interest in infected cells, however, the passage of t-DNA inside the nucleus is transient.

[00177] Also considered part of this invention are transgenic plants, plant cells or seeds containing the gene construct of the present invention that may be used as a platform plant suitable for transient protein expression described herein. Methods of regenerating whole plants from plant cells are also known in the art (for example see Guerineau and Mullineaux (1993, Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). In general, transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be used to establish repetitive generations, either from seeds or using vegetative propagation techniques. Transgenic plants can also be generated without using tissue culture. Methods for stable transformation, and regeneration of these organisms are established in the art and known to one of skill in the art. Available techniques are reviewed in Vasil et al. (Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications, Academic Press, 1984), and Weissbach and Weissbach (Methods for Plant Molecular Biology, Academic Press, 1989). The method of obtaining transformed and regenerated plants is not critical to the present invention.

[00178] If plants, plant portions or plant cells are to be transformed or co-transformed by two or more nucleic acid constructs, the nucleic acid construct may be introduced into the *Agrobacterium* in a single transfection event so that the nucleic acids are pooled, and the bacterial cells transfected. Alternatively, the constructs may be introduced serially. In this case, a first construct is introduced into the *Agrobacterium* as described, the cells are grown under selective conditions (e.g. in the presence of an antibiotic) where only the singly transformed bacteria can grow. Following this first selection step, a second nucleic acid construct is introduced into the *Agrobacterium* as described, and the cells are grown under doubly-selective

conditions, where only the doubly-transformed bacteria can grow. The doubly-transformed bacteria may then be used to transform a plant, plant portion or plant cell as described herein, or may be subjected to a further transformation step to accommodate a third nucleic acid construct.

5 [00179] Alternatively, if plants, plant portions, or plant cells are to be transformed or co-transformed by two or more nucleic acid constructs, the nucleic acid construct may be introduced into the plant by co-infiltrating a mixture of *Agrobacterium* cells with the plant, plant portion, or plant cell, each *Agrobacterium* cell may comprise one or more constructs to be introduced within the plant. In order to vary the relative expression levels within the plant, plant portion or plant cell, of a nucleotide sequence of interest within a construct, during the step of infiltration, the concentration of the various *Agrobacteria* populations comprising the desired constructs may be varied.

[00180] Table 1: Norovirus strains and constructs.

Trivial name	strain	SEQ ID NO:	Construct #	Figure #
VP1				
GI.1 (VP1; aa)	GI.1/Norwalk/1968/US	1	--	13A
GI.1 (VP1; na)	Wild type GI.1/Norwalk/1968/US	13		13B
GI.1 hCod (VP1; na)	VP1-hCod GI.1/US/Norwalk/1968	18	2724	13C
GI.2 (VP1; aa)	GI.2/Leuven/2003/Bel	2	--	14A
GI.2 (VP1; na)	hCod GI.2/Leuven/2003/Bel	54	3300	14B
GI.3 (VP1; aa)	GI.3/S29/2008/Lilla Edet/Sweden	3	--	15A
GI.3 (VP1; na)	hCod VP1 GI.3/S29/2008/Lilla Edet/Sweden	55	3302	15B
GI.5 (VP1; aa)	GI.5/Siklos/Hun5407/2013/HUN	44		16A
GII.1 (VP1; aa)	GII.1/Ascension208/2010/USA	45		16B
GII.2 (VP1; aa)	GII.2/CGMH47/2011/TW	66		16C
GII.3 (VP1; aa)	GII.3/Jingzhou/2013402/CHN	67		16D
GII.4 Syd12 (VP1; aa)	GII.4/Sydney/NSW0514/2012/AU	4	--	17A
GII.4 (VP1; na)	hCod VP1 GII.4/Sydney/NSW0514/2012/AU	56	3304	17B
GII.4 US96 (VP1; aa)	GII.4/Dresden174/1997/DE (variant: US 1995/96)	8	--	21A
GII.4 FH02 (VP1; aa)	GII.4/FarmingtonHills/2002/US	9	--	21B
GII.4 Hnt04 (VP1; aa)	GII.4/Hunter-NSW504D/2004/AU	10	--	21C
GII.4 2006b (VP1; aa)	GII.4/Shellharbour-NSW696T/2006/AU	11	--	21D
GII.4 NO09 (VP1; aa)	GII.4/Orange-NSW001P/2008/AU (variant New Orleans 2009)	12	--	21E
GII.5 (VP1; aa)	GII.5/AlbertaEI390/2013/CA	68		16E
GII.6 (VP1; aa)	GII.6/Ohio/490/12	5		18A
GII.6 (VP1; na)	hCod GII.6/Ohio/490/12	60	3306	18B
GII.7 (VP1; aa)	GII.7/Musahimurayama/2010/JP	69		16F

GII.12 (VP1; aa)	GII.12/HS206/2010/USA	28		22A
GII.13 (VP1; aa)	GII.13/VA173/2010/USA	6		19A
GII.13 (VP1; na)	hCod GII.13/VA173/2010/USA	61	3308	19B
GII.14 (VP1; aa)	GII.14/8610/Saga/2008/JP	46		22B
GII.17 (VP1; aa)	GII.17/Kawasaki323/2014/JP	7		20A
GII.17 (VP1; na)	hCod GII.17/Kawasaki323/2014/JP	62	3310	20B
GII.21 (VP1; aa)	GII.21/Salisbury150/2011/USA	47		22C
VP1 consensus (aa)	VP1 consensus sequence	70	--	16G
VP2				
GI.1 (VP2; aa)	VP2 GI.1/US/Norwalk/1968	14		23A
GI.1 (VP2; na)	VP2-GI.1/US/Norwalk/1968	15	2721	23B
GI.1 hCod (VP2; na)	VP2-hCod GI.1/US/Norwalk/1968	19	2725	23C
GII.4 hCod (VP2; na)	VP2 hCod GII.4/Sydney/NSW0514/2012/AU	120	3305	23D
GII.4 (VP2; aa)	VP2 GII.4/ Sydney/NSW0514/2012/AU	121		23E
VP1 fusions				
S(GI.1)+P(GI.2) (aa)	S(GI.1 Nor/68) +P (GI.2/Leuven/03)	22		25A
S(GI.1)+P(GI.2) (na)	hCod S(GI.1 Nor/68) +P (GI.2/Leuven/03)	57	3360	25B
S(GI.1)+P(GI.3) (aa)	S(GI.1 Nor/68) +P (GI.3/S29/08/Lilla Edet)	23	--	26A
S(GI.1)+P(GI.3) (na)	hCod S(GI.1 Nor/68) +P (GI.3/S29/08/Lilla Edet)	58	3361	26B
S(GI.1)+P(GII.4) (aa)	S(GI.1 Nor/68) +P (GII.4/Sydney/NSW0514/12)	24	--	27A
S(GI.1)+P(GII.4) (na)	hCod S(GI.1 Nor/68) +P (GII.4/Sydney/NSW0514/12)	59	3362	27B
S(GI.1)+P(GII.6) (aa)	S(GI.1 Nor/68) +P(GII.6/Ohio/490/12)	25	--	28A
S(GI.1)+P(GII.6) (na)	hCod S(GI.1 Nor/68) +P(GII.6/Ohio/490/12)	63	3363	28B
S(GI.1)+P(GII.12)(aa)	S(GI.1 Nor/68) +P (GII.12/HS206/2010/USA)	71	--	31A
S(GI.1)+P(GII.13) (aa)	S(GI.1 Nor/68) +P (GII.13/VA173/10)	26	--	29A
S(GI.1)+P(GII.13) (na)	hCod S(GI.1 Nor/68) +P (GII.13/VA173/10)	64	3364	29B
S(GI.1)+P(GII.17) (aa)	S(GI.1 Nor/68) +P (GII.17/Kawasaki323/14)	27	--	30A
S(GI.1)+P(GII.17) (na)	hCod S(GI.1 Nor/68) +P (GII.17/Kawasaki323/14)	65	3365	30B
S(GI.5)+P(GII.4) (aa)		48		31B
S(GII.1)+P(GI.3) (aa)		49		32A
S(GII.1)+P(GII.4) (aa)		50		32B
S(GII.1)+P(GII.17) (aa)		51		32C
S(GII.12)+P(GI.1) (aa)		29	--	33A
S(GII.12)+P(GI.2) (aa)		30	--	33B
S(GII.12)+P(GI.3) (aa)		31	--	33C
S(GII.12)+P(GI.5) (aa)		32	--	33D
S(GII.12)+P(GII.1) (aa)		33	--	33E
S(GII.12)+P(GII.2) (aa)		34	--	33F
S(GII.12)+P(GII.3) (aa)		35	--	33G
S(GII.12)+P(GII.4) (aa)		36	--	33H
S(GII.12)+P(GII.5) (aa)		37	--	33I

S(GII.12)+P(GII.6) (aa)		38	--	33J
S(GII.12)+P(GII.7) (aa)		39	--	33K
S(GII.12)+P(GII.13) (aa)		40	--	33L
S(GII.12)+P(GII.14) (aa)		41	--	33M
S(GII.12)+P(GII.17) (aa)		42	--	33N
S(GII.12)+P(GII.21) (aa)		43	--	33O
S(GII.14)+P(II.4) (aa)		52		34A
S9GII.21)+P(GII.4) (aa)		53		34B
S-P boundary				
S-P GI.1	S-P GI.1/Norwalk/1968/US	88	--	4A
S-P GI.2	S-P GI.2/Leuven/2003/Bel	89	--	4A
S-P GI.3	S-P GI.3/S29/2008/Lilla Edet/Sweden	90	--	4A
S-P GII.4	S-P GII.4/Sydney/NSW0514/2012/AU	91	--	4A
S-P GII.6	S-P GII.6/Ohio/490/12	92	--	4A
S-P GII.13	S-P GII.13/VA173/2010/USA	93	--	4A
S-P GII.17	S-P GII.17/Kawasaki323/2014/JP	94	--	4A
S-P boundary consensus		95		4A
ORF2/ORF3				
GI.1 VP1/VP2 (na)	GI.1/US/Norwalk/1968	16	2722	24A
GI.1 VP1/VP2/3'UTR (na)	GI.1/US/Norwalk/1968	17	2723	24B
GI.1 hCod VP1/VP2 (na)	hCod GI.1/US/Norwalk/1968	20	2726	24C
GI.1 hCod VP1/VP2/3'UTR (na)	hCod GI.1/US/Norwalk/1968	21	2727	24D
Primers				
IF- NoV(US68)VP1(ORF2).c		72		7A
IF- NoV(US68)VP1(ORF2).r		73		7B
IF- NoV(US68)VP1(ORF2)(h Cod).c		76		9A
IF- NoV(US68)VP1(ORF2)(h Cod).r		77		9B
IF- NoV(US68)VP2(ORF3)(h Cod).c		79		10A
IF- NoV(US68)VP2(ORF3)(h Cod).r		80		10B
IF-GI2Leu03VP1.c		82		11A
IF-GI2Leu03VP1.r		83		11B
GI2Leu+GI1VP1.r		85		12A
GI1VP1+GI2Leu.c		86		12B
IF-GI3Lil08VP1.c		111		35
IF-GI3Lil08VP1.r		98		35
IF-GII4Syd12VP1.c		112		35
IF-GII4Syd12VP1.r		101		35
IF-GII6Ohi12VP1.c		113		35
IF-GII6Ohi12VP1.r		104		35
IF-GII13VA10VP1.c		114		35
IF-GII13VA10VP1.r		107		35

IF-GII17Kaw14VP1.c		115		35
IF-GII17Kaw14VP1.r		110		35
GI3Lil+GI1VP1.r		96		35
GI1VP1+GI3Lil.c		97		35
GII4Syd+GI1VP1.r		99		35
GI1VP1+GII4Syd.c		100		35
GII6Ohi+GI1VP1.r		102		35
GI1VP1+GII6Ohi.c		103		35
GII13Va+GI1VP1.r		105		35
GI1VP1+GII13Va.c		106		35
GII17Kaw+GI1VP1.r		108		35
GI1VP1+GII17Kaw.c		109		35
IF-GII4Syd12VP2.c		117		35
IF-GII4Syd12VP2.r		119		35
IF- NoV(US68)VP2(ORF3).c		116		35
IF- NoV(US68)VP2(ORF3).r		122		
IF- NoV(US68)VP1/VP2(ORF3)NoV3'UTR.r		118		35
Constructs				
2X35S/CPMV-160/NOS (na)	2X35S/CPMV-160/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor	74	1190	7C
2X35S-WT VP1 GI.1/Norwalk/1968/US-NOS terminator (na)	2X35S promoter to NOS terminator. Wild-type VP1 from Norovirus GI.1/Norwalk/1968/US strain	75	2720	8A
2X35S-hCod-optimized VP1 GI.1/Norwalk/1968/US-NOS terminator	2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.1/Norwalk/1968/US	78	2724	9C
2X35S-hCod-optimized VP2 GI.1/Norwalk/1968/US-NOS terminator	2X35S promoter to NOS terminator. Human codon-optimized VP2 from Norovirus GI.1/Norwalk/1968/US	81	2725	10C
2X35S-hCod optimized VP1 GI.2/Leuven/2003/Bel-NOS terminator	2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.2/Leuven/2003/Bel	84	3300	11C
2X35S-hCod-optimized fusion VP1 S(GI.1)+P(GI.2)- NOS terminator	2X35S promoter to NOS terminator. Human codon-optimized fusion VP1 S(GI.1)+P(GI.2)	87	3360	12C

[00181] The present invention will be further illustrated in the following examples.

Example 1: Norovirus VP1 Constructs

5 [00182] The candidate sequences for VP1 and VP2 are available in Genbank (see Figures 2A and 2B). Non-limiting examples of these sequences are:

- [00183] GI.1/Norwalk/1968/US (GI.1) NCBI M87661 (SEQ ID NO:1); VP1
- [00184] GI.2/Leuven/2003/Bel (GI.2) NCBI FJ515294 (SEQ ID NO:2)
- [00185] GI.3/S29/2008/Lilla Edet/Sweden NCBI JN603244 (SEQ ID NO:3)
- [00186] GI.5/Siklos/Hun5407/2013/HUN (SEQ ID NO:44)
- 5 [00187] GII.1/Ascension208/2010/USA (SEQ ID NO:45)
- [00188] GII.2/CGMH47/2011/TW (SEQ ID NO:66)
- [00189] GII.3/Jingzhou/2013402/CHN (SEQ ID NO:67)
- [00190] GII.4/Sydney/NSW0514/2012/AU NCBI JX459908 (SEQ ID NO:4)
- [00191] GII.5/AlbertaEI390/2013/CA (SEQ ID NO:68)
- 10 [00192] GII.6/Ohio/490/2012/USA NCBI KC464321 (SEQ ID NO:5; VP1),
NCBI J407072 (VP2)
- [00193] GII.7/Musahimurayama/2010/JP (SEQ ID NO:69)
- [00194] GII.12/HS206/2010/USA (SEQ ID NO:28)
- [00195] GII.13/VA173/2010/USA NCBI JN899242 (SEQ ID NO:6)
- 15 [00196] GII.14/8610/Saga/2008/JP (SEQ ID NO:46)
- [00197] GII.17/Kawasaki323/2014/JP NCBI AB983218 (SEQ ID NO:7)
- [00198] GII.21/Salisbury 150/2011/USA NCBI XX (SEQ ID NO:47)
- A2X35S/CPMV 160/ wt VP1 GI.1/ NOS (Construct number 2720)
- [00199] A wild-type sequence encoding VP1 from Norovirus strain
- 20 GI.1/Norwalk/1968/US was cloned into 2X35S/CPMV 160/NOS expression system
using the following PCR-based method. A fragment containing the GI.1 VP1 coding
sequence was amplified using primers IF-NoV(US68)VP1(ORF2).c (SEQ ID NO: 72)
and IF-NoV(US68)VP1(ORF2).r (SEQ ID NO: 73), using native GI.1 VP1 gene
sequence (SEQ ID NO: 13; Figure 13B) as template. The PCR product was cloned in
- 25 2X35S/CPMV 160/NOS expression system using In-Fusion cloning system
(Clontech, Mountain View, CA). Construct number 1190 (Figure 7D) was digested
with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-
Fusion assembly reaction. Construct number 1190 is an acceptor plasmid intended for
“In Fusion” cloning of genes of interest in a 2X35S/CPMV 160/NOS-based

expression cassette (for a description of CMPV 160 see WO2015/103704 and WO2015/143567; both of which are incorporated herein by reference). It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in SEQ ID NO: 74 (Figure 7C). The resulting construct was given number 2720 (SEQ ID NO: 75; Figure 8A). The amino acid sequence of native VP1 from Norovirus strain GI.1/Norwalk/1968/US is presented in SEQ ID NO: 1. A representation of plasmid 2720 is presented in Figure 8B.

2X35S/CPMV 160/ VP1 GI.1 (hCod)/ NOS (Construct number 2724)

[00200] A human codon-optimized sequence encoding VP1 from Norovirus strain GI.1/Norwalk/1968/US was cloned into 2X35S/CPMV 160/NOS expression system using the following PCR-based method. A fragment containing the GI.1 VP1 coding sequence was amplified using primers IF-NoV(US68)VP1(ORF2)(hCod).c (SEQ ID NO: 76) and IF-NoV(US68)VP1(ORF2)(hCod).r (SEQ ID NO: 77), using human codon-optimized GI.1 VP1 gene sequence (SEQ ID NO: 18; Figure 13C) as template. For sequence optimization, GI.1/Norwalk/1968/US VP1 protein sequence (Genbank accession number NP_056821) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV 160/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1190 (Figures 7C and 7D) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1190 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a 2X35S/CPMV 160/NOS-based expression cassette (For a description of CMPV 160 see WO2015/103704 and WO2015/143567; both of which are incorporated herein by reference). It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in SEQ ID NO: 74. The resulting construct was given number 2724 (SEQ ID NO: 78; Figure 9C). The amino acid sequence of native VP1 from Norovirus strain

GI.1/Norwalk/1968/US is presented in SEQ ID NO: 1. A representation of plasmid 2724 is presented in Figure 9D.

2X35S/CPMV 160/ VP2 GI.1 (hCod)/ NOS (Construct number 2725)

[00201] A human codon-optimized sequence encoding VP2 from Norovirus strain GI.1/Norwalk/1968/US was cloned into 2X35S/CPMV 160/NOS expression system using the following PCR-based method. A fragment containing the GI.1 VP2 coding sequence was amplified using primers IF-NoV(US68)VP2(ORF3)(hCod).c (SEQ ID NO: 79) and IF-NoV(US68)VP2(ORF3)(hCod).r (SEQ ID NO: 80), using human codon-optimized GI.1 VP2 gene sequence (SEQ ID NO: 19; Figure 23C) as template. For sequence optimization, GI.1/Norwalk/1968/US VP2 protein sequence (Genbank accession number NP_056822) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV 160/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1190 (Figures 7C and 7D) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1190 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a 2X35S/CPMV 160/NOS-based expression cassette (for a description of CPMV 160 see WO2015/103704 and WO2015/143567; both of which are incorporated herein by reference). It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in SEQ ID NO: 74. The resulting construct was given number 2725 (SEQ ID NO: 81; Figure 10C). The amino acid sequence of native VP2 from Norovirus strain GI.1/Norwalk/1968/US is presented in SEQ ID NO: 14. A representation of plasmid 2725 is presented in Figure 10D.

2X35S/CPMV 160/ VP1 GI.2 (hCod)/ NOS (Construct number 3300)

[00202] A human codon-optimized sequence encoding VP1 from Norovirus strain GI.2/Leuven/2003/Bel was cloned into 2X35S/CPMV 160/NOS expression system using the following PCR-based method. A fragment containing the GI.2 VP1 coding sequence was amplified using primers IF-GI2Leu03VP1.c (SEQ ID NO: 82)

and IF-GI2Leu03VP1.r (SEQ ID NO: 83), using human codon-optimized GI.2 VP1 gene sequence (SEQ ID NO: 54; Figure 14B) as template. For sequence optimization, GI.2/Leuven/2003/Bel VP1 protein sequence (Genbank accession number ACU56258) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV 160/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1190 (Figures 7C and 7D) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1190 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a 2X35S/CPMV 160/NOS-based expression cassette (for a description of CPMV 160 see WO2015/103704 and WO2015/143567; both of which are incorporated herein by reference). It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCambia binary plasmid and the sequence from left to right t-DNA borders is presented in SEQ ID NO: 74. The resulting construct was given number 3300 (SEQ ID NO: 84; Figure 11C). The amino acid sequence of native VP1 from Norovirus strain GI.2/Leuven/2003/Bel is presented in SEQ ID NO: 2. A representation of plasmid 3300 is presented in Figure 11D.

[00203] A summary of the primers and templates used to prepare the above VP1 and VP2 constructs described above is provided in Table 2 below.

[00204] Norovirus VP1 Fusion Constructs

2X35S/CPMV 160/ fusion VP1 S(GI.1)+P(GI.2) (hCod)/ NOS (Construct number 3360)

[00205] A human codon-optimized sequence encoding fusion VP1 comprising of S domain from Norovirus strain GI.1/Norwalk/1968/US fused to P domain from Norovirus strain GI.2/Leuven/2003/Bel (VP1 S(GI.1)+P(GI.2)) was cloned into 2X35S/CPMV 160/NOS expression system using the following PCR-based method. In a first round of PCR, a fragment containing S domain from Norovirus strain GI.1/Norwalk/1968/US was amplified using primers IF-NoV(US68)VP1(ORF2).c (SEQ ID NO: 72) and GI2Leu+GI1VP1.r (SEQ ID NO: 85), using human codon-

optimized GI.1 VP1 gene sequence (SEQ ID NO: 18; Figure 13C) as template. A second fragment containing the P domain of GI.2/Leuven/2003/Bel was amplified using GI1 VP1+GI2Leu.c (SEQ ID NO: 86) and IF-GI2Leu03VP1.r (SEQ ID NO: 83), using human codon-optimized GI.2 VP1 gene sequence (SEQ ID NO: 54; Figure 14B) as template. For sequence optimization, GI.1/Norwalk/1968/US VP1 protein sequence (Genbank accession number NP_056821) and GI.2/Leuven/2003/Bel VP1 protein sequence (Genbank accession number ACU56258) were backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR products from both amplifications were then mixed and used as template for a second round of amplification using IF-NoV(US68)VP1(ORF2).c (SEQ ID NO: 72) and IF-GI2Leu03VP1.r (SEQ ID NO: 83) as primers. The final PCR product was cloned in 2X35S/CPMV 160/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1190 (Figure 7D) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1190 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a 2X35S/CPMV 160/NOS-based expression cassette (for a description of CMPV 160 see WO2015/103704 and WO2015/143567; both of which are incorporated herein by reference). It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in SEQ ID NO: 74, Figure 7C. The resulting construct was given number 3360 (SEQ ID NO: 87; Figure 12C). The amino acid sequence of fusion VP1, VP1 S(GI.1)+P(GI.2) is presented in SEQ ID NO: 22 (Figure 25A). A representation of plasmid 3360 is presented in Figure 12D.

[00206] A summary of the VP1 fusion proteins, primers, templates and products is provided in Table 2 below. The VP1 fusion proteins were constructed using the same methods as described above, with reference to construct # 3360.

Table 2: Summary of VP1 and VP2 proteins of interest, primers, templates, construct numbers, and final sequence identifiers of the resulting proteins. Each construct also comprises a 2X 35S promoter, a CPMV-160 5'UTR*, a CPMV 3' UTR, a Poly-A linker and a NOS terminator.

Protein of Interest	Construct No	Primer 1*	Primer 2**	Primer 3***	Primer 4^	Template ^^	Resulting protein (s)
NoV (Gl.1/US/68) VP1 (hCod)	2724	76	N/Ap~	N/Ap	77	18	SEQ ID NO: 1
NoV (Gl.2 Leu03) VP1 (Opt)	3300	82	N/Ap	N/Ap	83	54	SEQ ID NO: 2
NoV (Gl.3 Lii08) VP1 (Opt)	3302	111	N/Ap	N/Ap	98	55	SEQ ID NO: 3
NoV (Gl.4 Syd12) VP1 (Opt)	3304	112	N/Ap	N/Ap	101	56	SEQ ID NO: 4
NoV (Gl.6 Ohi12) VP1 (Opt)	3306	113	N/Ap	N/Ap	104	60	SEQ ID NO: 5
NoV (Gl.13 VA10) VP1 (Opt)	3308	114	N/Ap	N/Ap	107	61	SEQ ID NO: 6
NoV (Gl.17 Kaw14) VP1 (Opt)	3310	115	N/Ap	N/Ap	110	62	SEQ ID NO: 7
NoV (Gl.1/US/68) VP2	2721	116	N/Ap	N/Ap	122	13	SEQ ID NO: 14
NoV (Gl.1/US/68) VP2 (hCod)	2725	79	N/Ap	N/Ap	80	19	SEQ ID NO: 14
VP1 S(Gl.1)+P(Gl.2)	3360	76	85	86	83	18 (S) and 54 (P)	SEQ ID NO: 22
VP1 S(Gl.1)+P(Gl.3)	3361	76	96	97	98	18 (S) and 55 (P)	SEQ ID NO: 23
VP1 S(Gl.1)+P(Gl.4)	3362	76	99	100	101	18 (S) and 56 (P)	SEQ ID NO: 24
VP1 S(Gl.1)+P(Gl.6)	3363	76	102	103	104	18 (S) and 60 (P)	SEQ ID NO: 25
VP1 S(Gl.1)+P(Gl.13)	3364	76	105	106	107	18 (S) and 61 (P)	SEQ ID NO: 26

VP1 S(GI.1)+P(GII.17)	3365	76	108	109	110	18 (S) and 62 (P)	SEQ ID NO: 27
NoV (GI.1/US/68) VP1/2	2722	72	N/Ap	N/Ap	122	17	SEQ ID NO: 1 and 14
NoV (GI.1/US/68) VP1/2/3'UTR	2723	72	N/Ap	N/Ap	118	17	SEQ ID NO: 1 and 14
NoV (GI.1/US/68) VP1/2 (hCod)	2726	76	N/Ap	N/Ap	80	21	SEQ ID NO: 1 and 14
NoV (GI.1/US/68) VP1/2 (hCod)/3'UTR	2727	76	N/Ap	N/Ap	118	21	SEQ ID NO: 1 and 14
NoV (GI.1/US/68) VP1	2720	72	N/Ap	N/Ap	73	13	SEQ ID NO: 1
NoV (GII.4 Syd12) VP2 (Opt)	3305	117	N/Ap	N/Ap	119	120	SEQ ID NO: 121

*^ For a description of CMPV 160 see WO2015/103704 and WO2015/143567 (both of which are incorporated herein by reference)

* For In-fusion cloning; SEQ ID NO:

** To amplify S domain with primer 1; SEQ ID NO:

*** To amplify P domain with primer 4; SEQ ID NO:

^ For In-fusion cloning; SEQ ID NO:

^^ Complete VP1, S domain or P domain; SEQ ID NO:)

~ Not Applicable

Example 2: Methods

Agrobacterium tumefaciens Transfection

[00207] *Agrobacterium tumefaciens* strain AGL1 was transfected by electroporation
5 with the native norovirus VP1, native norovirus VP2, or norovirus VP1 fusion protein
expression vectors using the methods described by D'Aoust *et al.*, 2008 (*Plant
Biotech. J.* 6:930-40). Transfected *Agrobacterium* were grown in YEB medium
supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES), 20 μ M
acetosyringone, 50 μ g/ml kanamycin and 25 μ g/ml of carbenicillin pH5.6 to an OD₆₀₀
10 between 0.6 and 1.6. *Agrobacterium* suspensions were centrifuged before use and
resuspended in infiltration medium (10 mM MgCl₂ and 10 mM MES pH 5.6).

[00208] Preparation of Plant Biomass, Inoculum and Agroinfiltration

[00209] *N. benthamiana* plants were grown from seeds in flats filled with a
commercial peat moss substrate. The plants were allowed to grow in the greenhouse
15 under a 16/8 photoperiod and a temperature regime of 25° C. day/20° C. night. Three
weeks after seeding, individual plantlets were picked out, transplanted in pots and left
to grow in the greenhouse for three additional weeks under the same environmental
conditions

[00210] *Agrobacteria* transfected with each native norovirus VP1, native norovirus
20 VP2, or norovirus VP1 fusion expression vector were grown in a YEB medium
supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES), 20 μ M
acetosyringone, 50 μ g/ml kanamycin and 25 μ g/ml of carbenicillin pH5.6 until they
reached an OD₆₀₀ between 0.6 and 1.6. *Agrobacterium* suspensions were centrifuged
before use and resuspended in infiltration medium (10 mM MgCl₂ and 10 mM MES
25 pH 5.6) and stored overnight at 4° C. On the day of infiltration, culture batches were
diluted in 2.5 culture volumes and allowed to warm before use. Whole plants of *N.
benthamiana* were placed upside down in the bacterial suspension in an air-tight
stainless steel tank under a vacuum of 20-40 Torr for 2-min. Plants were returned to
the greenhouse for a 6 or 9 day incubation period until harvest.

[00211] Leaf Harvest and Total Protein Extraction

[00212] Following incubation, the aerial part of plants was harvested, frozen at -80°C . and crushed into pieces. Total soluble proteins were extracted by homogenizing (Polytron) each sample of frozen-crushed plant material in 3 volumes of cold 100 mM NaOAc pH 5.2 + 150 mM NaCl, 0.4 $\mu\text{g/ml}$ Metabisulfite and 1 mM phenylmethanesulfonyl fluoride. After homogenization, the slurries were centrifuged at 10,000 g for 10 min at 4°C . and these clarified crude extracts (supernatant) kept for analyses.

[00213] The total protein content of clarified crude extracts was determined by the Bradford assay (Bio-Rad, Hercules, California) using bovine serum albumin as the reference standard. Proteins were separated by SDS-PAGE under reducing conditions using Criterion™ TGX Stain-Free™ precast gels (Bio-Rad Laboratories, Hercules, CA) and proteins were visualized with Gel Doc™ EZ imaging system (Bio-Rad Laboratories, Hercules, CA) and electrotransferred onto polyvinylene difluoride (PVDF) membranes (Roche Diagnostics Corporation, Indianapolis, Indiana) for immunodetection. Prior to immunoblotting, the membranes were blocked with 5% skim milk and 0.1% Tween-20 in Tris-buffered saline (TBS-T) for 16-18 h at 4°C .

[00214] Protein Analysis and Immunoblotting

[00215] Immunoblotting was performed with a first incubation with a primary mAb 242P antibody specific to VP1 from GI and GII genotypes, diluted 1/500 in 2% skim milk in TBS-Tween 20 0.1%. Peroxydase-conjugated goat anti-mouse (Jackson ImmunoResearch, cat #115-035-146) diluted 1/10000 was used as secondary antibody for chemiluminescence detection were as indicated in Table 4, diluted as indicated in 2% skim milk in TBS-Tween 20 0.1% Immunoreactive complexes were detected by chemiluminescence using luminol as the substrate (Roche Diagnostics Corporation). Horseradish peroxidase-enzyme conjugation of human IgG antibody was carried out by using the EZ-Link Plus® Activated Peroxidase conjugation kit (Pierce, Rockford, Ill.).

[00216] Analysis of VLP Formation/Iodixanol Gradients

[00217] Proteins were extracted from frozen biomass by mechanical extraction in a blender with 2 volumes of extraction buffer (100 mM NaOAc pH 5.2 + 150 mM NaCl). The slurry was filtered through a large pore nylon filter to remove large debris and centrifuged 5000 g for 5 min at 4°C. The supernatant was collected and
5 centrifuged again at 5000 g for 30 min (4°C) to remove additional debris. The supernatant is then loaded on a discontinuous iodixanol density gradient. Analytical density gradient centrifugation was performed as follows: 38 ml tubes containing discontinuous iodixanol density gradient in acetate buffer (1 ml at 45%, 2 ml at 35%, 2 ml at 33%, 2 ml at 31%, 2 ml at 29% and 5 ml at 25% of iodixanol) were prepared
10 and overlaid with 25 ml of the extracts containing the rotavirus-like particles. The gradients were centrifuged at 175 000 g for 4 hours (4°C). After centrifugation, 1 ml fractions were collected from the bottom to the top and fractions were analyzed by SDS-PAGE combined with protein staining or Western blot.

[00218] Electron microscopy

[00219] Following centrifugation of partially clarified plant extracts on
15 discontinuous iodixanol density gradients, as described above, fractions (1 ml/fraction) containing the samples were pooled, mixed with 100 mM PBS pH 7.2 + 150 mM NaCl buffer to completely fill the tube and centrifuged 120 minutes at 100000g. The pellets were re-suspended in 300-1000 µl of buffer depending of the
20 VP1 quantity.

[00220] Carbon-coated copper grids with a 200 nm mesh size were made hydrophilic by placing the carbon side face up on a Whatman paper in a petri dish and incubating overnight at 4 deg C. Pooled fractions (20 µl) from density gradient
25 centrifugation to be observed by transmission electron microscopy (TEM) were deposited on a Parafilm and grids were floated with the carbon side facing down and incubated at room temperature for 5 minutes. Grids were washed 4 times on 20 µl water droplet and the excess water from the last wash drained by touching a Whatman paper with the side of the grid. Grids were incubated 1 minute on a 20 µl droplet of
30 2% uranyl acetate in water. Grids were allowed to dry 5 minutes on a Whatman paper. Observation was performed under transmission electron microscopy at magnifications ranging from 10,000X to 150,000X.

Example 3: VP1 protein production in plants

[00221] *N. benthamiana* leaves were, vacuum infiltrated, as described in Example 2, with *Agrobacterium tumefaciens* comprising expression vectors encoding wildtype GI.1 VP1 as a single nucleic acid construct, GI.1 VP2 (GI.1/Norwalk/1968/US; SEQ ID NO:15, Figure 23B) as a single nucleic acid construct, both GI.1 VP1 and VP2, with VP1 and VP2 nucleic acid sequences introduced in separate vectors (“VP1+/VP2”; dual constructs), or on the same vector (“VP1/VP2” or “VP1/VP2/3’UTR”; single nucleic acid constructs) to permit co-expression of the VP1 and/or VP2 sequences, and the leaves examined for VP1 and VP2 production. After 6 or 9 days post infiltration (6 DPI and 9 DPI, respectively), total crude protein extracts were prepared from leaf homogenates, separated by SDS-PAGE, and stained with Coomassie Brilliant Blue dye. The results are shown in Figure 3A,

[00222] Leaves infiltrated with expression vectors comprising nucleotide sequences that correspond to wildtype GI.1 VP1 (GI.1/Norwalk/1968/US; SEQ ID NO:13; Figure 13B), produced low or non-detectable levels of GI.1 VP1 as determined using Coomassie stained gels. See lanes 3-4, 7-10 and 19-20 of Figure 3A. VP1 expression was observed when expression was assayed by Western analysis (data not provided).

[00223] Leaves infiltrated with expression vectors comprising GI.1 VP1 nucleotide sequences that were codon optimized for human expression (hCod GI.1/Norwalk/1968/US; SEQ ID NO:18; Figure 13C), or enriched for GC content when compared to the GC content of the wildtype VP1 nucleic acid sequence (hCod), produced increased amounts of GI.1 VP1 protein (see lanes 11, 12, 21, 22; “VP1”, 55-70 kDa band, Figure 3A).

[00224] Leaves infiltrated with vectors comprising either wildtype GI.1 VP1 (GI.1/Norwalk/1968/US; SEQ ID NO:13; Figure 13B) and VP2 (GI.1/Norwalk/1968/US; SEQ ID NO:15, Figure 23B; see lanes 7-10, Figure 3A) or human codon optimized GI.1 VP1 and VP2 (lanes 15-18, Figure 3A; dual nucleic acid

constructs) produced low or non-detectable levels of GI.1 VP1 protein in Coomassie stained gels.

[00225] Co-expression of human codon optimized GI.1 VP1 (GI.1/Norwalk/1968/US; SEQ ID NO:13; Figure 13B) and GI.1 VP2 (GI.1/Norwalk/1968/US; SEQ ID NO:15, Figure 23B) using separate vectors resulted in production of increased amounts of VP1 protein of approx. 55-60kDa (lanes 21-22, Figure 3A; single nucleic acid constructs). These data show that VP1 protein can be expressed in plants in the presence or absence of VP2 co-expression.

Norovirus VP1 VLPs

[00226] Components of crude plant extracts prepared from *N. benthamiana* leaves expressing GI.1 VP1 (single nucleic acid human codon optimized constructs; hCod GI.1/Norwalk/1968/US; SEQ ID NO:18; Figure 13C), or single nucleic acid human codon optimized constructs one vector comprising VP1 (hCod GI.1/Norwalk/1968/US; SEQ ID NO:18; Figure 13C) and the second vector comprising VP2 (GI.1/Norwalk/1968/US; SEQ ID NO:19, Figure 23C), were separated using discontinuous iodixanol density gradients as described in Example 2. Fractions following density gradient centrifugation were examined using Coomassie-stained SDS-PAGE analysis. The results are shown in Figure 3B (upper panel), with norovirus VP1 proteins, of approx. 55-60kDa band, observed in in high density (33% and 36%) fractions.

[00227] The protein components from the high density iodixanol gradient fractions were analyzed by scanning electron microscopy Figure 3B; lower panel). Norovirus VP1 proteins and norovirus VP1+VP2 proteins were found to self- assemble into VLPs in plants. The isolated VLPs exhibit a structural conformation similar to that of wildtype norovirus GI.1 virion particles (insert, Figure 3B).

[00228] Example 4: Differential Expression of Norovirus VP1 in Plants

[00229] The expression levels of norovirus human codon optimized sequences encoding VP1 protein from norovirus strains, GI.1/Norwalk/1968/US (SEQ ID NO:18; Figure 13C), GI.2/Leuven/2003/Bel (SEQ ID NO:54; Figure 14B),

GI.3/S29/2008/Lilla Edet/Sweden (SEQ ID NO:55; Figure 15B),
 GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:56; Figure 17B), GII.6/Ohio/490/12
 (SEQ ID NO:60; Figure 18B), GII.13/VA173/2010/USA (SEQ ID NO:61; Figure
 19B), and GII.17/Kawasaki323/2014/JP (SEQ ID NO:62; Figure 20B), were
 5 compared in *N. benthamiana*. VP1 protein production was determined using
 Coomassie-stained SDS-PAGE analysis of extracts obtained from plant leaves
 vacuum infiltrated with expression vectors as described in Example 2. The results are
 presented in Figures 5A and 5B

[00230] Strong, or high, VP1 protein production was observed when human codon
 10 optimized GI.1/Norwalk/1968/US (SEQ ID NO:18), GI.3/S29/2008/Lilla
 Edet/Sweden (SEQ ID NO:55), GII.13/VA173/2010/USA (SEQ ID NO:61), and
 good, or medium, expression of VP1 was observed when GI.2/Leuven/2003/Bel (SEQ
 ID NO:54), were expressed in plant leaves (Figures 5A and 5B). Low or non-
 detectable amount of VP1 protein production was observed in plant leaves expressing
 15 human codon optimized GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:56),
 GII.6/Ohio/490/12 (SEQ ID NO:60), and GII.17/Kawasaki323/2014/JP (SEQ ID
 NO:62).

[00231] Strong, or high expression of GI.5/Siklos/HUN5407/2013/HUN;
 GII.1/Ascension208/2010/USA; GII.12/HS206/2010/USA; GII.12/HS206/2010/USA;
 20 and GII.21/Salisbury150/2011/USA, and good or medium expression of
 GII.2/CGMH47/2011/TW; GII.5/AlbertaE1390/2013/CA;
 GII.7/Musashimurayama/2010/JP, was also observed in plants.

[00232] Electron micrographs (prepared as described in Example 2), of high density
 iodixanol gradient fractions of several human codon optimized VP1 preparations were
 25 observed following expression of the following norovirus strains in plants (see
 Figures 5C, 5D, 6A (left hand panel) and Figure 6B (left hand panel):

- GI.2/Leuven/2003/Bel (SEQ ID NO's: 2 (aa) and 54 (na); Figure 14B);
- GI.3 S29/2008/Lilla Edet/Sweeden (SEQ ID NO:3 (aa);55 (na); Figure 15B);
- GI.5 Siklos/HUN5407/2013/HUN (SEQ ID NO:44; Figure 16A);

- GII.1 Ascension208/2010/USA SEQ ID NO:45; Figures 16B);
- GII.7 Musashimurayama/2010/JP (SEQ I NO:69; Figure 16F)
- GII.12 HS206/2010/USA (SEQ ID NO:28 , Figure 22A);
- GII.13 VA173/2010/USA (SEQ ID NO:61 , Figure 19B);
- GII.14 8610/Saga/2008/JPN (SEQ ID NO:46 , Figure 22B); and
- GII.21 Salisbury150/2011/USA (SEQ ID NO:47 , Figure 22B).

[00233] VP1 proteins derived from the above strains were observed to self-assembled into VLPs having a structural conformation and diameter of about 15 nm to 50 nm (for example, of either about 23 nm, for T=1 icosahedral symmetry; or about 38 to 40 nm, for T=3 icosahedral symmetry), similar to that of wildtype norovirus.

Example 5: VP1 fusion protein production in plants

[00234] *N. benthamiana* leaves were, vacuum infiltrated, as described in Example 2, with *Agrobacterium tumefaciens* comprising expression vectors encoding VP1 fusion proteins described below were co-expressed with VP2 (GI.1/Norwalk/1968/US; SEQ ID NO:15, Figure 23B). Nucleic acid segments encoding VP1 fusion proteins and VP2 were provided to the plants as a nucleic acid complex. After 6 or 9 days post infiltration (6 DPI and 9 DPI, respectively), total crude protein extracts were prepared from leaf homogenates, separated by SDS-PAGE, and stained with Coomassie Brilliant Blue dye to determine VP1 fusion protein production. Additionally electron micrographs of high density iodixanol gradient fractions of several VP1 fusion products were also prepared. The results are shown in Figures 5A, 5B, 5E, 6A (right hand panel), 6B (right hand panel), Figure 6C and 6D.

[00235] Leaves were infiltrated with expression vectors (nucleic acid complex) comprising human codon optimized nucleotide sequences encoding VP1 fusion of the GI.1 Norwalk S domain (GI.1/Norwalk/1968/US (SEQ ID NO:18; Figure 13C), to the P domain of:

- GI.2/Leuven/2003/Bel (SEQ ID NO:54; Figure 14B); to produce “GI.1-GI.2”, comprising S(GI.1)+P(GI.,2); SEQ ID NO’s 22(aa), 57(na);
- GI.3/S29/2008/Lilla Edet/Sweden (SEQ ID NO:55; Figure 15B); to produce “GI.1-GI.3”, comprising S(GI.1)+P(GI.3); SEQ ID NO’s: 23 (aa) and 58 (na);
- GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:56; Figure 17B); to produce “GI.1+GII.4”, comprising S(GI.1)+P(GII.4); SEQ ID NO’s: 24 (aa) and 59 (na);
- GII.6/Ohio/490/12 (SEQ ID NO:60; Figure 18B); to produce “GI.1+GII.6”, comprising S(GI.1)+P(GII.6); SEQ ID NO’s:25 (aa) and 63(na);
- GII.13/VA173/2010/USA (SEQ ID NO:61; Figure 19B); to produce “GI.1S+GII.13P”, comprising S(GI.1)+P(GII.13); SEQ ID NO’s:26 (aa) and 64 (na); and
- GII.17/Kawasaki323/2014/JP (SEQ ID NO:62; Figure 20B); to produce “GI.1+GII.17”, comprising S(GI.1)+P(GII.17); SEQ ID NO’s:27 (aa) and 65 (na).

[00236] In this example, VP1 and VP2 nucleic acid segments, with each nucleic acid segment comprising a regulatory region and a terminator, were introduced into the plants as a nucleic acid complex. As described below, with reference to Figure 5E, when VP1 fusion proteins are expressed in plants, it is preferred that the ORF3 sequence encoding VP2 is obtained from the same norovirus strain as used to obtain the S domain of fusion VP1 sequence.

[00237] Expression of VP1 fusion proteins comprising S(GI.1)+P(GI.,2), S(GI.1)+P(GI.3), S(GI.1)+P(GII.4), S(GI.1)+P(GII.13), S(GI.1)+P(GII.17), when co-expressed with VP2, resulted in similar or greater levels of expression of norovirus VP1 fusion proteins as compared to their native non-fusion counterparts (see Example 3; Figures 5A and 5B). These results demonstrate that VP1 fusion proteins may be expressed in a plant, portion of a plant, or a plant cell. Expression of the VP1 fusion proteins S(GI.1)+P(GII.6) was below detection levels (Figure 5B).

[00238] Electron micrographs (prepared as described in Example 2), of high density iodixanol gradient fractions of several human codon optimized VP1 fusion preparations were prepared as shown in Figure 6A (right hand panel), Figure 6B (right hand panel), Figure 6C (left and right hand panel) and 6D. VP1 fusion proteins

derived from S(GI.1)+P(GI.2), S(GI.1)+P(GII.3), S(GI.1)+P(GII.13),
S(GI.1)+P(GII.17) and S(GI.1) +P(GII.4), and co-expressed with VP2, were observed
to self-assembled into VLPs having a structural conformation and diameter of about
15 nm to 50 nm, for example, of either about 23 nm, for T=1 icosahedral symmetry;
or about 38 to 40 nm, for T=3 icosahedral symmetry, similar to that of wildtype
norovirus.

[00239] Even though protein product was below detectable levels using SDS-PAGE
analysis for the VP1 fusion S(GI.1) +P(GII.4) (S(GI.1 Nor/68)+P
(GII.4/Sydney/NSW0514/12; SEQ ID NO:59, Figure 27B) in Figure 5A, and for
S(GI.1)+P(GII.17) (S(GI.1 Nor/68)+P (GII.17/Kawasaki323/14; SEQ ID NO:65,
Figure 30B) in Figure 5B, VLPs comprising S(GI.1) +P(GII.4) and
S(GI.1)+P(GII.17) VP1 fusion protein could be purified from plant extracts (see
Figures 6C and 6D). However, no VLPs were detected from plant extracts expressing
S(GI.1)+P(GII.6) consistent with the low or undetectable expression levels of this
VP1 fusion protein (Figure 5B).

[00240] Additional nucleic acid segments encoding human codon optimized VP1
fusion proteins were prepared and co-expressed with nucleic acid segments encoding
VP2, in *N. benthamiana* leaves, as described above. These VP1 fusion proteins
included:

S(GI.1)+P(X), where X= GI.2, GI.3, GII.4, GII.6, GII.12, GII.13, GII.17;

S(GI.5)+P(Y), where Y= GII.4;

S(GII.1)+P(Z), where Z= GI.3, GII.4, GII.17;

S(GII.12)+P(W), where W= GI.1, GI.2, GI.3, GI.5, GII.1, GII.2, GII.3, GII.4,
GII.5, GII.6, GII.7, GII.13, GII.14, GII.17, GII.21;

S(GII.14)+P(T), where T= GII.4;

S(GII.21)+P(Q), where Q= GII.4

[00241] After 6 or 9 days post infiltration (6 DPI and 9 DPI, respectively) with the
nucleic acid coomplex, total crude protein extracts were prepared from leaf

homogenates, separated by SDS-PAGE, and stained with Coomassie Brilliant Blue dye to determine VP1 fusion protein production. Expression levels of the various VP1 fusion proteins was determined from the Coomassie stained gels. Additionally electron micrographs of high density iodixanol gradient fractions of several VP1 fusion products were also prepared.

[00242] Expression of various a nucleic acid segments encoding VP1 fusion proteins, comprising an S domain fused with heterologous P domain, with both domains obtained from VP1 proteins from a range of norovirus strains was observed, including, an S domain from GI.1, GI.5, GII.1, GII.12, GII.14 and GII.21, and a P domain obtained from GI.1, GI.2, GI.3, GI.5, GII.1, GII.2, GII.4, GII.6, GII.7, GII.12, GII.13, GII.14, GII.17 and GII.21. For example S(GI.1)+P(GI.2), S(GI.1)+P(GI.3), S(GI.1)+P(GII.4), S(GI.1)+P(GII.6), S(GI.1)+P(GII.12), S(GI.1)+P(GII.13), S(GI.1)+P(GII.17); S(GI.5)+P(GII.4); S(GII.1)+P(GI.3), S(GII.1)+P(GII.4), S(GII.12)+P(GI.1), S(GII.12)+P(GI.2), S(GII.12)+P(GI.3), S(GII.12)+P(GI.5), S(GII.12)+P(GII.1), S(GII.12)+P(GII.2), S(GII.12)+P(GII.4), S(GII.12)+P(GII.7), S(GII.12)+P(GII.13), S(GII.12)+P(GII.14), S(GII.12)+P(GII.17), S(GII.12)+P(GII.21), when co-expressed with a nucleic acid segment encoding VP2.

[00243] For example, strong, or high levels of expression of VP1 fusion protein in plants was observed using nucleic acid segments encoding: S(GI.1/US/68)+P(X); or S(GI.5/Siklos/HUN5407/2013/HUN)+P(Y), or S(GII.1/Ascension208/2010/USA)+P(Z); S(GII.12/HS206/2010/USA)+P(W); where:

X= P(GI.2/Leuven/2003/BEL); P(GII.4/Sydney/NSW0514/2012/AU); P(GII.12/HS206/2010/USA); P(GII.13/ VA173/2010/USA);

Y= P(GII.4/Sydney/NSW0514/2012/AU);

Z= P(GI.3/ S29/2008/Lilla Edet/Sweedden); or

W= P(GI.1/US/68); P(GI.3/S29/2008/Lilla Edet/Sweedden); P(GI.5/Siklos/HUN5407/2013/HUN); P(GII.1/Ascension208/2010/USA); P(GII.13/VA173/2010/USA); P(GII.14/8610/Saga/2008/JPN); P(GII.21/Salisbury 150/2011/USA).

[00244] Good, or medium levels of expression levels in plants were observed using nucleic acid segments encoding VP1 fusion proteins comprising:

S(GI.1/US/68)+P(X); S(GII.12/HS206/2010/USA)+P(W); or

S(GII.14/8610/Saga/2008/JPN)+P(T), where:

5 X= P(GI.3/S29/2008/Lilla Edet/Sweedden); P(GII.6/Ohio/490/2012/USA);
P(GII.17/Kawasaki323/2014/JP);

W=P(GI.2/Leuven/2003/BEL); P(GII.2/CGMH47/2011/TW);
P(GII.7/Musashimurayama/2010/JP); P(GII.17/Kawasaki323/2014/JP); or

T= P(GII.4/Sydney/NSW0514/2012/AU).

10 [00245] Expression that was below detectable levels was observed with nucleic acid segments encoding VP1 fusion proteins comprising:

S(GII.12/HS206/2010/USA)+P(GII.4/Sydney/NSW0514/2012/AU);

S(GII.1/Ascension208/2010/USA+ P(GII.4/Sydney/NSW0514/2012/AU); or

S(GII.21/Salisbury150/2011/USA)+ P(GII.4/Sydney/NSW0514/2012/AU).

15 [00246] These results demonstrate that VP1 fusion proteins comprising various combinations of S domains and P domains may be produced when expressed in plants.

Increased expression of VLPs comprising Norovirus VP1 fusion proteins and VP2 native proteins from the S domain genotype

20 [00247] The expression of a nucleic acid complex comprising norovirus nucleic acid segments encoding VP1 protein or VP1 fusion proteins co-expressed with a nucleic acid segment encoding VP2, were compared in *N. benthamiana* as described in Example 2. VP1 or VP1 fusion protein production was determined using

25 Coomassie-stained SDS-PAGE analysis of extracts obtained from plant leaves vacuum infiltrated with expression vectors were loaded onto discontinuous iodixanol density gradients. Fractions collected from the bottom to the top and fractions were analyzed by SDS-PAGE. The following constructs were expressed and analyzed:

VP1 GII.4: human codon optimized native VP1
 GII.4/Sydney/NSW0514/2012/AU (construct #3304; SEQ ID NO:56; Figure 17B)

VP1 GII.4 and VP2 GII.4: human codon optimized native VP1 co-expressed
 with human codon optimized native VP2 GII.4/Sydney/NSW0514/2012/AU
 (construct #3305; SEQ ID NO:120; Figure 23D);

VP1 fusion S(GI.1)+P(GII.4): human codon optimized VP1 S(GI.1)+P(GII.4)
 fusion protein (construct 3362; SEQ ID NO:59; Figure 27B);

VP1 fusion S(GI.1)+P(GII.4) and VP2 GI.1: human codon optimized native
 VP1 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B)
 co-expressed with human codon optimized native VP2 GI.1/Norwalk (construct
 #2725; SEQ ID NO:19; Figure 23C);

VP1 fusion S(GI.1)+P(GII.4) and VP2 GII.4: human codon optimized VP1
 S(GI.1)+P(GII.4) fusion protein (construct 3362; SEQ ID NO:59; Figure 27B) co-
 expressed with human codon optimized native VP2 GII.4/Sydney (construct #3305;
 SEQ ID NO:133; Figure 23D).

The results are presented in Figure 5E.

[00248] The level of expression of the human codon-optimized GII.4/Sydney
 native VP1 protein (construct #3304) is low when the GII.4 VP1 construct is
 expressed alone (Figure 5E; Panel A, left hand side). The level of expression of the
 same GII.4 VP1 (construct #3304) remains low when co-expressed with human
 codon-optimized native minor structural VP2 protein from the GII.4 genotype and
 strain (construct #3305; Figure 5E Panel A, left hand side). T

[00249] The level of expression of the VP1 fusion, human codon optimized
 VP1 S (GI.1)+P (GII.4; construct #3362), is greatly increased when compared to the
 native VP1 of the GII.4 genotype (Panel B, Figure 5E, left hand side). Furthermore,
 the level of expression of the VP1 fusion S(GI.1)+P(GII.4; construct #3362), when
 co-expressed with human codon-optimized VP2 from GI.1/Norwalk (construct
 #2725), that is where the S domain of the VP1 fusion and the VP2 protein are
 obtained from the same genotype and strain, resulted in even higher VLP yield (Panel

B; Figure 5E, right hand side) when compared to the expression of the VP1 fusion S(GI.1)+P(GII.4). Additionally, the VP2 minor structural protein is incorporated on the VLPs as it is visible at the correct protein size (21-24 kDa; indicated by a square; Figure 5E; Panel B right hand side, and Panel C left hand side) in the high-molecular weight fractions of the density gradient that contain Norovirus VLPs.

[00250] This production of VLPs when co-expressing a VP1 fusion having an S domain and VP2 from same genotype and strain is to be contrast with the co-expression of a VP1 fusion, human codon optimized VP1 S (GI.1)+P (GII.4; construct #3362) with human codon-optimized VP2 from GII.4/Sydney (construct #3305), where the S domain of the VP1 fusion and the VP2 protein are obtained from different genotypes and strains. Co-expression of VP1 fusion comprising an S domain with a VP2 obtained from a different genotype and strain resulted in a dramatic decrease in VLP production (Panel C; Figure 5E, right hand side), when compared to the co-expression of the VP1 fusion S(GI.1)+P(GII.4) and VP2 from GI.1/Norwalk, construct #2725; Panel C; Figure 5E, left hand side) where the S domain and the VP2 are obtained from the same genotype and strain.

[00251] Without wishing to be bound by theory, these results are consistent with the proposal that VP2 is located on the inside of the viral particle and that VP2 may play a role in particle stability. When VP1 fusion proteins are expressed in plants, it is preferred that the ORF3 sequence encoding VP2 is obtained from the same norovirus strain as used to obtain the S domain of fusion VP1 sequence.

Enhanced Stability of VLPs Comprising Norovirus VP1 Fusion Proteins

[00252] Levels of VLPs comprising of high-expressing native VP1 GI.1/Norwalk/1968/US (encoded by construct 2724; SEQ ID NO:78; Figure 9C) peaked in fractions four through eight following iodixanol gradient centrifugation (see Figure 3C upper panel). In contrast, VLPs comprising of native VP1 GI.2/Leuven/2003/Bel (encoded by construct 3300; SEQ ID NO:84; Figure 11C) Figure 3C lower panel, left hand side) peaked in lower-density fractions six through nine, suggesting that native GI.2 VLPs may be less stable, more susceptible to

malformed capsid particles and the generation of fragmentation products, or a combination thereof, when compared to GI.1 VLPs.

[00253] In contrast, increased stability of VP1 fusion protein was observed with VLPs comprising S(GI.1 Nor68) +P(GI.2 Leu03) norovirus VP1 fusion proteins (encoded by construct 3360; SEQ ID NO:87; Figure 12C). As shown in Figure 3C, (lower panel, right hand side) VP1 fusion protein peaked in fractions four through eight, indicating that VLPs comprising norovirus VP1 fusion proteins having a GI.1 S domain core maybe more stable than their native VLP counterparts where the S domain is not derived from GI.1.

[00254] A similar shift in density was also observed in VLPs comprising S(GI.1)+P(GI.3) norovirus VP1 fusion proteins GI.1 Nor68+GI.3 Lil08 (see Figure 6B, right hand pannel), encoded by construct 33601; SEQ ID NO:58; Figure 26B) when compared to expression of VP1 GI.3 Lil08 (SEQ ID NO:55; Figure 15B) as shown in Figure 6B (left hand panel).

Example 6: Immune response using VP1

[00255] Studies on the immune response to Norovirus native GI.1 (SEQ ID NO:1) VLP administration were performed with 6-8 week old female BALB/c mice (Charles River Laboratories). Thirty seven mice were randomly divided into four groups of eight animals for Norovirus VLP vaccine and a group of five animals for placebo. All groups were injected using intramuscular immunization. All groups were immunized in a two-dose regimen, the boost immunization being administered 3 weeks following the first immunization.

[00256] For intramuscular administration in hind legs, two groups (eight animals) of unanaesthetized mice were immunized with the plant-made VLP native VP1 from Norovirus GI.1 genotype vaccine (1 or 10 µg). Placebo group (five animals) was immunized using the same route and regimen as the candidate vaccine using vaccine buffer (PBS at pH 6.0). In a similar manner plant-produced VP1 fusion proteins as described herein, for example VP1 fusion proteins produced using construct #3360, 3361, 3361, 3363, 3364, 3365, or SEQ ID NO's: 22 to 27, 29 to 43, 49 to 53, and 71,

may also administered to mice following the same protocol as described in this example.

[00257] To measure the potential benefit of adjuvant, two groups of animals (8 animals) were immunized by intramuscular administration in hind legs on unanaesthetized mice with 1 or 10 µg plant-made VLP Norovirus vaccine plus one volume Alhydrogel 2% (alum, Cedarlane Laboratories Ltd., Burlington, Ontario, Canada). All groups were immunized according to a prime-boost regimen with the boost immunization performed 3 weeks following the first immunization.

[00258] Mice were evaluated through clinical observations during the in-life period as followed: daily monitoring for mortality and clinical signs, weekly detailed examinations, injection site observations and body weight measurements. All animals were under observation and sacrificed on Day 42 for gross examination. Blood was collected from all animals prior to dosing on Day 0, on Days 21 and 42 (21 days after each immunization). Samples were processed to isolate the serum for specific antibody response analyses.

[00259] Serum samples from blood collected on Days 21 and 42 from all animals were analyzed individually by ELISA for GI.1 VLP-specific total IgG and IgA antibodies using GI.1 VLP-coated plates. Pre-immune serum samples (Day 0 – prior dosing) collected from all animals were pooled by treatment group and each pool was analyzed to insure that they were negative (or below the cut-off value of the analytical test).

[00260] Descriptive statistics were performed using GraphPad Prism software (Version 6.05; GraphPad Software, La Jolla, CA, USA). Antibody titers measured for each group were reported as geometric mean titer (GMT) with 95 % confidence intervals (CI). Half of the value of the limit of detection was attributed to antibody titers below the limit of detection of the method specific to the tested antibodies. Therefore, in this study, an animal was considered to be a positive responder if its GMT value for a determined condition was equal or above the limit of detection of the method (LOQ = 100). Statistical comparisons between IgG titers of treatment groups were performed using one-way ANOVA followed by a Tukey's test on log10-transformed data. A comparison between the placebo group and each treatment group

was also performed using oneway ANOVA followed by a post hoc Dunnett's test on log10-transformed data.

[00261] The GI.1 VLP-specific total IgG titers that were measured in serum samples from all animals after IM immunization with one dose (Day 21) and two doses (Day 42) of 1 µg or 10 µg of each formulation. Total IgG titers were measured by ELISA using GI.1 VLP-coated plates (LOQ = 100). The results are present in Figure 6E. Total IgG titers per treatment group (n=8 animals/group) are represented by geometric mean titer (GMT) with a 95 % confidence interval. Statistical comparisons between IgG titers of treatment groups were performed using one-way ANOVA followed by a Tukey's test on log10-transformed data. A comparison between the placebo group and each treatment group was also performed using one-way ANOVA followed by a post-hoc Dunnett's test on log10-transformed data. Significant differences were annotated as letters in Figure 6E (the same letter indicates that no significant difference was detected between treatment groups; $p > 0.05$).

[00262] Mouse immune response to Norovirus native VP1 VLPs

[00263] As demonstrated in Figure 6E, mice immunized with plant-made Norovirus native VP1 VLPs from GI.1 genotype had shown GI.1 VLP-specific IgG antibody titers in sera and were detected for each treatment group on Days 21 and 42. IgG titer levels that were induced by each treatment on Days 21 and 42 were statistically higher than the titers quantified for the placebo group ($p < 0.05$). On each day, IgG titer level increased in a dose-dependent manner as demonstrated by the significant differences detected between the 1 µg and 10 µg treatments formulated with Alhydrogel or not ($p < 0.05$) and the addition of Alhydrogel to the NoV VLP vaccine enhanced significantly the induced immune response at doses of 1 µg and 10 µg ($p < 0.05$). A significant increase of IgG titer level was also detected for each treatment group between Days 21 and 42 ($p < 0.05$). These results collectively demonstrate the ability of plant produced Norovirus native VP1 VLPs to elicit a robust immune response in mice.

[00264] Similar results area observed with the administration of VP1 fusion proteins, VP1 fusion proteins produced for example, using construct #3360, 3361,

3361, 3363, 3364, 3365, or SEQ ID NO's: 22 to 27, 29 to 43, 49 to 53, and 71, as described herein.

[00265] All citations are hereby incorporated by reference.

5 [00266] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made to the described subject matter. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole

10

WHAT IS CLAIMED IS:

1. A nucleic acid encoding a norovirus VP1 fusion protein comprising, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain, the first and second sequence under the control of a promoter that is active in plants, the first and second sequence are selected from norovirus genogroups GI, GII, and GIV.
2. The nucleic acid of claim 1 wherein the first and second norovirus strains are selected from norovirus genotypes GI.1, GI.2, GI.3, GI.4, GI.5, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.12, GII.13, GII.14, GII.17 and GII.21.
3. The nucleic acid of claim 2 wherein the first norovirus strain and the second norovirus strain are selected from norovirus subtypes GI.1/US/1968; GI.2/Leuven/2003/Bel; GI.3/S29/2008/Lilla Edet/Sweden; I.5/AlbertaEI390/2013/CA; GII.1/Ascension208/2010/USA; GII.12/HS206/2010/USA; GII.13/VA173/2010/USA; GII.14/8610/Saga/2008/JPN; and GII.21/Salisbury 150/2011/USA.
4. The nucleic acid of claim 1 further comprising a third sequence encoding a CPMV enhancer, the CPMV enhancer operatively linked with the first and second sequences.
5. The nucleic acid of claim 1, where the first, the second, or both the first and second, sequence is optimized for human codon usage, increased GC content, or a combination thereof.
6. A norovirus VP1 fusion protein encoded by the nucleic acid of claim 1.
7. A virus like particle (VLP) comprising the norovirus VP1 fusion protein of claim 6.
8. The VLP of claim 7, further comprising a norovirus VP2 protein.
9. A method of producing a norovirus VP1 fusion protein in a plant, portion of a plant, or a plant cell comprising, introducing the nucleic acid of claim 1 into the plant, the portion of a plant, or the plant cell, and incubating the plant, the portion of a plant,

or the plant cell under conditions that permit the expression and production of the norovirus VP1 fusion protein.

10. The method of claim 9, wherein the method further comprises a step of harvesting the plant, the portion of a plant, or the plant cell.

5 11. The method of claim 10, wherein the method further comprises a step of extracting, purifying, or both extracting and purifying, the norovirus VP1 fusion protein from the plant, the portion of a plant, or the plant cell.

12. A norovirus VP1 fusion protein produced by the method of claim 11.

10 13. The method of claim 10, wherein the method further comprises a step of purifying a virus like particle (VLP) from the plant, the portion of a plant, or the plant cell, wherein the VLP comprises the norovirus VP1 fusion protein and has a diameter of about 15 nm to 50 nm.

14. A virus like particle (VLP) comprising the norovirus VP1 fusion protein produced by the method of claim 13.

15 15. The method of claim 13, wherein the VLP has a diameter of either about 23 nm or about 38nm.

20 16. The method of claim 9, wherein in the step of introducing, a second nucleic acid sequence encoding a norovirus VP2 protein is introduced in the plant, portion of the plant, or the plant cell, and in the step of incubating, the conditions permit co-expression and co-production, of both the norovirus VP1 fusion protein and the norovirus VP2 protein in the plant, the portion of a plant, or the plant cell.

17. The method of claim 16 further comprising a step of harvesting the plant, the portion of a plant, or the plant cell.

25 18. The method of claim 17 further comprising a step of extracting, purifying, or both extracting and purifying the norovirus VP1 fusion protein and norovirus VP2 protein.

19. The method of claim 17 further comprising a step of extracting, purifying, or both extracting and purifying a virus like particle (VLP) from the plant, the portion of a plant, or the plant cell, wherein the VLP comprises the norovirus VP1 fusion protein and the norovirus VP2 protein, and has a diameter of about 15 nm to 50 nm.

5 20. A virus like particle (VLP) comprising the norovirus VP1 fusion protein and the norovirus VP2 protein produced by the method of claim 19.

21. The method of claim 19, wherein the VLP has a diameter of either about 23 nm or about 38nm.

10 22. A method of producing an antibody or an antibody fragment comprising, administering the norovirus VP1 fusion protein of claim 6 to a subject in need thereof, or a host animal, thereby producing the antibody or the antibody fragment.

23. A method of producing an antibody or an antibody fragment comprising, administering the norovirus VP1 fusion protein of claim 12 to a subject in need thereof, or a host animal, thereby producing the antibody or the antibody fragment.

15 24. A method of producing an antibody or an antibody fragment comprising, administering the VLP of claim 7 into a subject in need thereof or a host animal, thereby producing the antibody or the antibody fragment.

20 25. A method of producing an antibody or an antibody fragment comprising, administering the VLP of claim 8 into a subject in need thereof or a host animal, thereby producing the antibody or the antibody fragment.

26. A method of producing an antibody or an antibody fragment comprising, administering the VLP of claim 14 into a subject in need thereof or a host animal, thereby producing the antibody or the antibody fragment.

25 27. A method of producing an antibody or an antibody fragment comprising, administering the VLP of claim 20 into a subject in need thereof or a host animal, thereby producing the antibody or the antibody fragment.

28. A plant, portion of the plant, or the plant cell comprising the norovirus VP1 fusion protein of claim 6.

29. A plant, portion of the plant, or the plant cell comprising the norovirus VP1 fusion protein of claim 12.
30. A plant, portion of the plant, or the plant cell comprising the VLP of claim 7.
31. A plant, portion of the plant, or the plant cell comprising the VLP of claim 8.
- 5 32. A plant, portion of the plant, or the plant cell comprising the VLP of claim 14.
33. A plant, portion of the plant, or the plant cell comprising the VLP of claim 20.
34. A plant, portion of the plant, or the plant cell comprising the nucleic acid of claim 1.
- 10 35. A plant extract comprising the norovirus VP1 fusion protein, or a virus like particle comprising the norovirus VP1 fusion protein, produced by the method of claim 9.
36. A plant extract comprising the norovirus VP1 fusion protein, or a virus like particle comprising the norovirus VP1 fusion protein, produced by the method of claim 10.
- 15 37. A plant extract comprising the norovirus VP1 fusion protein or VLP comprising the norovirus VP1 fusion protein, produced by the method of claim 17.
38. A composition for inducing an immune response comprising, an effective dose of the norovirus VP1 fusion protein of claim 6, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.
- 20 39. A composition for inducing an immune response comprising, an effective dose of the norovirus VP1 fusion protein of claim 12, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.
- 25 40. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 7, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.

41. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 8, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.
- 5 42. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 14, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.
43. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 20, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.
- 10 44. A vaccine comprising an effective dose of the norovirus VP1 fusion protein of claim 6 for inducing an immune response.
45. A vaccine comprising an effective dose of the norovirus VP1 fusion protein of claim 12 for inducing an immune response.
- 15 46. A vaccine comprising an effective dose of the VLP of claim 7 for inducing an immune response.
47. A vaccine comprising an effective dose of the VLP of claim 8 for inducing an immune response.
48. A vaccine comprising an effective dose of the VLP of claim 14 for inducing an immune response.
- 20 49. A vaccine comprising an effective dose of the VLP of claim 20 for inducing an immune response.
50. An antibody or antibody fragment prepared using the norovirus VP1 fusion protein of claim 6, wherein the antibody recognizes an epitope of the P domain.
- 25 51. An antibody or antibody fragment prepared using the norovirus VP1 fusion protein of claim 12, wherein the antibody recognizes an epitope of the P domain.
52. An antibody or antibody fragment prepared using the VLP of claim 7, wherein the antibody recognizes an epitope of the P domain.

53. An antibody or antibody fragment prepared using the VLP of claim 8, wherein the antibody recognizes an epitope of the P domain.

54. An antibody or antibody fragment prepared using the VLP of claim 14, wherein the antibody recognizes an epitope of the P domain.

5 55. An antibody or antibody fragment prepared using the VLP of claim 20, wherein the antibody recognizes an epitope of the P domain.

56. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the VLP of claim 7 to the subject.

10 57. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the VLP of claim 8 to the subject.

58. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the VLP of claim 14 to the subject.

59. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the VLP of claim 20 to the subject.

15 60. The method of claim 57, wherein the VLP is administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

20 61. A nucleic acid complex comprising, a VP1 sequence encoding a norovirus VP1 fusion protein, and a VP2 sequence encoding a norovirus VP2 protein, the VP1 sequence comprising a first and a second nucleic acid sequence, the first nucleic acid sequence encoding an S domain derived from a first norovirus strain, the second nucleic acid sequence encoding a P domain derived from a second norovirus strain, the VP2 sequence comprising a third nucleic acid sequence derived from the first norovirus strain and encoding the norovirus VP2 protein, wherein the VP1 sequence
25 is operatively linked to a first regulatory region, and the VP2 sequence is operatively linked to a second regulatory region, and the VP1 sequence and the VP2 sequence are located on one nucleic acid segment, or the VP1 sequence and the VP2 sequence are located on separate nucleic acid segments.

62. The nucleic acid complex of claim 61, wherein the first regulatory region, the second regulatory region, or the first and second regulatory region comprise a CPMV enhancer element operatively linked with a promoter active in the plant.

5 63. The nucleic acid complex of claim 62, wherein the first and the second regulatory region comprise the CPMV enhancer element, and the first and the second regulatory region comprise the same promoter.

64. The nucleic acid complex of claim 62, wherein the first and the second regulatory region comprise a CPMV enhancer element, and the CPMV enhancer sequence of the first and the second regulatory region is the same.

10 65. The nucleic acid complex of claim 61, wherein the first, the second, the third nucleic acid sequence, or all of the first, second and third nucleic acid sequence is optimized for human codon usage, increased GC content, or a combination thereof.

66. A virus like particle (VLP) comprising the norovirus VP1 fusion protein and the norovirus VP2 protein encoded by the nucleic acid complex of claim 61.

15 67. The VLP of claim 66, wherein the VLP has a diameter of about 15 nm to 50 nm.

68. A virus like particle (VLP) comprising the norovirus VP1 fusion protein and the norovirus VP2 protein encoded by the nucleic acid complex of claim 65.

20 69. The VLP of claim 68, wherein the VLP has a diameter of about 15 nm to 50 nm.

70. The VLP of claim 69, wherein the VLP has a diameter of either about 23 nm or about 38nm.

25 71. A method of producing a virus like particle (VLP) in a plant, portion of a plant, or a plant cell comprising, introducing the nucleic acid complex of claim 61 into the plant, the portion of a plant, or the plant cell, and incubating the plant, the portion of a plant, or the plant cell under conditions that permit the production of the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein.

72. The method of claim 71, wherein the method further comprises a step of harvesting the plant, the portion of a plant, or the plant cell.

73. The method of claim 72, wherein the method further comprises a step of extracting, purifying, or both extracting and purifying, the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein from the plant, the portion of a plant, or the plant cell.

74. The method of claim 73, wherein the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein has a diameter of about 15 nm to 50 nm.

75. A virus like particle (VLP) comprising the norovirus VP1 fusion protein and the norovirus VP2 protein produced by the method of claim 74.

76. The method of claim 74, wherein the VLP has a diameter of either about 23 nm or about 38nm.

77. A method of producing an antibody or an antibody fragment comprising, administering the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein of claim 66 to a subject in need thereof, or a host animal, thereby producing the antibody or the antibody fragment.

78. A plant, portion of the plant, or the plant cell comprising the VLP comprising the VP1 fusion protein and the norovirus VP2 protein of claim 66.

79. A plant, portion of the plant, or the plant cell comprising the nucleic acid complex of claim 61.

80. A plant extract comprising the VLP comprising the norovirus VP1 fusion protein and the norovirus VP2 protein, produced by the method of claim 73.

81. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 66, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.

82. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the composition of claim 81 to the subject.

83. The method of claim 82, wherein the composition is administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

5 84. A vaccine comprising an effective dose of the VLP of claim 66 for inducing an immune response.

85. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the vaccine of claim 84 to the subject.

10 86. The method of claim 85, wherein the vaccine is administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

87. An antibody or antibody fragment prepared using the VLP of claim 66, wherein the antibody recognizes an epitope of the P domain.

15 88. A method for inducing immunity to a norovirus infection in a subject, the method comprising administering the VLP of claim 66 to the subject.

89. The method of claim 88, wherein the VLP is administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

Figure 1A




Figure 1B




Figure 1C




FIGURE 2A

Norovirus VP1 major capsid amino acid sequences		
Access (Uniprot)	Access (NCBI)	Strain name
Q83884	NP_056821	Hu/GI.1/United States/Norwalk/1968
D2DEL3	ACU56258	Hu/GI.2/Leuven/2003/BEL
H2DG70	AEY77318	Hu/GI.3/S29/2008/Lilla Edet/Sweden
K4LM89	AFV08795	Hu/GII.4/Sydney/NSW0514/2012/AU
M9T020	AGI96397	Hu/GII.6/Ohio/490/2012/USA
H9AWU4	AFC89656	Hu/GII.13/VA173/2010/USA
A0A077KVU6	AID51513	Hu/GII.17/Kawasaki323/2014/JP

Norovirus VP2 major capsid amino acid sequences		
Access (Uniprot)	Access (NCBI)	Strain name
Q83885	NP_056822	Hu/GI.1/United States/Norwalk/1968
D2DEL4	ACU56259	Hu/GI.2/Leuven/2003/BEL
H2DG71	AEY77319	Hu/GI.3/S29/2008/Lilla Edet/Sweden
K4LB50	AFV08796	Hu/GII.4/Sydney/NSW0514/2012/AU
W6APLO	AHI59155	Hu/GII.6/HS245/2010/USA
H9AWU5	AFC89657	Hu/GII.13/VA173/2010/USA
A0A077KP84	BAP33935	Hu/GII.17/Kawasaki323/2014/JP

FIGURE 2B

DNA accession numbers for VP1 and VP2 gene sequences		
Genotype	Genome access no (NCBI)	Strain name
GI.1	M87661	Hu/GI.1/United States/Norwalk/1968
GI.2	FJ515294	Hu/GI.2/Leuven/2003/BEL
GI.3	JN603244	Hu/GI.3/S29/2008/Lilla Edet/Sweden
GII.4	JX459908	Hu/GII.4/Sydney/NSW0514/2012/AU
GII.6	KC464321 (VP1), KJ407072 (VP2)	Hu/GII.6/Ohio/490/2012/USA (VP1), Hu/GII.6/HS245/2010/USA (VP2)
GII.13	JN899242	Hu/GII.13/VA173/2010/USA
GII.17	AB983218	Hu/GII.17/Kawasaki323/2014/JP

FIGURE 2C

Norovirus VP1 major capsid protein homology							
	GI.1	GI.2	GI.3	GII.4	GII.6	GII.13	GII.17
GI.1		69.5%	65.8%	41.8%	44.2%	44.4%	44.7%
GI.2			66.1%	41.7%	42.1%	43.5%	43.2%
GI.3				43.3%	44.9%	43.5%	45.4%
GII.4					60.8%	62.3%	65.6%
GII.6						66.6%	71.5%
GII.13							75.7%

Norovirus VP2 minor capsid protein homology							
	GI.1	GI.2	GI.3	GII.4	GII.6	GII.13	GII.17
GI.1		70.4%	62.5%	31.1%	35.0%	36.3%	34.1%
GI.2			63.0%	30.6%	34.1%	36.6%	34.9%
GI.3				30.5%	34.2%	38.3%	31.7%
GII.4					52.4%	53.9%	57.3%
GII.6						62.6%	60.3%
GII.13							67.2%

FIGURE 2D

VP1 protein homology (GII.4 strains)						
	US96	FH02	Hnt04	2006b	NO09	Syd12
US96		95.4%	94.1%	93.1%	93.3%	92.4%
FH02			95.7%	95.0%	94.1%	93.1%
Hnt04				94.1%	93.9%	93.1%
2006b					95.2%	94.8%
NO09						97.4%
Syd12						

VP1 (P domain only) protein homology (GII.4 strains)						
	US96	FH02	Hnt04	2006b	NO09	Syd12
US96		93.7%	92.2%	89.7%	90.3%	88.7%
FH02			94.7%	92.5%	91.2%	90.3%
Hnt04				92.2%	91.5%	90.9%
2006b					93.4%	92.8%
NO09						96.9%
Syd12						

VP1 (P2 sub-domain only) protein homology (GII.4 strains)						
	US96	FH02	Hnt04	2006b	NO09	Syd12
US96		89.6%	86.1%	81.3%	83.3%	81.3%
FH02			91.0%	84.0%	83.3%	82.6%
Hnt04				86.1%	84.0%	84.0%
2006b					87.5%	87.5%
NO09						94.4%
Syd12						

FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 4A

	← S DOMAIN	P DOMAIN → 230	SEQ ID NO:
VP1_Norwalk_1968_GI_1_Q83884_Rf	LVPPTVE	QKTRPFTL	88
VP1_Leuven_2003_GI_2_D2DEL3	LVPPTIE	QKTRAFTV	89
VP1_LillaEdet_2008_GI_3_H2DG70	LVPPNVE	QKTKPFVS	90
VP1_Sydney_2012_GII_4_K4LM89	LVPPTVE	SRTKPFVS	91
VP1_Ohio_2012_GII_6_M9T020	VLPPTVE	SKTKPFSL	92
VP1_VA173_2010_GII_13_H9AWU4	LVPPSVE	SKTKPFTL	93
VP1_Kawasaki_2014_GII_17_A0A077KVU6	LVPPSVE	SKTKPFSL	94
CONSENSUS	LVPPTvE	sKTKpFsI	95

FIGURE 4B

Norovirus VP1 major capsid protein homology									
GI.1	S(GI.1) +P(GI.2)	S(GI.1) +P(GI.3)	S(GI.1) +P(GII.4)	S(GI.1) +P(GII.6)	S(GI.1) +P(GII.12)	S(GI.1) +P(GII.13)	S(GI.1) +P(GII.17)		
GI.1	75.8%	75.0%	60.4%	60.8%	62.6%	61.8%	62.4%		
S(GI.1) +P(GI.2)		74.6%	59.6%	59.1%	61.3%	60.5%	60.7%		
S(GI.1) +P(GI.3)			60.2%	61.2%	60.9%	60.2%	62.2%		
S(GI.1) +P(GII.4)				70.2%	75.0%	73.0%	76.1%		
S(GI.1) +P(GII.6)					76.6%	74.7%	79.1%		
S(GI.1) +P(GII.12)						78.3%	80.8%		
S(GI.1) +P(GII.13)							79.0%		

FIGURE 4C

Norovirus VP1 major capsid protein homology											
GII.12	S(GII.12) +P(GI.1)	S(GII.12) +P(GI.2)	S(GII.12) +P(GI.3)	S(GII.12) +P(GI.5)	S(GII.12) +P(GII.1)	S(GII.12) +P(GII.2)	S(GII.12) +P(GII.3)	S(GII.12) +P(GII.4)			
GII.12	62.2%	61.0%	60.7%	60.1%	86.9%	80.3%	77.1%	74.6%			
S(GII.12) +P(GI.1)								60.0%			
S(GII.12) +P(GI.2)								59.3%			
S(GII.12) +P(GI.3)								59.6%			
S(GII.12) +P(GI.5)								60.1%			
S(GII.12) +P(GII.1)								73.5%			
S(GII.12) +P(GII.2)								70.7%			
S(GII.12) +P(GII.3)								73.2%			
S(GII.12) +P(GII.5)	S(GII.12) +P(GII.6)	S(GII.12) +P(GII.7)	S(GII.12) +P(GII.13))	S(GII.12) +P(GII.14)	S(GII.12) +P(GII.17)	S(GII.12) +P(GII.21)					
GII.12	82.1%	76.2%	76.6%	77.9%	75.7%	80.4%	79.5%				
S(GII.12) +P(GII.3)	73.0%	70.0%	73.6%	72.8%	72.7%	76.0%	72.7%				

FIGURE 4D

Norovirus VP1 major capsid protein homology									
	GI.5	S(GI.5) +P(GII.4)	GII.1	S(GII.1) +P(GI.3)	S(GII.1) +P(GII.4)	S(GII.1) +P(GII.17)	GII.14	S(GII.14) +P(GII.4)	GII.21 S(GII.21) +P(GII.4)
GI.5		60.6%	45.7%	60.1%	44.6%	45.9%	46.0%	44.0%	45.9%
S(GI.5) +P(GII.4)			57.4%	44.3%	83.7%	60.1%	56.0%	83.2%	84.1%
GII.1				60.8%	73.3%	80.4%	69.0%	65.7%	66.7%
S(GII.1) +P(GI.3)					59.6%	61.9%	52.6%	52.2%	53.1%
S(GII.1) +P(GII.4)						76.0%	64.9%	92.4%	93.3%
S(GII.1) +P(GII.17)							68.5%	68.4%	71.3%
GII.14								72.5%	65.1%
S(GII.14) +P(GII.4)									63.8%
GII.21									91.3%
S(GII.21) +P(GII.4)									72.5%

FIGURE 5A




FIGURE 5B







FIGURE 5C




GI.3 S29/2008/Lilla Edet/Sweedén



GI.5 Siklos/HUN5407/2013/HUN




GI.1 Ascension208/2010/USA




GI.7 Musashimurayama/2010/JP


FIGURE 5D




GI.12 HS206/2010/USA



GI.14 8610/Saga/2008/JPN



GI.13 VA173/2010/USA



GI.21 Salisbury150/2011/USA

FIGURE 6A




FIGURE 6B




FIGURE 6C





FIGURE 6D



S(GI.1) +P(GII.4)
S(GI.1/Norwalk/68/US)+
P(GII.4 Sydney/NSW0514/2012/AU)

FIGURE 6E




Figure 7A

IF-NoV(US68)VP1(ORF2).c (SEQ ID NO: 72)

TCGTGCTTCGGCACCAAGTACAATGATGATGGCGTCTAAGGACGCTACAT

Figure 7B

IF-NoV(US68)VP1(ORF2).r (SEQ ID NO: 73)

ACTAAAGAAAATAGGCCTTTATCGGCGCAGACCAAGCCTACCTCTTGCCGAGCTGGCAG

Figure 7C

Construct 1190 from left to right t-DNA borders (underlined). 2X35S/CPMV-160/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette (SEQ ID NO: 74)

TGGCAGGATATATTGTGGTGTAACAAATTGACGCTTAGACAACCTTAATAACACATTGCGGACGTTTTAATGTACTGAATTAACG
CCGAATCCCGGGCTGGTATATTATATGTTGTCAAATAACTCAAAAACCATAAAAGTTAAGTTAGCAAGTGTGTACATTTTACTT
GAACAAAAATATTACCTACTACTGTTATAAATCATTATTAACATTAGAGTAAAGAAATATGGATGATAAGAACAAGAGTAGTGA
TATTTTGACAACAATTTTGTGCAACATTTGAGAAAATTTTGTGTTCTCTTTTCATTGGTCAAAAACAATAGAGAGAGAAAAAG
GAAGAGGGAGAATAAAAAACATAATGTGAGTATGAGAGAGAAAGTTGTACAAAAGTTGTACAAAATAGTTGTACAAATATCATT
GAGGAATTTGACAAAAGCTACACAAATAAGGGTTAATTGCTGTAAATAAATAAGGATGACGCATTAGAGAGATGTACCATTAGAG
AATTTTGGCAAGTCATTAATAAGAAAGAAATAAATTATTTTAAAAATTAAGGTTGAGTCATTTGATTAAACATGTGATTATTAAT
GAATTGATGAAAGAGTTGGATTAAAGTTGATTAGTAATTAGAATTTGGTGCAAAATTAATTGACATTTGATCTTTTCTATATA
TTGCCCATAGAGTCAGTTAACTCATTTTATATTTTCATAGATCAAATAAGAGAAATAACGGTATATTAATCCCTCAAAAAA
AACGGTATATTTACTAAAAATCTAAGCCACGTAGGAGGATAACAGGATCCCCGTAGGAGGATAACATCCAATCCAACCAATCAC
AACAATCCTGATGAGATAACCCACTTAAGCCACGCATCTGTGGCACATCTACATTATCTAAATCACACATTCTTCCACACATCTG
AGCCACACAAAAACCAATCCACATCTTTATCACCATTCTATAAAAAATCACACTTTGTGAGTCTACACTTTGATTCCCTTCAAACAC
ATACAAAGAGAAGAGACTAATTAATTAATTAATCATCTTGAGAGAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAAC
AAGCTAACAGTGAACGTTGGGATGGAGGATCAGGAGGTACCATTCTCCCTTCAAACCTTCTGACGAAAGTCCGAGTTGGACTGA
GTGGCGGCTACATAACGATGAGACGAATTCGAATCAAGATAATCCCTTGGTTTCAAGGAAAGCTGGGGTTTCGGGAAAGTTGTA
TTTAAGAGATATCTCAGATACGACAGGACGGAAGCTTCACTGCACAGAGTCCTTGGATCTTGGACGGGAGATTCCGTTAACTATG
CAGCATCTCGATTTTTCGGTTTCGACCAGATCGGATGTACCTATAGTAATTCGGTTTCGAGGAGTTAGTATCACCGTTTCTGGAGGG
TCGCGAACTCTTCAGCATCTCTGTGAGATGGCAATTCGGTCTAAGCAAGAACTGCTACAGCTTGCCCAATCGAAGTGGAAGTA
ATGTATCAAGAGGATGCCCTGAAGTACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTTAAATGCTTCTCTCTCTCTATTTATA
ATATGGTTTGTATTGTTAATTTTGTCTGTAGAAGAGCTTAATTAATCGTTGTTGTTATGAAATACTATTTGTATGAGATGAAGTG
GTGTAATGTAATTCATTACATAAGTGGAGTCAGAATCAGAATGTTTCTCCATAACTAAGTACATGAAGACCTGCCGCGTACA
ATTGCTTATATTTGAACAACTAAAATTGAACATCTTTGCCACAACCTTATAAGTGGTTAATATAGCTCAAATATATGGTCAAGTTC
AATAGATTAATAATGGAAATATCAGTTATCGAAATTCATTAACAATCAACTTAACGTTATTAAGTACTAATTTTATATCATCCCCTT
GATAAATGATAGTACACCAATTAGGAAGGAGCATGCTCGCCTAGGAGATTGTCGTTTCCGCTTCAGTTTCAAGCTGCTCTAGC
CGTGTAGCCAATACGCAACCGCTCTCCCGCGCGTTGGGAATTACTAGCGCGTGTGACAAAGCTTGCATGCCGGTCAACATGG
TGGAGCACGACACACTTGTCTACTCAAAAAATCAAGATACAGTCTCAGAAGACCAAGGGCAATTGAGACTTTTCAACAAAG
GGTAATATCCGGAACCTCCTCGGATTCATTGCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCT
ACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCAAAGATGGACCCCAACCCAC
GAGGAGCATCGTGGAAAAAGAACGTTCCAACACGCTCTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACAC
ACTTGTCTACTCAAAAAATCAAGATACAGTCTCAGAAGACCAAGGGCAATTGAGACTTTTCAACAAAGGGTAAATATCCGGA
AACCTCCTCGATTCCATTGCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATCA
TTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCAAAGATGGACCCCAACCCACGAGGAGCATCGT
GGAAAAAGAACGTTCCAACACGCTCTCAAAGCAAGTGGATTGATGTGATATCTCACTGACGTAAGGGATGACGCACAATCC
CACTATCCTTCGCAAGACCTTCTCTATATAAGGAAGTTCAATTTCAATTGGAGAGGTATTAATCTTAATAGGTTTTGATAAAG

CGAACGTGGGGAAACCCGAACAAACCTTCTCTAAACTCTCTCATCTCTCTTAAAGCAAACCTCTCTTGTCTTTCTTGCGTGA
GCGATCTTCAACGTTGTGAGATCGTGCTTCGGCACCGCGGATGCGAAAAACGTTGCGATTTTCGGCTTATTGTTTCTCTTCTGT
GTTGGTTCCTTCTCAGATCTTGCCTGCAGGCTCTCAGC AAAACGACACCCCATCTGTCTATCCACTGCCCCCTGGATCTGCTG
CCCCAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACCTGCGATC
CTGTCCAGCGGTGTGCACACCTTCCAGCTGTCTGCAAGTCTGACCTTACACTCTGAGCAGCTCAGTGACTGTCCCTCCAGCAC
TGGCCACGCGAGACCGTACCTGCAACGTTGCCACCCGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCAGGGATTGT
GGTTGTAAGCCTTGCATATGTACAGTCCAGAAATATCATCTGTCTTCTATTTCCCCCAAAGCCAAAGGATGTGCTACCATTA
CTGACTCCTAAGGTACAGTGTGTTGTGGTAGACATCAGCAAGGATGATCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGG
AGGTGCACACAGCTCAGACGCAACCCCGGAGGAGCAGTTCAACAGCACTTTCGGCTCAGTCAGTGAACCTCCCATCATGCACCA
GGACTGGCTCAATGGCAAGGAGCGATCGCTACCATCACCATCACCATCACCATTAAAGGCCATTTTCTTTAGTTTGAAI
TTACTGTTATTCGGTGTGCATTTCATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTATTTTATGTAATTTAATTTCTTTG
AGCTCCTGTTTAGCAGGTGTCCTTCAGCAAGGACACAAAAAGATTTTAATTTTATTA AAAAAAAAAAAAAAAAAAAGACCGGAA
TTCGATATCAAGCTATTCGACCTGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAAGATTGAATCCTGTTGCCGGTCTTGCGA
TGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGTTTTAT
GATTAGAGTCCCGCAATTATACATTTAATACGCGTAAAGAAAAACATATAGTCGCGCAAACTAGGATAAATTATCGCGCGCGGTG
TCATCTATGTACTAGATCTCTAGAGTCTCAAGCTTGGCGGCCACGTCAGTACTGTGGCACTGGCCGTCGTTTTACAACGTCGTGA
CTGGGAAAACCTGGCGTTACCAACTTAATCGCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCGCA
CCGATCGCCCTTCCAACAGTTGCGCAGCCTGAATGGCGAATGCTAGAGCAGCTTGAGCTTGATCAGATTGTCGTTTCCCGCCT
CAGTTTAAACTATCAGTGTGTGACAGGATATATTGGCGGGTAAACCTAAGAGAAAAAGAGCGTTTA

Figure 7D




Figure 8A

Expression cassette number 2720 from 2X35S promoter to NOS terminator. Wild-type VP1 from Norovirus GI.1/Norwalk/1968/US strain is underlined. (SEQ ID NO: 75)

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA
 TTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGA
 AGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTC
 TGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGAAAAAGAAGACGTTCCAACCACGTCT
 TCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGT
 CTCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAG
 CTATCTGTCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAG
 GCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGAAAAAG
 AAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCC
 CACTATCCTTCGCAAGACCCTTCTCTATATAAGGAAGTTCATTTCAATTTGGAGAGGTATTAATACTTAATAGGTTTT
 GATAAAGCGAACGTGGGGAACCCGAACCAACCTTCTTCAAACCTCTCTCATCTCTCTTAAAGCAAACCTCTCT
 CTTGTCTTTCTGCGTGAGCGATCTTCAACGTTGTGAGATCGTGCTTCGGCACCAGTACAATGATGATGGCGTCTAAG
GACGCTACATCAAGCGTGGATGGCGTAGTGGCGTGGTCAGTTGGTACCGGAGGTTAATGCTTCTGACCTCTTGC
AATGGATCCTGTAGCAGGTTCTTCGACAGCAGTCGCGACTGCTGGACAAGTTAATCCTATTGATCCCTGGATAATTA
ATAATTTTGTGCAAGCCCCCAAGGTGAATTTACTATTTCCCAAATAATACCCCGGTGATGTTTTGTTGATTTGAG
TTTGGTCCCATCTTAATCCTTTCTTGTCCATCTATCACAATGTATAATGGTTGGTTGGTAACATGAGAGTCAG
GATTATGCTAGCTGGAATGCCTTTACTGCGGGGAAGATAATAGTTTCTGCATACCCCTGGTTTTGGTTACATAA
TCTTACTATAGCACAAGCAACTCTTTCCACATGTGATTGCTGATGTTAGGACTCTAGACCCATTGAGGTGCCTTT
GGAAGATGTTAGGAATGTTCTTTTATAATAATGATAGAAATCAACAAACCATGCGCCTTGTGTGCATGCTGTACA
CCCCCTCCGCACTGGTGGTGGTACTGGTGATTCTTTGTAGTTGCAGGGCGAGTTATGACTTGCCCCAGTCCTGATT
TTAATTTCTTGTTTTAGTCCCTCTACGGTGGAGCAGAAAACAGGCCCTTCACACTCCCAAATCTGCCATTGAGTTC
TCTGTCTAACTCACGTGCCCTCTCCCAATCAGTAGTATGGGCATTTCCCAGACAATGTCCAGAGTGTGCAGTTCCA
AAATGGTCGGTGTACTCTGGATGGCCGCTGGTTGGCACCACCCAGTTTCATTGTCACATGTTGCCAAGATAAGAG
GGACCTCCAATGGCACTGTAATCAACCTTACTGAATTGGATGGCACACCTTTACCCCTTTGAGGGCCCTGCCCCA
TTGGGTTTCCAGACCTCGGTGGTTGTGATTGGCATATCAATATGACACAGTTTGGCCATTCTAGCCAGACCCAGTAT
GATGTAGACACCACCCCTGACACTTTTGTCCCCATCTTGGTTCAATTCAGGCAAATGGCATTGGCAGTGGTAATTAT
GTTGGTGTTCTTAGCTGGATTTCCCCCATCACACCCGTCTGGCTCCCAAGTTGACCTTTGGAAGATCCCAATTAT
GGGTCAAGTATTACGGAGGCAACACATCTAGCCCTTCTGTATACCCCTGGTTTCGGAGAGGTATTGGTCTTTTTC
ATGTCAAAAATGCCAGGTCTGGTGCTTATAATTTGCCCTGTCTATTACCACAAGAGTACATTTACATCTTGCTAGT
GAACAAGCCCCTACTGTAGGTGAGGCTGCCCTGCTCCACTATGTTGACCCTGATACCGGTGGAATCTTGGGGAATT
CAAAGCATACCCTGATGGTTTCTCACTTGTGTCCCAATGGGGCTAGCTCGGGTCCACAACAGCTGCCGATCAATG
GGGTCTTTGTCTTTGTTTCATGGGTGTCAGATTTTATCAATTAAGCCTGTGGGAAGTCCAGCTCGGCAAGAGGT
AGGCTTGGTCTGCGCCGATAAAGGCCTATTTTCTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGT
 GAGCGTTTTCTGTGCTCAGAGTGTGTTTATTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTCGTCCC
 TTCAGCAAGGACACAAAAAGATTTTAAATTTATTAATAAAAAAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTA
 TCGACCTGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCATGATTAT
 CATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTT

ATGATTAGAGTCCCGCAATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAAGTAGGATAAATTATC
GCGCGCGGTGTCATCTATGTTACTAGAT

Figure 8B




Figure 9A

IF-NoV(US68)VP1(ORF2)(hCod).c (SEQ ID NO: 76)

TCGTGCTTCGGCACCAGTACAATGATGATGGCTAGTAAAGATGCGACCT

Figure 9B

IF-NoV(US68)VP1(ORF2)(hCod).r (SEQ ID NO: 77)

ACTAAAGAAAATAGGCCTTTATCTCCGCAGACCGAGGCGTCCGCGGGCAGAA

Figure 9C

Expression cassette number 2724 from 2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.1/Norwalk/1968/US strain is underlined. (SEQ ID NO: 78)

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA
TTGAGACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGA
AGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTC
TGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGAAAAAGAAGACGTTCCAACCACGTCT
TCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGT
CTCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAG
CTATCTGTCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAG
GCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGAAAAAG
AAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCC
CACTATCCTTCGAAGACCCTTCTCTATATAAGGAAGTTCATTTCAATTTGGAGAGGTATTAATAATAGGTTTT
GATAAAGCGAACGTGGGGAACCCGAACCAACCTTCTTAACTCTCTCTCATCTCTTAAAGCAAACCTTCTCT
CTTGCTTTCTTGCCTGAGCGATCTTCAACGTTGTGAGATCGTGCTTCGGCACCAGTACAATGATGATGGCTAGTAA
GATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGAGGACAACCTCGTACCCGAGGTAACGCCAGCGACCCACTTG
CCATGGACCCGTTGCCGAAGTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCCAATTGATCCGTGGATTATC
AACAATTTCTGTCAGGCACCCAGGGCGAGTTCACAATTTACCAAACAATACACCGGGCGATGTGCTATTGATCT
TTCTTGGGTCCTCACCTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTGGGTAGGAAACATGAGAGT
CCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTCTCCCGGATTGGATCTCA
TAATCTGACCATTTGCTCAAGCGACTCTTTTCCCATGTCTCGCCGACGTTAGGACCCTGGACCCCATCGAGGTGCC
CCTGGAGGACGTCGGAATGTTTTGTTCCACAACAACGACAGAAACCAGCAGACGATGAGACTTGTCTGTATGCTCT
ATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAGTGATGACATGCCCTCCCC
CGACTTCAACTTTCTTTTCTGGTCCCAACCGTTGAGCAGAAGACGCGGCCCTTTACTGCCCCAATCTCCCGCTT
TCAAGTCTGAGTAATTCACGGGCCCCATTGCCGATCTCCTCAATGGGAATCTCCCCGACAACGTCAGTCTGTCCAA
TTCCAAATGGGAGATGCACACTGGACGGTCGCTGGTGGGAACAACCTCCGGTGCCCTCTCATGTGCCCCAAAT
CCGCGGCACATCAAATGGTACCGTAATCAATCTGACAGAACCTTGATGGCACGCCCTTCCATCCCTTTGAAGGACCAG
CCCCTATTGGATTCTCTGATCTGGGAGGTTGCGACTGGCACATAAATGACACAGTTTGCCACTCCAGCCAGACA
CAGTATGATGTCGATACAACCCAGATACCTTCGTGCCACACCTGGGATCTATTCAAGCTAACGGTATTGGATCCGG
CAACTACGTGGGAGTCTTATCTTGATCTCACCACCATCCACCCCTCAGGATCCCAGGTTGACTTGTTGGAAGATACC
GAATTATGGATCCTCGATCACTGAAGCCACGCACCTCGCACCTTCGCTACCCACCAGGTTTTGGAGAAGTCTTGGT

GTTTTCATGAGCAAAATGCCCGGCCCTGGAGCCTACAATCTCCCTTGCCTACTCCCTCAAGAGTATATTAGTCACCT
 CGCATCTGAGCAGGCCCCGACCGTTGGCGAGGCAGCCCTGCTGCATTATGTGGATCCGGACACCGGCAGGAACCTG
 GGTGAGTTCAAAGCTTATCCTGACGGTTTTCTAACATGTGTACCAAATGGCGCTTCCAGCGGCCCTCAACAGCTCCCA
 ATCAATGGCGTGTTTCGTTTTTGTGAGCTGGGTAAGCCGCTTCTACCAGCTGAAGCCCGTGGGGACAGCTTCTTCTGC
 CCGCGGACGCTCGGTCTGCGGAGATAAAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTA
 TGTGTTGGTGAGCGTTTTCTGTGCTCAGAGTGTGTTATTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAG
 GTCGTCCCTTCAGCAAGGACACAAAAAGATTTAATTTATTAATAAAAAAAAAAAAAAAAAAGACCGGGAATTCGATAT
 CAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCG
 ATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGAT
 GGGTTTTATGATTAGAGTCCGCAATTATACATTTAATACGCGATAGAAAACAAATATAGCGCGCAAACCTAGGAT
 AAATTATCGCGCGCGGTGTCATCTATGTTACTAGAT

Figure 9D




Figure 10A

IF-NoV(US68)VP2(ORF3)(hCod).c (SEQ ID NO: 79)

TCGTGCTTCGGCACCAGTACAATGGCTCAGGCCATTATTGGCGCCAT

Figure 10B

IF-NoV(US68)VP2(ORF3)(hCod).r (SEQ ID NO: 80)

ACTAAAGAAAATAGGCCTTCAGCGGCGGTTGTTAGCGAACAGAGGAAGTC

Figure 10C

Expression cassette number 2725 from 2X35S promoter to NOS terminator. Human codon-optimized VP2 from Norovirus GI.1/Norwalk/1968/US strain is underlined. (SEQ ID NO: 81)

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA
 TTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGA
 AGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTC
 TGCCGACAGTGGTCCCAAAGATGGACCCCAACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCT
 TCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGT
 CTCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAG
 CTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAG
 GCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCAACCCACGAGGAGCATCGTGGAAAAAG
 AAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCACTGACGTAAGGGATGACGCACAATCC
 CACTATCCTTCGCAAGACCTTCTCTATATAAGGAAGTTCATTTCAATTTGGAGAGGTATTAATAATAGGTTTT
 GATAAAAGCGAACGTGGGGAAACCCGAACCAACCTTCTTAACTCTCTCTCATCTCTTAAAGCAAACCTTCTCT
 CTTGTCTTCTTGTGCGTGAAGCATCTCAACGTTGTCAGATCGTGCTTCGGCACCAGTACAATGGCTCAGGCCATTATT
GGCGCCATCGCTGCAAGTACAGCCGGGAGTGCATTGGGGGCCGGAATACAGGTGGGCGGGGAAGCTGCATTGCA
GAGCCAGCGGTACCAGCAAAACCTGCAGTTACAGGAGAATAGCTTTAAACACGACAGGGAGATGATTGGATATCA
GGTGGAGGCCAGCAATCAGCTGCTCGCCAAAACCTTGGCTACTCGATACTCATTACTGCGCGCCGGGGGTTGACT
AGCGCCGACGCCGACGATCTGTGCGAGGCGCCCCGTGACTCGGATCGTAGACTGGAACGGGGTACGAGTCTCG
GCTCCCGAGTCTGTGCAACCACCTGAGGTGGGAGGGTTTATGTCCGTGCCATCCCATTGCTAGCAAAACAGAA
ACAGGTCCAGAGCTCCGGAATCTCAATCCCAATTACTCCCTAGCTCTATCTCTGTACCACTTCTGGGTCGAGAG
TCAGAACAGCAGTAGATTTGGCAACCTGAGCCCTACCATGCTGAAGCCCTGAACACTGTGTGGTTGACTCCACCTG
GTAGCACGGCCTCCTCAACCCTGAGTTCGGTGCCTCGCGGGTACTTCAATACCGACAGACTTCCTCTGTTGCTAACA
ACCGCCGCTGAAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTGCGTGTGCAATTTCTATGTTTGGTGAGCGGTTTT
 CTGTGCTCAGAGTGTGTTATTTTATGTAATTAATTTCTTTGTGAGCTCCTGTTAGCAGGTGCTCCCTTCAGCAAGG
 ACACAAAAGATTTTAATTTTATTAATAAAAAAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCA
 GATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCGATGATTATCATATAATTC
 TGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAG

TCCGCAATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGAACTAGGATAAATTATCGCGCGCGGTG
TCATCTATGTTACTAGAT

Figure 10D




Figure 11A

IF-GI2Leu03VP1.c (SEQ ID NO: 82)

TCGTGCTTCGGCACCAGTACAATGATGATGGCTTCAAAGGATGCTCCCCAAA

Figure 11B

IF-GI2Leu03VP1.r (SEQ ID NO: 83)

ACTAAAGAAAATAGGCCTTCAGATTCGGCGGACCCCTAGCCTGCCGCGTGCCGTAGA

Figure 11C

Expression cassette number 3300 from 2X35S promoter to NOS terminator. Human codon-optimized VP1 from Norovirus GI.2/Leuven/2003/Bel strain is underlined. (SEQ ID NO: 84)

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA
 TTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGA
 AGATAGTGGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTC
 TGCCGACAGTGGTCCCAAAGATGGACCCCAACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCT
 TCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGT
 CTCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAG
 CTATCTGTCACTTTATTGTGAAGATAGTGGAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAG
 GCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCAACCCACGAGGAGCATCGTGGAAAAAG
 AAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCC
 CACTATCCTTCGAAGACCCTTCCTATATAAGGAAGTTCATTTCAATTTGGAGAGGTATTAATAATCTTAATAGGTTT
 GATAAAGCGAACGTGGGGAAACCCGAACCAACCTTCTTCTAACTCTCTCATCTCTTAAAGCAAACCTCTCT
 CTTGTCTTTCTTGCCTGAGCGATCTTCAACGTTGTCAGATCGTGCTTCGGCACCAAGTACAATGATGATGGCTTCAAAG
GATGCTCCCAAAGCGCGGACGGAGCTAGCGGCGCCGGACAGTTGGTTCCGGAAGTCAACACTGCCGATCCACTGC
CCATGGAACCCGTAGCTGGTCCAACAACCGCTGTTGCCACCGCCGCGCCAGGTTAACATGATCGATCCATGGATTGTT
AATAACTTTGTACAGAGCCCCAGGGGGAGTTCACAATTTCTCCGAACAATACCCCTGGGGACATTCTGTTTCGATCT
GCAACTGGGCCCACACTTGAATCCTTTCCTGAGCCATCTTTCACAGATGTACAACGGATGGGTTGGGAACATGCGTG
TCGGATCTCCTTGCTGGCAACGCCTTCAGTGCTGGCAAGATTATCGTGTGCTGCGTACCACCAGGGTTTACCTCGA
GTTCAATTAACATTGCTCAGGCCACCCTTTCCCTCACGTGATCGCAGACGTGCGTACCTTAGAACCAATCGAAATGC
CCCTGGAAGATGTACGGAACGTGCTGTACCATACTAATGATAACCAGCCAACGATGAGATTAGTGTGCATGCTGTAC
ACCCCTGAGAACTGGAGGAGGTTCTGGAAATTCGACAGTTTTGTGGTGGCTGGCAGGGTCTGACCGCTCCCA
GTAGCGACTTCAGCTTTTGTTCCTCGTTCCTCTACAATCGAACAACCAAGAGCATTACAGTGCCCAACATTC
CACTGCAGACTTTAAGCAATTCAGGTTTCCAGCTTGATCCAGGGTATGATCCTTTCTCCGACGCTCCCAAGTTG
TGCAGTTCCAGAATGGGAGATGTCTATCGACGGTCAGCTTCTGGGAACAACCCCTGCCACCTCCGGGCAACTCTTC
CGGGTGAGAGGCAAAATCAATCAGGGCGCCAGAACACTGAATCTGACAGAAGTGACGGGAAACCCCTTTATGGCG
TTGATAGCCCCGCGCCGTTGGATTCCCTGACTTCGGCAAGTGTGATTGGCACATGCGCATCAGTAAGACTCCCAA

CAACACTTCATCTGGAGACCCCATGAGGAGCGTGGATGTCCAGACCGACGTGCAGGGCTTCGTGCCGCACTTGGGA
 TCTATCCAGTTCGATGAGGTGTTCAATCACCTACTGGCGACTACATAGGCACAATTGAGTGGATAAGTCAACCATCT
 ACACCTCCAGGGACCGACATAAACCTGTGGGAAATCCTGATTACGGGTCATCCCTGAGTCAAGCTGCCAATCTTGC
 ACCCCCTGTCTTTCCCCCGGCTTTGGTGAGGCTCTTGTTTACTTCGTCTCTGCATTTCTGGTCCTAACACCGCTCC
 GCCCCTAACGATGTTCCGTGTTTGTACCCAGGAATATGTGACTCATTTCGTTTCCGAACAGGCACCCACCATGGGG
 GACGCTGCCCTGCTACACTATGTGGACCCCGACACCAATAGAAACCTCGGCGAGTTCAAACCTCTACCCCGGGGGATA
 CCTGACCTGTGTTCCAAATGGAGTGGGAGCAGGCCACAACAGCTGCCCTGAATGGGGTCTTCCTGTTTCGTTTCTT
 GGGTGTCACGCTTTTACCAGCTGAAGCCCGTTGGCACAGCTTCTACGGCACGCGGCAGGCTAGGGGTCCGCCGAAT
 CTGAAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTGAGCGGTTTTCTGTGCT
 CAGAGTGTGTTTATTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTACGAGTCTGCCCTTCAGCAAGGACACAAA
 AAGATTTTAATTTATTAATAAAAAAAAAAAAAAAAAAGACCGGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTT
 CAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCATGATTATCATATAATTTCTGTTGAA
 TTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCA
 ATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAACCTAGGATAAATTATCGCGCGCGGTGTCATCTA
 TGTTACTAGAT

Figure 11D




Figure 12A

GI2Leu+GI1VP1.r (SEQ ID NO: 85)

ATGCTCTTGTTTTTCTCAACGGTTGGTGGGACCAGAAAAAGAAAGTTGAAGTCG

Figure 12B

GI1VP1+GI2Leu.c (SEQ ID NO: 86)

TCCCACCAACCGTTGAGCAAAAAACAAGAGCATTACAGTGCCCAACAT

Figure 12C

Expression cassette number 3360 from 2X35S promoter to NOS terminator. Human codon-optimized fusion VP1 S(GI.1)+P(GI.2) protein gene sequence is underlined. (SEQ ID NO: 87)

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA
TTGAGACTTTTCAACAAAGGGTAATATCCGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGA
AGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTC
TGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCT
TCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGT
CTCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGAAACCTCCTCGGATTCCATTGCCAG
CTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAG
GCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGGAAAAAG
AAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCACTGACGTAAGGGATGACGCACAATCC
CACTATCCTTCGCAAGACCCTTCTCTATATAAGGAAGTTCATTTCAATTTGGAGAGGTATTAATACTTAATAGGTTTT
GATAAAGCGAACGTGGGGAACCCGAACCAACCTTCTTAACTCTCTCTCATCTCTTAAAGCAAACCTTCTCT
CTTGCTTTCTTGCGTGAGCGATCTTCAACGTTGTGAGATCGTGCTTCGGCACCAGTACAATGATGATGGCTAGTAAA
GATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGACGAGCAACTCGTACCCGAGGTAAACGCCAGCGACCCACTTG
CCATGGACCCCGTTGCCGGAAGTTCACAGCAGTGGCCACAGCCGGTCAAGTGAATCCAATTGATCCGTGGATTATC
AACAATTTCTGTCAGGCACCCAGGGCGAGTTCACAATTCACCAACAATACACCGGGCGATGTGCTATTGATCT
TTCCTTGGGTCCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTGGGTAGGAAACATGAGAGT
CCGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTCTCCCGATTGGATCTCA
TAATCTGACCAATTGCTCAAGCGACTCTTTTCCCCATGTCATCGCCGACGTTAGGACCTGGACCCCATCGAGGTGCC
CCTGGAGGACGTCCGGAATGTTTTGTTCCACAACAACGACAGAAACCAGCAGACGATGAGACTTGTCTGTATGCTCT
ATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAGTGATGACATGCCCCTCCCC
CGACTTCAACTTTCTTTTCTGGTCCCACCAACCGTTGAGCAAAAAACAAGAGCATTACAGTGCCCAACATTCCACT
GCAGACTTTAAGCAATTCCAGGTTTCCAGCTTGATCCAGGGTATGATCCTTTCTCCGACGCCTCCCAAGTTGTGCA
GTTCCAGAATGGGAGATGCTTATCGACGGTCAGCTTCTGGGAACAACCCCTGCCACCTCCGGGCAACTCTTCCGGG
TGAGAGGCAAAATCAATCAGGGCGCCAGAACACTGAATCTGACAGAAGTGGACGGGAAACCTTTATGGCGTTTCG
ATAGCCCCGCGCCCGTTGGATTCCCTGACTTCGGCAAGTGTGATTGGCACATGCGCATCAGTAAGACTCCCAACAAC
ACTTCATCTGGAGACCCCATGAGGAGCGTGGATGTCCAGACCGACGTGCAGGGCTTCGTGCCGCACTTGGGATCTA
TCCAGTTCGATGAGGTGTTCAATCACCTACTGGCGACTACATAGGCACAATTGAGTGGATAAGTCAACCATCTACA

CCTCCAGGGACCGACATAAACCTGTGGGAAATTCCTGATTACGGGTCATCCCTGAGTCAAGCTGCCAATCTTGCACC
 CCCTGTCTTTCCCCCGGCTTTGGTGAGGCTCTGTTACTTCGTCTCTGCATTTCCTGGTCCTAACACCGCTCCGCCC
 CTAACGATGTTCCGTGTTTGTACCCAGGAATATGTGACTCATTTTCGTTTCCGAACAGGCACCCACCATGGGGGAC
 GCTGCCCTGCTACACTATGTGGACCCCGACACCAATAGAAACCTCGGCGAGTTCAAACCTACCCCGGGGATACCT
 GACCTGTGTTCCAAATGGAGTGGGAGCAGGCCACACAACAGCTGCCCTGAATGGGGTCTTCTGTTCGTTTCTTGGG
 TGTCACGCTTTTACCAGCTGAAGCCCGTTGGCACAGCTTCTACGGCACGCGGCAGGCTAGGGGTCCGCCGAATCTG
 AAGGCCTATTTTCTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAG
 AGTGTGTTTATTTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTCGTCCCTCAGCAAGGACACAAAAA
 GATTTTAATTTTATTAATAAAAAAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCA
 AACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGTCTTGCGATGATTATCATATAATTTCTGTTGAATT
 ACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCAAT
 TATACATTTAATACGCGATAGAAAACAAAATATAGCGCGCAACTAGGATAAATTATCGCGCGCGGTGTCATCTATG
 TTACTAGAT

Figure 12D




Figure 13A

Amino acid sequence of VP1 G1.1 (SEQ ID NO: 1)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFIQAPQGEFTISPNNT
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIIVSCIPPGFGSHNLTIAQATLFPHVIADVRTLD
 PIEVPLEDVNRNLFHNNDNRNQQTMLVCMYLTPLRTGGGTGDSFVAGRVMTCPSPDFNLFVLPPTVEQKTRPFTLPN
 LPLSSLSNSRAPLPISSMGISPDNVQSVQFQNGRCTLGRLVGTTVPVSLSHVAKIRGTSNGTVINLTLDGTPFHPFEGPAPI
 GFPLDGGCDWHINMTQFGHSSQTQYDVTTPDTFVPHLGSIQANGIGSGNYVGVLSWISPPSHPSGSQVDLWKIPNYG
 SSITEATHLAPSVYPPGFGEVLVFFMSKMPGPGAYNLCLLPQEYISHLASEQAPTVEAALLHYVDPDTGRNLGEFKAYP
 DGFLTCVPNGASSGPQQLPINGVFVFSWVSRFYQLKPVGTASSARGRLGLRR

Figure 13B

Nucleic acid sequence of wild-type VP1 G1.1 (SEQ ID NO: 13)

ATGATGATGGCGTCTAAGGACGCTACATCAAGCGTGATGGCGCTAGTGGCGCTGGTCAGTTGGTACCGGAGGTTA
 ATGCTTCTGACCTCTTGAATGGATCCTGTAGCAGGTTCTTCGACAGCAGTCGCGACTGCTGGACAAGTTAATCCTA
 TTGATCCCTGGATAATTAATAATTTTGTGCAAGCCCCCAAGGTGAATTTACTATTTCCCAAATAATACCCCGGTG
 ATGTTTTGTTGATTTGAGTTTGGGTCCCCATCTTAATCCTTTCTTGCTCCATCTATCACAAATGTATAATGGTTGGGT
 GGTAACATGAGAGTCAGGATTATGCTAGCTGGTAATGCCTTTACTGCGGGGAAGATAATAGTTTCTGCATACCCCC
 TGGTTTTGGTTCACATAATCTTACTATAGCACAAGCAACTCTCTTCCACATGTGATTGCTGATGTTAGGACTCTAGAC
 CCCATTGAGGTGCCTTTGGAAGATGTTAGGAATGTTCTTTTCATAAATGATAGAAATCAACAAACCATGCGCCTT
 GTGTGCATGCTGTACACCCCCCTCCGCACTGGTGGTGGTACTGGTGATTCTTTGTAGTTGCAGGGCGAGTTATGAC
 TTGCCCCAGTCCTGATTTTAATTTCTGTTTTAGTCCCTCCTACGGTGGAGCAGAAAACAGGCCCTTCACACTCCCA
 AATCTGCCATTGAGTTCTCTGTCTAACTCACGTGCCCCCTCTCCAATCAGTAGTATGGGCATTTCCCCAGACAATGTCC
 AGAGTGTGCAGTTCCAAATGGTCGGTGTACTCTGGATGGCGCCTGGTTGGCACCACCCAGTTTCATTGTCACAT
 GTTGCCAAGATAAGAGGGACCTCCAATGGCACTGTAATCAACCTTACTGAATTGGATGGCACACCCTTTCACCTTTT
 GAGGGCCCTGCCCCATTGGGTTTCCAGACCTCGGTGGTGTGATTGGCATATCAATATGACACAGTTTGGCCATTC
 TAGCCAGACCCAGTATGATGTAGACACCACCCCTGACACTTTTGTCCCCATCTTGTTCAATTCAGGCAAATGGCAT
 TGGCAGTGGAATTATGTTGGTGTCTTAGCTGGATTTCCTCCCATCACACCCGTCTGGCTCCCAAGTTGACCTTTG
 GAAGATCCCAATTATGGGTCAAGTATTACGGAGGCAACACATCTAGCCCCTCTGTATACCCCCCTGGTTTCGGAG
 AGGTATTGGTCTTTTTCATGTCAAAATGCCAGGTCTGGTGCTTATAATTTGCCCTGTCTATTACCACAAGAGTACA
 TTTCACATCTTGCTAGTGAACAAGCCCCCTACTGTAGGTGAGGCTGCCCTGCTCCACTATGTTGACCTGATACCGGTC
 GGAATCTTGGGGAATTCAAAGCATACCCTGATGGTTTCTCACTTGTGTCCCAATGGGGCTAGCTCGGGTCCACAA
 CAGCTGCCGATCAATGGGGTCTTTGTCTTTGTTTCATGGGTGTCCAGATTTTATCAATTAAAGCCTGTGGGAAGTCC
 AGCTCGGCAAGAGGTAGGCTTGGTCTGCGCCGATAA

Figure 13C

Nucleic acid sequence of human codon-optimized VP1 G1.1 (SEQ ID NO: 18)

ATGATGATGGCTAGTAAAGATGCGACCTCTCTGTGGATGGTGCCTCAGGGGAGGACAACTCGTACCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTTCTGCCAGGCACCCAGGGCGAGTTCACAATTTACCAAACAATACACCGG
 GCGATGTGCTATTCGATCTTTCCTTGGGTCCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTC
 CTCCCGGATTTGGATCTCATAATCTGACCATTGCTCAAGCGACTCTCTTTCCCATGTATCGCCGACGTTAGGACCCT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACCAGCAGACGATG
 AGACTTGCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTCTTTTTCTGGTCCCAACCGTTGAGCAGAAGACGCGGCCCTTTA
 CACTGCCCAATCTCCCGCTTTCAAGTCTGAGTAATTCACGGGCCCCATTGCCGATCTCTCAATGGGAATCTCCCCCG
 ACAACGTCCAGTCTGTCCAATTCCAAAATGGGAGATGCACACTGGACGGTCGCCTGGTGGGAACAACCTCCGGTGT
 CCTCTCACATGTCGCCAAAATCCGCGGCACATCAAATGGTACCGTAATCAATCTGACAGAAGTTGATGGCAGCCCTT
 CCATCCCTTTGAAGGACAGCCCTATTGGATTCTCTGATCTGGGAGGTTGCGACTGGCACATAAACATGACACAGT
 TTGGCCACTCCAGCCAGACACAGTATGATGTCGATACAACCCAGATACCTTCGTGCCACACCTGGGATCTATTCAA
 GCTAACGGTATTGGATCCGGCAACTACGTGGGAGTCTTATCTTGGATCTCACCACCATCCACCCCTCAGGATCCAG
 GTTGACTTGTGGAAGATACCGAATTATGGATCCTCGATCACTGAAGCCACGCACCTCGCACCTCCGTCTACCCACCA
 GGTTTTGGAGAAGTCTTGGTGTTTTTCATGAGCAAAATGCCCGGCCCTGGAGCCTACAATCTCCCTTGCCTACTCCCT
 CAAGAGTATATTAGTCACCTCGCATCTGAGCAGGCCCGACCGTTGGCGAGGCAGCCCTGCTGCATTATGTGGATCC
 GGACACCGGCAGGAACCTGGGTGAGTTCAAAGCTTATCCTGACGGTTTTCTAACATGTGTACCAAATGGCGCTTCCA
 GCGGCCCTCAACAGCTCCCAATCAATGGCGTGTTCGTTTTGTGAGCTGGGTAAGCCGCTTCTACCAGCTGAAGCCC
 GTGGGGACAGCTTCTTCTGCCGCGGACGCCTCGGTCTGCGGAGATAA

Figure 14A

Amino acid sequence of VP1 G1.2_Leuven_2003_D2DEL3 (SEQ ID NO: 2)

MMMASKDAPQSADGASGAGQLVPEVNTADPLPMEPVAGPTTAVATAGQVNMIDPWIVNNFVQSPQGEFTISPNT
 PGDILFDLQLGPHLNPFLSHLSQMYNGWVGNMRVIRLLAGNAFSAAGKIIVCCVPPGFTSSSLTIAQATLFPHVIADVRTLEP
 IEMPLDVRNVLYHTNDNQPTMRLVCMLYTPLRTGGGSGNSDSFVAGRVLTAPSSDFSFLFLVPPTIEQKTRAFTVPNIP
 LQTLNSRFPSLIQGMILSPDASQVVQFQNGRCLIDGQLLGTTPATSGQLFRVRGKINQGARTLNLTVDGKPFMAFDSP
 APVGFPDFGKCDWHMRISKTPNNTSSGDPMRSVDVQTDVQGFVPHLGSIQFDEVFNHPTGDYIGTIEWISQSTPPGT
 DINLWEIPDYGSSLSQAANLAPPVFPFGFGEALVYFVSAPFPNPNRSAPNDVPCLLPQEYVTHFVSEQAPTMGDAALLHY
 VDPDTNRNLGEFKLYPGGYLTCVPNGVGAGPQQLPLNGVFLFVSWVSRFYQLKPVGTASTARGRLGVRI

Figure 14B

Nucleic acid sequence of human codon-optimized VP1 G1.2_Leuven_2003_D2DEL3 (SEQ ID NO: 54)

ATGATGATGGCTTCAAAGGATGCTCCCCAAAGCGCGGACGGAGCTAGCGGCGCCGGACAGTTGGTTCCGGAAGTC
 AACACTGCCGATCCACTGCCCATGGAACCCGTAGCTGGTCCAACAACCGCTGTTGCCACCGCCGCCAGGTTAACAT
 GATCGATCCATGGATTGTTAATAACTTTGTACAGAGCCCCAGGGGGAGTTACAATTTCTCCGAACAATACCCCTG
 GGGACATTCTGTTGATCTGCAACTGGGCCACACTTGAATCCTTTCTGAGCCATCTTTCACAGATGTACAACGGAT
 GGGTTGGGAACATGCGTGTTGCGATCCTCCTTGCTGGCAACGCCTTCAGTGCTGGCAAGATTATCGTGTGCTGCGTA
 CCACCAGGGTTTACCTCGAGTTCATTAAACATTGCTCAGGCCACCCTTTTCCCTCACGTGATCGCAGACGTGCGTACC
 TTAGAACCAATCGAAATGCCCTGGAAGATGTACGGAACGTGCTGTACCATACTAATGATAACCAGCCAACGATGA
 GATTAGTGTGCATGCTGTACACCCCTGAGAAGTGGAGGAGGTTCTGGAAATCCGACAGTTTTGTGGTGGCTGG
 CAGGGTCCTGACCGCTCCAGTAGCGACTTCAGCTTTTTGTTCTCGTTCCTCTACAATCGAACAAAAACAAGAGC
 ATTCACAGTGCCCAACATTCCACTGCAGACTTAAAGCAATTCAGGTTTCCAGCTTGATCCAGGGTATGATCCTTTCT
 CCCGACGCTCCCAAGTTGTGCAGTTCAGAATGGGAGATGTCTATCGACGGTCAGCTTCTGGGAACAACCCCTGC
 CACCTCCGGGCAACTTCCGGGTGAGAGGCAAAATCAATCAGGGCGCCAGAACACTGAATCTGACAGAAGTGGAC
 GGGAAACCTTTATGGCGTTCGATAGCCCCGCGCCGTTGGATTCCCTGACTTCGGCAAGTGTGATTGGACATGCG
 CATCAGTAAGACTCCCAACAACACTTCTGAGAGCCCCATGAGGAGCGTGGATGTCCAGACCGACGTGCAGGGC
 TTCGTGCCGCACTTGGGATCTATCCAGTTCGATGAGGTGTTCAATCACCTACTGGCGACTACATAGGCACAATTGA
 GTGGATAAGTCAACCATCTACACCTCCAGGGACCGACATAAACCTGTGGGAAATCCTGATTACGGGTATCCCTGA
 GTCAAGCTGCCAATCTGCACCCCTGTCTTCCCCCGGCTTTGGTGAGGCTCTTGTCTTACTTCGTCTCTGCATTTCT
 GGTCTAACAACCGCTCCGCCCTAACGATGTTCCGTGTTTGTACCCAGGAATATGTGACTCATTTCTGTTCCGAA
 CAGGCACCCACCATGGGGGACGCTGCCTGCTACACTATGTGGACCCGACACCAATAGAAACCTCGGCAGATTCA
 AACTCTACCCCGGGGGATACCTGACCTGTGTTCCAAATGGAGTGGGAGCAGGCCACAACAGCTGCCCTGAATGG
 GGTCTTCTGTTCTTCTTGGGTGTACGCTTTTACCAGCTGAAGCCCGTTGGCACAGCTTCTACGGCACGCGGCAG
 GCTAGGGGTCCGCCGAATCTGA

Figure 15A

Amino acid sequence of VP1 G1.3_LillaEdet_2008_H2DG70 (SEQ ID NO: 3)

MMMASKDAPTNMDGTSGAGQLVPEVSTAEPISMEPVAGAATAAATAGQVNMIDPWIMSNYVQAPQGEFTISPNN
 PGDILFDLQLGPHLNPFLSHLAQMYNGWVGNMKVRVLLAGNAFTAGKIIISCVPPGFAAQNVSIQAATMFPHVIADVRV
 LEPIEVPLEDVRNVLHNNSTPTMRLICMLYTLRASGSSSGTDPFVIAGRVLTCPSPDFNFLVPPNVEQKTKPFSVPNL
 PLNVLSNSRVPSLIKSMMSVQDHGQMVQFQNGRVTLDGQLQGTTPTSASQLCKIRGTVYHATGGQGLNLTEIDGTPYH
 AFESPAPIGFDPDLGECDWHINASPANAFTDGSIIHRIDVAQDSTFAPHLGTIHYTNADYNANVGLICSLWLSPSPSGGAPK
 VNPWAIAPRYGSTLTEAAQLAPPIYPPGFGEAIVFMSDFPIANGSDGLSVPCTIPQEFVTHFVNEQAPTRGEAALLHYVDP
 DTHRNLGFEKLYPEGFMTCVPSGSGPQTLPIGVFTFISWVSRYQLKPVGTTGPVRRLGIRRS

Figure 15B

Nucleic acid sequence of human codon-optimized VP1 GI.3_LillaEdet_2008_H2DG70 (SEQ ID NO: 55)

ATGATGATGGCTTCCAAGGATGCTCCACAAACATGGATGGAACAAGCGGCGCGGGGCAACTTGTGCCGAGGTG
TCCACGGCGGAACCCATTTCCATGGAACCTGTGGCCGGCGCAGCCACTGCTGCCGCCACCGCAGGACAGGTAAACA
TGATCGACCCCTGGATCATGTCAAATTACGTTCAAGGCTCCACAGGGGGAGTTTACCATAAGCCCAAACAACACCCCG
GGTGACATCTTGTGACCTGCAGCTAGGACCACACTTGAATCCGTTTCTGAGTCACTTGGCTCAGATGTATAATGGA
TGGGTTGGAACATGAAGGTGCGCGTGCTCCTGGCGGGCAATGCATTACAGCCGGGAAGATTATTATCTCTTGCG
TGCCACCTGGATTTGCAGCCCAGAACGTGTCTATCGCACAGGCAACCATGTTTCCGCATGTATCGCAGATGTGCGC
GTGCTAGAGCCCATCGAGGTGCCCCCTTGAGGACGTGCGCAACGTCTATTCCATAACAATGATAGCACCCCCACCAT
GCGCTTGATATGTATGTTATATACTCCCCTCCGCGCCAGTGGGTCCAGCTCCGGGACCGATCCTTTTGTGATTGCTGG
GCGGGTGTTGACTTGTCTAGCCCTGACTTCAACTTCCTTTTCTGGTGCCTCCAAATGTAGAACAGAAAACAAAGCC
ATTCAGCGTGCCAAACCTGCCCCCTAACGTGCTGTCGAATCCCGAGTGCCTTCCCTTATTAAGTCCATGATGGTATC
TCAGGATCACGGTCAAATGGTGCAGTTTCAAGACGGCCGAGTGACGTTAGACGGGCAGCTGCAGGGCACAAACCC
AACCAGTGCCAGTCAGCTGTGTAAGATCAGAGGCACCGTCTACCACGCAACTGGCGGACAGGGGCTGAATCTTACT
GAGATCGATGGTACCCCTACCATGCATTGAGTGCACCTGCACCTATTGGATTTCCCGATCTTGGGGAGTGTGATTG
GCATATCAATGCTTCACTGCCAACGCTTTCACAGACGGGTCTATTATTCATCGCATTGACGTAGCACAGGATAGCAC
ATTTGCCCGCACCTGGGTACCATCCACTATACGAACGCAGATTACAACGCAACGTTGGGTCTTATCTGTAGCCTAG
AGTGGCTATCTCCGCAAGCGGTGGGGCCCCCTAAAGTTAACCCATGGGCTATTCTCGGTACGGGTCTACGCTGACT
GAGGCCGCTCAGCTGGCACCCCCCATATACACAGGATTCGGGGGAAGCCATTGTTTTCTTTATGTCCGATTTTCCG
ATAGCCAACGGTTCAGATGGCCTTAGTGTCCCTTGACAGATTCCACAGGAATTTGTGACACACTTCGTAAACGAGCA
GGCTCCTACTCGGGGCGAGGCTGCCTTGTTGCATTACGTAGACCCCGATACCCATAGAAACCTGGGCGAATTCAAAC
TCTACCTGAAGGTTTCATGACCTGCGTACCTAACTCCTCCGGCAGTGGCCCTCAAACCTTGCCGATCAACGGCGTGT
TCACGTTTATCAGCTGGGTTTCACGGTTTACCAACTCAAGCCCGTCGGAACAACCTGGGCCAGTTCGGAGGCTCGGG
ATCAGACGGAGCTAG

Figure 16A

Amino acid sequence of VP1 GI.5_Siklos_HUN5407_2013_HUN_AHW99832 (SEQ ID NO: 44)

MMMASKDAPSSADGANGAGQLVPEVNNAEPLPLDPVAGASTALATAGQVNMIDPWIFNNFVQAPQGEFTISPNNTP
GDILFDLQLGPHLNPFLAHLNQMYNGWVGNMVRVILAGNAFTAGKVIICVPPGFQSRSLIAQATLFPHIIADVRTLEPI
EIPLEDVRNTLYHTNDNQPTMRLLCMLYPLRTGGSGGTDAFVAVAGRVLTCPSSDFNFLFLVPPTVEQKTRPFVSPNIPL
QLLSNSRVNLIQSMVLSPDQAQNVQFQNGRCTTDGQLLGTTPVSVSILKFRGKVSAGSKVINLTLDGSPFLAFEAPAP
TGFPDLGTSWVHVEMLNSNSQSSGNPILLRDIHPNSSEFVPHLGSVCVTAIEVAGDYTGTIQWTSQPSNVTPVPDVNF
WTIPHYGSNLAEASQLAPVVYPFGGEAIVYFMSPIPGPNTAHKPNLVPCLLPQEFVTHFVSEQAPSMGEAALVHYVDPD
TNRNLGEFKLYPEGFITCVPNGTGPQQLPLNGVVFASVWSRFYQLKPVGTASSARGRLGVRR

Figure 16B

Amino acid sequence of GII.1_Ascension208_2010_USA_AFA55174 native VP1 (SEQ ID NO: 45)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRMNQVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPFLAHLARMYNGYAGGVEVQVLLAGNAFTAGKLVFAAIPPHFPLENLSPGQITMFPVHVIDVRTLEPVLLPLP
 DVRNFFHYNQPEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFTLPILTIGELSNS
 RFPVPIDELYTSPNEGVEVQVQNGRSTLDGELLGTTQLVPSNICALRGRINAQVPDDHHQWNLQVTNANGTSFDPTEVD
 PAPLGTPDFLANIYGVTQSRNPNTCRAHDGVLATWSPKFTPKLGSVVLGTWEESDLDLNQPTRFTPVGLYDTGHFDQ
 WVLPNYSGRLLTNMNLAPSVAPLFPGEQLFFRSHIPLKGGTSNGAIDCLLPQEWIQHFYQESAPSPTDVALIRYTNPDG
 RVLFEAKLHRQGFITVANSRPIVPPNGYFRFDSWVNQFYSLAPMGTGNGRRRVQ

Figure 16C

Amino acid sequence of VP1 GII.2_CGMH47_2011_TW_AGT39206 (SEQ ID NO: 66)

MKMASNDAAPSTDGAAGLVPESNNEVMALEPVAGAAALAPVTGQTNIIDPWIRANFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLARMYNGYAGGMEVQVMLAGNAFTAGKLVFAAVPPHFPVENLSPQQITMFPVHVIDVRTLEPVLL
 PLPDVRNFFHYNQKDDPKMRIVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFTYLVPPPTVESKTKPFTLPILTIGELS
 NSRFPVSIDQMYTSPNEVISVQCQNGRCTLGELGTTQLQVSGICAFKGEVTAHLHDNDHLYNVITITNLNGSPFDPSSED
 IPAPLGVPDFQGRVFGVISQRDKHNTPGHNEPANRAHDAVVPTYTAQYTPKLGQIQIGTWQTDLTNVNQPVKFTPVGL
 NDTDFHNQWVVPYAGALNLTNLAPSVAPVFPGERLLFFRSYIPLKGGYGTPAIDCLLPQEWVQHFYQEAAPSMSEVA
 LVRYINPDTGRALFEAKLHRAGFMTVSSNTSAPVV

VPANGYFRFDSWVNQFYSLAPMGTGNGRRRIQ

Figure 16D

Amino acid sequence of VP1 GII.3_Jingzhou_2013402_CHN_AGX01095 (SEQ ID NO: 67)

MKMASNDAAPSNDGAAGLVPEISSEAMALEPVAGAAIAAPLTGQNNVIDPWIMNNFVQAPNGEFTVSPRNSPGEVLLN
 LELGPEINPYLAHLARMYNGYAGGFEVQVVLAGNAFTAGKIIFAAIPPNFIDNLSAAQITMCPHVIVDVRQLEPVNLPMP
 DVRNFFHYNQGSRSRLRIAMLYTPLRANNSGDDVFTVSCRVLTRPSPDFSFNLPPTVESKTKPFTLPILTISEMSNSRF
 PVPIDSLHTSPTENIVVQCQNGRVTLGELMGTTQLPSQICAFRGTLTRSTSRASDQADTATPRLFNYYWHIQLDNLNG
 TPYDPAEDIPAPLGTPDFRGKVFVQASQRNPDAATRAHEAKIDTTSGRFTPKLSLEISTESGDFDQNPTRFTPVGIGVD
 HEPDFQQWALPDYAGQFTHNMNLAPAVAPNFPGEQLFFRSQPLSSGGRSNGILDCLVPQEWVQHFYQESAPSQTQV
 ALVRYVNPDTGRVLFEAKLHKLRFMTIAKSGDSPITVPPNGYFRFESWVNPFYTLAPMGTGNGRRRIQ

Figure 16E

Amino acid sequence of VP1 GII.5_Alberta_2013_CA_ALT54485 (SEQ ID NO: 68)

MKMASNDATPSNDGAAGLVPESNNEAMALEPVVGASLAAPVTGQTNIIDPWIRTNFVQAPNGEFTVSPRNSPGEILVN
LELGPELNPYLAHLARMYNGYAGGMEVQVLLAGNAFTAGKIIFAAVPPYFPVENLSPSQITMFPHVIIDVRTLEPVLLPMP
DVRSTLFHFNQKDEPKMRLVAMLYTPLRSNGSGDDVFTVSCRILTRPSPEFDFTYLPPTVESKTKPFTLPVLTGELSNSRF
PLSIDEMVTSPNESIVVQPQNGRVTLDGELLGTTQLQACNICSIKGVKGQVPNEQHMWNLEITNLNGTQFDPTDDVPA
PLGVPDFAGEVFGVLSQRNRGESNPANRAHDAVVATYSDKYTPKLGLVQIGTWNTNDVENQPTKFTPIGLNEVANGHR
FEQWTLPRYSGALTNMNLAPAVAPLFPGERLLFFRSYVPLKGGFGNPAIDCLVPQEWVQHFYQESAPSLGDVALVRYV
NPDTGRVLFEAKLHKGGFLTVSSTSTGPVVVPANGYFRFDSWVNQFYSLAPMGTGNGRRRFQ

Figure 16F

Amino acid sequence of VP1 GII.7_Musa_2010_AII73774 (SEQ ID NO: 69)

MKMASNDAAPSNDGAAGLVPEINNEVMLEPVAGASLATPVVGQQTNIIDPWIRNNFVQAPAGEFTVSPRNSPGEILLD
LELGPELNPYLAHLARMYNGHAGGMEVQIVLAGNAFTAGKIIFAAIPPGFYPYENLSPSQITMCPHVIIDVRQLEPVLLPMP
DIRNNFFHYNQGNPKRLIAMLYTPLRANNSGDDVFTVSCRVLTKPSPDFEFTFLVPPTVESKTKQFTLPILKISEMTNSRF
PVPVEMMYTARNENQVVQPQNGRVTLDGELLGTTPLAVNICKFKGEVIAKNGDVRSYRMDMEITNTDGTPIIDPTEDT
PGPIGSPDFQGILFGVASQRNKNEQNPATRAHEANINTGGDQYAPKLAQVKFFSESQDFEVHQPTVFTPVGVAGDTSH
FRQWVLPYRGGHLTNNTHLAPAVAPLFPGEQILFFRSQIPSSGGHELGYMDCLVPQEWVQHFYQEAATAQSEVALIRFIN
PDTGRVLFEAKLHKQGFITVAHTGDNPIVMPPNGYFRFEAWVNQFYSLAPVGTGNGRRRIQ

Figure 16G

Amino acid sequence of VP1 consensus sequence from genotypes GI.1, GI.2, GI.3, GII.4, GII.6, GII.13 and GII.17 (SEQ ID NO: 70)

GI.1	SEQ	ID NO:1	MMASKDATSV	DGASGAGQLV	PEVNASDPL	LAMD	PVAGS	STAV	ATAGQVN	PI	IDPW	I	INNF
GI.2	SEQ	ID NO:2	MMASKDAPQ	SADGASGAGQLV	PEVNTADPL	PMPE	PVAGPT	TAV	ATAGQVN	MI	IDPW	I	VNNF
GI.3	SEQ	ID NO:3	MMASKDAPT	NMDGTSAGAGQLV	PEVSTAEPI	SME	PVAGAA	TAA	ATAGQVN	MI	IDPW	I	WMSNY
GII.4	SEQ	ID NO:4	MKMASSDAN	PSDGS---	AANLV	PEVNN-	EVM	ALE	PVVGAA	LAAP	VAGQ	QNV	IDPW
GII.6	SEQ	ID NO:5	MKMASSDAN	PSDGS---	AANLV	PEANN-	EVM	ALE	PVVGAS	LAAP	VVGQ	QNI	IDPW
GII.13	SEQ	ID NO:6	MKMASSDAN	PSDGS---	AASLV	PEAIN-	ETM	PLE	PVAGAS	LAAP	VAGQ	TNI	IDPW
GII.17	SEQ	ID NO:7	MKMASSDAN	PSDGS---	AAGLV	PEGNN-	ETL	PLE	PVAGAA	LAAP	VTGQ	NNI	IDPW
VP1 Con	SEQ	ID NO:70	MkMASXDAX	psXdGa	SgAa	XLVPE	vnXne	XXXle	pVa	GaXi	Aap	vaGQ	XXN
GI.1	SEQ	ID NO:1	VQAPQGEFTI	SPNNTPGD	VLFDLS	LGPH	LNPF	LLHL	SQMY	NGWV	GNM	RVR	IM
GI.2	SEQ	ID NO:2	VQSPQGEFTI	SPNNTPGD	ILFDLQ	LGPH	LNPF	FLSH	LSQMY	NGWV	GNM	RVR	IL
GI.3	SEQ	ID NO:3	VQAPQGEFTI	SPNNTPGD	ILFDLQ	LGPH	LNPF	FLSH	LAQMY	NGWV	GNM	KVR	VL
GII.4	SEQ	ID NO:4	VQAPGGEFTV	SPRNAPGE	ILMSAP	LGPD	LNPLY	SLH	ARMY	NGYAGG	FEVQ	VIL	LAG
GII.6	SEQ	ID NO:5	VQAPQGEFTV	SPRNSPGE	MLLNLE	LGPE	LNPLY	SLH	SRMY	NGYAGG	MQVQ	VV	LAG
GII.13	SEQ	ID NO:6	VQAPNGEFTV	SPRNSPGE	ILLNLE	LGPD	LNPLY	LAH	LSRM	YNGYAGG	VEVQ	VV	LAG
GII.17	SEQ	ID NO:7	VQAPNGEFTV	SPRNSPGE	ILLNLE	LGPD	LNPLY	LAH	LSRM	YNGYAGG	VEVQ	VV	LAG
VP1 Con	SEQ	ID NO:70	VQaPqGEFTv	SPrNX	PGeilXXl	XLGP	XLNPyl	SLsr	MYNGya	GgmXV	qvl	LAG	NA
GI.1	SEQ	ID NO:1	GKIIIVSCIP	PGFGSH	NLTIAQ	ATLF	PHVI	AD	VRTLD	PI	EV	PLE	VR
GI.2	SEQ	ID NO:2	GKIIIVCCV	PPPGFTSS	SLTIAQ	ATLF	PHVI	AD	VRTLE	PI	EM	PLE	VR
GI.3	SEQ	ID NO:3	GKIIISCV	PPPGFAAQ	NVSIAQ	ATMF	PHVI	AD	VRVLE	PI	EV	PLE	VR
GII.4	SEQ	ID NO:4	GKVI	FAAV	PPNFP	TEGL	SPSQ	VTMF	PHIV	DVRQ	LE	PVLI	PL
GII.6	SEQ	ID NO:5	GKII	FAAV	PPHFP	VEN	INAAQ	ITMC	PHIV	DVRQ	LE	PVLI	PL
GII.13	SEQ	ID NO:6	GKIL	FAAI	PPNFP	VD	MTSP	QAQIT	MLPH	LI	VD	VRTLE	PI
GII.17	SEQ	ID NO:7	GKIL	FAAV	PPNFP	VE	FLSPAQ	ITML	PHLI	VD	VRTLE	PI	PL

VP1 Con SEQ ID NO:70 GKiiifaavPPXfPpXXXlsXaQXtmPHviDyRtLePiXXPLpDvRNVfHhXNXXnXpctm

GI.1 SEQ ID NO:1 RLVCMlyTPlRTGGTG--DSFVAGRVMTCPSPDFNfLVpPtVE||QKTRPFTlPNLPL

GI.2 SEQ ID NO:2 RLVCMlyTPlRTGGSGNSDSFVAGRVLTAPSSDFsFlVpPtIE||QKTRAFtVPNIPL

GI.3 SEQ ID NO:3 RLICMlyTPlRASGSSGTDPEVIAGRVLTCPSPDFNfLVpPENVE||QKTKPFsVPNLPL

GII.4 SEQ ID NO:4 KLIAMlyTPlRANNA--GDDVFtVSCRVLTRSPDFDFEiLVpPtVE||SRtkPFsVPVLTV

GII.6 SEQ ID NO:5 RLVAMlyTPlRAN-S--GEDVFtVSCRVLTRAPDFEFTFlVpPtVE||SKtkPFsLPILTL

GII.13 SEQ ID NO:6 RLVAMlyTPlRSNGS--GDDVFtVSCRVLTRPTPDFEfiLVpPsVE||SKtkPFtLPILTI

GII.17 SEQ ID NO:7 RLVAMlyTPlRSNGS--GDDVFtVSCRVLTRPTPDFEFTLVpPsVE||SKtkPFsLPILTL

VP1 Con SEQ ID NO:70 rLVaMlyTPlRXngsXXXXvFtvsCrVlTrPspDfXfXfLVpPtVE||sktkpfsLPXitl

GI.1 SEQ ID NO:1 SSLSNSRAFLPISSNGISPDNVQSVQFQNGRCTLdGRlVGTTPVSLSHVAKIRGTSN---

GI.2 SEQ ID NO:2 QTLNSRFPsLIQMIlSPDASQVvQFQNGRCLIdQLlGTTPATSGQLFRVRGKIN--Q

GI.3 SEQ ID NO:3 NVLSNRVPsLIKSMVVSQDHGQWvQFQNGRVTLdGQLQGTTPTSASQLCKIRGTVYHAT

GII.4 SEQ ID NO:4 EEMTSRFPPIPLEKLTGPSSAFVvQFQNGRCTLdGVLLGTQLSPVNICTFRGDVTHIT

GII.6 SEQ ID NO:5 GELSRSRFPAPIDMLYTDpNEGIVvQFQNGRCTLdGTLQGTQLVPTQICAFRGTLIGQT

GII.13 SEQ ID NO:6 SELTSRFPPIsIEQLYtAPNENNVvQcQNGRCTLdGELQGTQLLSSAVCSYRGRTVANS

GII.17 SEQ ID NO:7 SELTSRFPVPIDSLFTAQNnVLQvQcQNGRCTLdGELQGTQLLPSGICAFRGRTVAFt

VP1 Con SEQ ID NO:70 xelsNSRfPXiXlXtXpXXXXvVQXNGRctlDGXLqGTqlXXsXXcXXRGXXXXt

GI.1 SEQ ID NO:1 -GT-----VINLTLDGTPeHFF-EGPAPiGFPDLGGCDWHINMTQFGHS

GI.2 SEQ ID NO:2 GAR-----TLNLTevDGKPFNAF-DSPAPVGPpDfGKCDWHMRISKTPNN

GI.3 SEQ ID NO:3 GGQ-----GLNLTEIdGTPYHAF-ESPAPiGFPDLGECdWHINASpANAF

GII.4 SEQ ID NO:4 GSR-----NYTMNLASQNWNdyDTEeIPAPLGTPDFVGKIQGVLTQTTR--

GII.6 SEQ ID NO:5 SRSPDSTDSAPRRRDHPLHVQLKNLDGTQYDPTDEVPAVLGAIdFKGTVFGVASQRDVSG

GII.13 SEQ ID NO:6 GDN-----WDQNVLQlTYPSGASyDPTDEVPAIGTQDFSGILYGVLTQDNVRE

GII.17 SEQ ID NO:7 D-H-----RDKWHMQlQNlNGTtYDPTDDVPAPiGTPDFKGVFGVASQRNVGN

VP1 Con SEQ ID NO:70 gRSPDSTDSAPRdXXXXXnLtXXdgtXyqdtXXXPAPlCXpDfXgXXXXgvXXXXXX

GI.1 SEQ ID NO:1 S-----QTQYDVDTTPDTFVPHLGSiQANGI---GSG-----NYVGVLsWSPSPSPSGS

GI.2 SEQ ID NO:2 TS-SGDPMRsVDVTQDVQGFVPHLGSiQDFEVFNHPTG-----DYIGTIEWIsQPSTPPGT

GI.3 SEQ ID NO:3 -T-DGSI IHRIDVA-QDSTFAPHLGTiHYTNADYNANv-----GLICsLEWLSPPSGG-AP

GII.4 SEQ ID NO:4 -TDGSTRGHKATVYTGsADFAPIGRVQFEFTDTRDfEAnQTKFTpVGVIQDGGTTTHRN

CONTINUATION OF FIGURE 16G

GII.6 SEQ ID NO:5	QOVGATRAHEVHINTDPRYTPKLGSIILMYSE-SDDFVTCQPVRFPIGMDN-----
GII.13 SEQ ID NO:6	NTGEAKNAKGVYISTTSKFTPKIGSIGLHSI-TEDVRNQQSRTFPVGAQNT-----
GII.17 SEQ ID NO:7	DAPGSTRAHEAVISTYSQFVPKLGSVNFRSN-DNDFQ-LQPTKFTPVGINDDGDH----
VP1 Con SEQ ID NO:70	XXXgXXXXhXXXXxtXsXXXXpXGgXXXXXXXxdXXXXXXXftpXXXXXXXpXXXX
GI.1 SEQ ID NO:1	QVDLWKIPNYGSSITEATHLAPSVYPPGFGVLFVFMKMPGPGA-----YNLPCLLPQE
GI.2 SEQ ID NO:2	DINLWEIPDYGSSLSQAANLAPPVFPFGGEALVYFVSAPFGPNRS-APNDVPCLLPQE
GI.3 SEQ ID NO:3	KVNPWAIPIRYGSTLTAAQLAPPIYPPGGEAIVFMSDPPIANG-S-DGLSVPCITPQE
GII.4 SEQ ID NO:4	EPQQWVLPYSGRNTHNVHLAPAVAPTFFGEQLLFFRGTMPGCSGY-P-NMDLDCLLPQE
GII.6 SEQ ID NO:5	DWHQWELPDYPGHLTLNMNLAPAVAPAFGERILFFRSIVPSAGYG--SQIDCLIPQE
GII.13 SEQ ID NO:6	PFQQWVLPHYAGALANTNLAPAVAPTFFGEQLLFFRSRVPVCVQLQGDADFIDCLIPQE
GII.17 SEQ ID NO:7	PFQWELPDYSGLLTLNMNLAPPVAPNPFGEQLLFFRSFVPCSGGYN--QGIVDCLIPQE
VP1 Con SEQ ID NO:70	XXXqWXlPXyXgXltXnXnLAPXvaPXfpGEXllffrSXXpXXgXXqXXXXXdcLLPQE
GI.1 SEQ ID NO:1	YISHLASEQAPTVEAALLHVDPDTGRNLGEFKAYPDGFLTCVPNGASSGPQQLPQNGV
GI.2 SEQ ID NO:2	YVTHFVSEQAPTMTGDAALLHVDPDTNRNLGEFKLYEGGYLTCVPNGVGAGPQQLPQNGV
GI.3 SEQ ID NO:3	FVTHFVNEQAPTRGEAALLHVDPDTNRNLGEFKLYDEGFMTCV PNSSGSGPQTL PINGV
GII.4 SEQ ID NO:4	WVQYFYQEAAPAQSDVALLRFVNPDTGRVLFECKLHKSQYVTVAH--TCQHDIVIPNGY
GII.6 SEQ ID NO:5	WVQHIFYQEAAPSQSAVALIRYVNPDTGRNIFEAKLHREGFITVAN--SGNNPIVVPNGY
GII.13 SEQ ID NO:6	WVNHIFYQEAAPSQADVALIRYVNPDTGRTLFEAKLHRSGFITVSH--TGAYPLVVPNGH
GII.17 SEQ ID NO:7	WIQHIFYQESAPSQSDVALIRYVNPDTGRTLFEAKLHRSQYITVAH--SGDYPLVVPANGY
VP1 Con SEQ ID NO:70	wvXhfyqEXAPXqXdvAlIryVnPDtGrnlfEXKlhXXGfXtVXXXgXgXXpXvXPXNGX
GI.1 SEQ ID NO:1	FVFSWVSRFYQLKPVGTASSARGRLGLRR-
GI.2 SEQ ID NO:2	FLFVSWVSRFYQLKPVGTASTARGRLGVRRl
GI.3 SEQ ID NO:3	FTFISWVSRFYQLKPVGTTCGPVR-RLGI RRS
GII.4 SEQ ID NO:4	FRFDSWVNQFYTLAPMNGNGTGRRRAV-----
GII.6 SEQ ID NO:5	FRFEAWNQFYTLTPMGTGQGRRDQ-----
GII.13 SEQ ID NO:6	FRFDSWVNQFYSLAPMGTGNGRRRVQ-----
GII.17 SEQ ID NO:7	FRFDSWVNQFYSLAPMGTGNGRRRAQ-----
VP1 Con SEQ ID NO:70	FrFXsWVnqFYXlXpMgtGxgrRrXXGXRRX

CONTINUATION OF FIGURE 16G

Figure 17A

Amino acid sequence of VP1 GII.4_Sydney_2012_K4LM89 (SEQ ID NO: 4)

MKMASSDANPSDGSAAANLVPEVNNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGFTVSPRNAPGEIL
WSAPLGPDLNPLYSLHARMYNGYAGGFEVQVILAGNAFTAGKVIFAAPVPPNFPTEGLSPSQVTMFPHIVVDVRQLEPVL
PLPDVRNNFYHYNQSNPTIKLIAMLYTPLRANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFVSPVLTEEMT
NSRFPIPLEKLTGPSSAFVVPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDPTTEEIP
APLGTDFVVGKIQGVLTQTTRTDGSTRGHKATVYTGSADFAPKLGRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHR
NEPQQWVLPSSYGRNTHNVHLAPAVAPTFFGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPASDVAL
LRFVNPDTGRVLFECKLHKSQYVTVAHGTQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV

Figure 17B

Nucleic acid sequence of human codon-optimized VP1 GII.4_Sydney_2012_K4LM89 (SEQ ID NO: 56)

ATGAAAATGGCCTCGAGTGACGCTAACCCTAGTGACGGCAGCGCCGCAATCTTGTGCCTGAGGTTAATAATGAGG
TGATGGCCCTGGAGCCTGTGGTGGGCGCAGCCATAGCAGCGCCCTGGCCGGTCAGCAGAATGTGATTGACCCGT
GGATACGCAACAATTTGTCCAAGCCCCCTGGTGGGGAGTTCACCGTTAGCCCGAGAAATGCGCCAGGAGAAATCCT
GTGGTCGGCCCCATTGGGACCCGATCTGAACCCTATTTGTACATCTCGCTCGGATGTACAACGGGTATGCCGGCG
GATTTGAAGTGCAGGTGATTCTGGCTGGGAACGCGTTCAGTCTGGCAAAGTGATCTTTGCAGCGGTGCCTCCCAAC
TTCCCACTGAAGGACTGTCTCCAAGCCAGGTCACAATGTTCCACACATCGTGGTGGACGTACGGCAGCTAGAGCC
TGTCCTGATTCCCTCCCTGATGTACGCAATAATTTCTACCACTACAATCAATCAATGATCCGACCATTAAATCATC
GCGATGTTGTACACCCTCTGCGCGCTAACAATGCTGGAGACGACGTATTCACCGTGTGATGCAGAGTGCTCACCAG
ACCTTACCAGACTTTGACTTTATCTTCTTAGTGCCCCCACTGTTGAGAGCCGAACCAAGCCCTTTAGTGCCCCGTA
CTCAGAGTCGAGGAGATGACAAATAGCCGCTTTCCAATCCCCCTTGAGAACTGTTACAGGACCTTCTCGGCATTCT
GTGGTTCAGCCACAGAACGGACGCTGCACAAGTACGGCGTGCTGCTCGGAACCAACCCAGCTTAGCCCTGTTAATAT
CTGTACGTTTAGAGGCGACGTAACCTACATAACTGGCTCACGGAACATACCATGAATCTGGCATCACAGAATTGGA
ATGACTACGACCAACCGAAGAGATTCCGCGACCTCTTGAACCCCGACTTTGTGGGAAAAATACAGGGCGTCCTG
ACACAAACCACCAAGACCGATGGCTCCACACGGGGACACAAGGCAACCGTCTACACTGGCTCTGCCGATTTGCCCC
GAACTGGGTAGAGTGCAGTTTGAACCGACACTGACCGGGACTTTGAAGCCAATCAGAATACTAAGTTCACACCT
GTAGGAGTGATTACAGACGGGGGCACTACCGGAACGAGCCGCAACAATGGGTCTGCTCTTATAGCGGG
AGGAATACTCATAATGTGATTTGGCTCTGCAGTGGCTCCACGTTTCCCGGGGAACAAGTCTCTTTTTCGTTCA
ACCATGCCTGGATGCTCCGGATATCCCAATATGGATCTCGATTGCTGCTCCACAGGAATGGGTGCAGTATTTTAT
CAAGAGGCCGACCAAGCCCAATCCGACGTCGCACTTCTGCGGTTCTGTAATCCAGACACAGGCCGCGTGTGTTGA
GTGCAAATTGCACAAATCAGGATACGTTACAGTGGCTCATACTGGACAGCATGACCTGGTGATCCCAACCAACGGAT
ATTTTAGGTTGACTCCTGGGTGAATCAGTTTTATACATTAGCCCCATGGGGAATGGGACTGGCAGACGACGGGCT
GTCTGA

Figure 18A

Amino acid sequence of VP1 GII.6_Ohio_2012_M9T020 (SEQ ID NO: 5)

MKMASNDAAPSNDGAANLVPEANNEVMALPVPVVGASIAAPVVGQQNIIDPWIRENFVQAPQGEFTVSPRNSPGEMLL
 NLELGPELNPLYSHLSRMYNGYAGGMQVQVVLAGNAFTAGKIIFAAVPPHFPVENINAAQITMCPHVIVDVRQLEPVLLP
 LPDIRNRRFFHYNQENTSRMRLVAMLYTPLRANSGEDVFTVSCRVLTRPAPDFEFTFLVPPTVESKTKPFSLPILTLGELSNSR
 FPAPIDMLYTDPNEGIVVQPQNGRCTLDTLQGTTLVPTQICAFRGTLIGQTSRSPDSTDSAPRRRDHPLHVQLKNLDG
 TQYDPTDEVPAVLGAIDFKGTVFGVASQRDVSGQQVGATRAHEVHINTTDPRTYTPKLSILMYSESDDFVTGQPVRFPTPI
 GMGDNDWHQWELPDYPGHLTLNMLNAPAVAPAFPGERILFFRSIVPSAGGYGSGQIDCLIPQEWVQHFYQEAAPSQS
 AVAIIRYVNPDTGRNIFEAKLHREGFITVANSNNPIVPPNGYFRFEAWVNQFYTLTPMGTGQGRRRDQ

Figure 18B

Nucleic acid sequence of human codon-optimized VP1 GII.6_Ohio_2012_M9T020 (SEQ ID NO: 60)

ATGAAGATGGCAAGCAACGACGACGCTCCCTCCAATGATGGTGCCGCCAACCTGGTCCCCGAAGCTAATAATGAGG
 TGATGGCGTTAGAGCCGGTGGTTGGCGCATCTATTGCAGCGCTGTGGTCGGACAGCAGAACATCATTGATCCCTG
 GATTCGCGAGAACTTCGTACAAGCTCCACAGGGGGAGTTACAGTCTCCCCCGGAACTCCCCGGGCGAGATGCTG
 CTAATCTGGAACCTCGGCCCTGAACCTAAACCTTATCTGTACACCTTTACGGATGTACAATGGCTACGCAGGAGG
 AATGCAAGTTCAGGTGGTCTGGCCGGCAATGCTTTCACCGCGGGCAAAATCATCTTTGCGGCCGTTCTCCACACT
 TCCCTGTGCAAAATATCAACGCCGCCAGATTACTATGTGCCCCACGTGATTGTGGATGTGCGACAGTTAGAGCCA
 GTTCTGCTGCCCTGCCCGACATCAGAAACCGTTCTTCCATTACAATCAAGAGAATACTTCACGGATGAGACTTGTT
 GCGATGCTGTACCCCTCTTCGTGCAAAATTCGGCGAAGACGTGTTCACTGTGTCTTGTGCGAGTACTTACCCGACCC
 GCCCCGATTTGCAATTCACCTTCTGGTTCCCTACTGTGGAGAGCAAGACAAAACCTTCAGCCTCCCAATCTTA
 AACTCGGGGAGCTGTCTAATTCACGCTTCCCGCACCTATTGATATGCTGTATACTGACCCCAACGAGGGGATAGT
 GGTGCAGCCCCAAATGGACGGTGTACTCTCGACGGCACGCTCCAGGGCACAACCAACTGGTGCCAACCCAGATT
 TGTGCATTACAGGGGCACTTTGATTGGGCAGACATCGAGATCTCCAGATTCTACTGATTCCGCGCCAAGGAGGAGGG
 ACCACCCACTCCACGTTCACTTAAAAAACCTGGACGGAACCCAGTACGACCCTACAGACGAGGTCCCCGCTGTCTC
 GGAGCCATCGACTTTAAAGGAAGTGTATTTGGAGTGGCATCCCAAAGGGATGTCTCGGGGACGAGGTGGGAGCT
 ACGAGAGCACATGAAGTCCACATTAACACCACAGACCAAGATATACCCCAAACTAGGGTCAATTTTAATGTATTC
 GGAATCAGACGATTTTGTACAGGTCAGCCCGTGCAGTTTACCCCGATCGGAATGGGGGACAACGATTGGCACCAG
 TGGGAATTGCCGATTACCTGGACACCTACCTTGAATATGAATCTGCCCCAGCCGTCGCGCCCGCTTCCCCGGT
 GAGCGGATCTCTTTTTAGAAAGCATAGTGCCTCCGACGGTGGGTATGGATCAGGGCAGATTGATTGCCTGATCCC
 CCAAGAATGGGTACAGCATTTCTACCAGGAAGCAGCCCCTAGCCAGTCCGAGTAGCACTGATCAGATATGTTAATC
 CTGATACGGGAAGGAACATCTTCAAGCAAACTGCACCGTGAGGGCTTCATTACCGTCGCCAACAGTGGTAATAA
 CCTATTGTGGTGCCTCTAATGGATACTTCAGGTTTGAGGCATGGGTGAATCAGTTTTATACTCTGACTCCCATGGG
 GACAGGCCAGGGGCGACGCCGGGATCAGTGA

Figure 19A

Amino acid sequence of VP1 GII.13_VA173_2010_H9AWU4 (SEQ ID NO: 6)

MKMASNDAAPSNDGAASLVPEAINETMPLEPVAGASIAAPVAGQTNIIDPWIRTNFVQAPNGEFTVSPRNS
PGEILLNLELGPDLNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKILFAAIPPFPVDMISPAQITMLPHLI
VDVRTLEPIMIPLDVRNVFYHFNNQPQPRMLVAMLYTPLRSNGSGDDVFTVSCRVLTRPTPDFEFIYLVP
SVESKTKPFTLPILTISELTNSRFPISIEQLYTAPNENNVMVQCQNGRCTLGELQGTQLLSSAVCSYRGRTVANS
GDNWDQNVQLQTYPSGASYDPTDEVPAPLGTQDFSGILYGVLTQDNVRENTGEAKNAKGVIYSTTSKGF
TPKIGSIGLHSITEDVRPNQQRFTPVGVAQNENTPFQQWVLPHYAGALALNTNLAPAVPTFPGEQLLFFRS
RVP CVQGLQGQDAFIDCLLPQEWVNHFYQEAAPSQADVALIRYVNPDTGRTLFEAKLHRSGFITVSHTGAYPLV
VPPNGHFRFDSWVNQFYSLAPMGTGNRRRVQ

Figure 19B

Nucleic acid sequence of human codon-optimized VP1 GII.13_VA173_2010_H9AWU4 (SEQ ID NO: 61)

ATGAAAATGGCTTCTAATGATGCCGCGCCAGCAATGATGGTGCCGCCAGCCTTGTCGCCGAAGCAATTAACGAGA
CAATGCCCTTGAGCCAGTCGCCGGGGCTTCTATTGCGGCCCCAGTTGCTGGACAGACGAATATCATCGATCCTTGG
ATACGGACTAATTTGTTCAGCTCCTAACGGAGAGTTCACTGTCTCCCCCGTAATAGTCCTGGCGAGATCCTGTTG
AACCTCGAGTTGGGGCCAGATCTCAATCCTTACCTGGCTCATCTGTCGAGAATGTACAACGGGTACGCGGGGGGGG
TTGAGGTGCAGGTCTTACTGGCAGGTAACGCATTACAGCAGGCAAGATTCTGTTTGGCGCCATCCCTCCTAATTTTC
CAGTGGATATGATATCTCCAGCACAGATTACAATGCTGCCCCATTTGATAGTGGATGTGCGGACACTTGAACCTATC
ATGATCCCTTTGCCGATGTCCGAAATGTGTTTATCATTTCAACAACCGCCGAGCCAAGAATGCGTCTCGTCGCG
ATGCTGTACACCCCGTTGCGGTCCAACGGCTCTGGCGATGATGTTTTCACAGTGTCTGTGCGAGTGTTAACCCGCCCT
ACCCAGATTTTGAGTTTATATCTAGTTCCCTTCTGTGGAAAGCAAGACTAAACCCTTTACTCTTCCCATTTCTGA
CTATATCCGAGCTTACCAACTCCCGTTCCCATCTCAATCGAGCAACTGTACACTGCACCCAACGAGAACAACGTAG
TCCAGTGCCAGAACGGGAGATGTACCCTGGACGGGGAGCTCCAAGGGACCACGCAACTGTTAAGTTCAGCCGTTTG
CAGTTACAGAGGCAGGACTGTGGCGAACTCTGGTGATAACTGGGATCAAAATGTGTTGCAGCTGACTTACCCATCC
GGCGCAAGCTACGATCCAACAGATGAGGTGCCAGCGCCCTTGGCACACAGGATTCTCAGGAATTCTATACGGGG
TGCTTACTCAGGATAATGTGCGAGAAAATACTGGCGAGGCCAAGAATGCTAAAGGAGTGATATAAGCACGACAAG
CGGTAAGTTTACCCCCAAAATTGGCAGTATTGGGCTCCACAGCATTACTGAGGACGTCCGCCAAACCAGCAGTCTC
GTTTCACTCCCGTGGGGGTGGCACAGAACGAGAACACACCTTTCCAGCAGTGGGTCTTGCCCCATTATGCAGGTGCT
TTGGCGCTCAATACAAATCTGGCACCCGCCGTAGCGCCGACATTTCTGGGGAGCAATTGCTGTTCTTTAGAACCG
CGTCCCGTGTGTTCAAGGGCTTGACGGGCCAGGACGCGTTTATTGATTGCCTCTTGCCCCAGGAATGGGTCAACCACT
TTTATCAGGAGGCAGCGCCCTCTCAAGCAGATGTGGCCCTGATAAGATATGTGAATCCCGACACAGGACGGACTTT
GTTTGAGGCAAACTCCACCGGTCAGGATTCATTCTGTGAGTCACACAGGAGCCTATCCCTTGTTGGTTCCACCTAA
TGGCCACTTCAGGTTTCGACTCTTGGGTCAATCAGTTTTATTCTGCTGGCACCAATGGGTACCGGAATGGTCGCCGTC
GGGTGCAATGA

Figure 20A

Amino acid sequence of VP1 GII.17_Kawa_2014_A0A077KVU6 (SEQ ID NO: 7)

MKMASNDAAPSNDGAAGLVPEGNNETLPLEPVAGAAIAAPVTGQNNIIDPWIRTNFVQAPNGEFTVSPRNS
PGEILLNLELGPDLNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKILFAAVPPNFPVEFLSPAQITMLPHLI
VDVRTLEPIMIPLDVRNTFFHYNNQPNRMRVLVAMLYTPLRSNGSGDDVFTVSCRVLTRTPDFEFTYLVPP
SVESKTKPFSLPILTSELNTRFPVPIDSLFTAQNNVLQVQCQNGRCTLDGELQGTTQLLPSGICAFRGRVTAE
TDHRDKWHMQLQNLNGTTYDPTDDVPAPLGTDFKGVVFGVASQRNVGNDAPGSTRAHEAVISTYSPQFV
PKLGSVNFRSNDNDFQLQPTKFTPVGINDDGDHPFRQWELPDYSGLLTLMNMLAPPVAPNFPGEQLLFRSF
VPCSGGYNQIVDCLIPQEWIQHFYQESAPSQSDVALIRYVNPDTGRTLFEAKLHRSGYITVAHSGDYPLVVPA
NGYFRFDSWVNQFYSLAPMGTGNRRRAQ

Figure 20B

Nucleic acid sequence of human codon-optimized VP1 GII.17_Kawa_2014_A0A077KVU6 (SEQ ID NO: 62)

ATGAAAATGGCATCTAACGACGCAGCCCCCTCAAACGATGGCGCTGCTGGACTCGTGCCGGAGGGGAATAATGAG
ACACTTCCACTAGAGCCGTTGCAGGCGCCGCTATAGCTGCCCCAGTGACAGGGCAGAATAATTATAGACCCTTG
GATTCGACAACTTCGTGCAGGCACCCAACGGCGAGTTTACAGTATCCCCCGGAACTCCCCAGGTGAGATACTCC
TGAATCTTGAGCTCGGCCCTGACCTCAATCCATATCTGGCTCATCTGAGCCGCATGTACAATGGTTACGCTGGGGG
GTCGAAGTGCAGGTCTCTCTGGCCGGAAACGCCTTTACCGCTGGCAAAATTCTGTTTGCCGCCGTTCCACCAAACTTT
CCAGTCAATTCTCTCTCCCGCGCAATAACCATGCTGCCACATTTGATCGTTGACGTGCGGACCCTGGAGCCAATA
ATGATTCCTCGCCGATGTGCGTAACACCTTTTTCCATTATAACAATCAGCCAACTCTCGGATGAGACTTGTTGCT
ATGCTGTACACCCCTGCGGAGCAACGGCAGTGCGCATGATGTGTTTACCGTGAGTTGCAGAGTCCTGACGCGCC
CAACCCCGACTTCGAGTTCACCTACCTGGTGCCCTTCTGTGGAATCTAAGACCAAACCGTTTTCACTGCCAATCT
TAACTCTCTCCGAACTGACTAACAGCCGGTTTCCAGTACCCATAGATTCTTTTTACCGCTCAAAACAACGTACTCCA
AGTCCAGTGCCAGAACGGCCGCTGTACGCTTGATGGTGAGTTGCAGGGGACAACACAGCTACTCCCCAGTGGCATC
TGTGCATTCCGGGGCCGCTGACCGCTGAGACAGACCATCGTGACAAATGGCACATGCAACTCCAAACTTAAACG
GGACCACCTACGACCAACCGACGACGTCCCTGCTCCGCTAGGGACTCCTGACTTTAAGGGGGTGGTGTTCGGAGT
GGCCTCTCAGCGGAATGTTGGGAATGACGCCCCGGCTCTACCGAGCTCACGAGGCCGTTATCTCAACATATAGCC
CCCAATTTGTGCCAAGCTCGGATCCGTTAATTTTCGTAGTAACGACAACGACTTCCAAGTCAACCAACGAAGTTTA
CGCCAGTGGGGATTAATGATGATGGAGACCATCCTTTCCGCCAATGGGAACTACCAGATTATTCTGGGCTGCTCACC
CTCAATATGAACCTCGCCCCACCGTGGCCCCAATTTCCCGGTGAGCAGCTGCTGTTTTTCGGAGCTTTGTGCCA
TGCAGTGGCGGATATAATCAAGGCATCGTAGACTGCTTGATTCCCCAAGAGTGGATAACAACATTTTACCAGGAAAG
TGCGCCCTCCAGTCCGATGTGGCCCTGATACGGTACGTTAACCCCGATACCGGAAGAACATTATTGAAGCGAAAT
TGCACAGATCAGGGTACATTACCGTTGCACATTCCGGCGATTATCCCCTGGTGGTTCGCGCAACGGTTACTTTAGGT
TCGATAGTTGGGTCAACCAGTTCTATCTACTAGCCCCAATGGGCACCGGTAACGGCAGACGCCGGGCTCAGTAG

Figure 21A

Amino acid sequence of VP1 US96: GII.4/Dresden174/1997/DE_AY741811 (SEQ ID NO: 8)

MKMASNDANPSDGSTANLVPEVNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGGEFTVSPRNAPGEIL
WSAPLGPDLNPYLSHLARMYNGYAGGFEVQVILAGNAFTAGKVIFAAPVPPNFPTEGLSPSQVTMFPHIIVDVRQLEPVLIP
LPDVRNNFYHYNQSDSTIKLIAMLYTPLKANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFTVPILTVEEMSN
SRFPIPLEKLYTGSSAFVVQPQNGRCTTDGVLLGTTQLSAVNICTFRGDVTHIAGSHDYTMNLSQNWNNYDPTTEEIPA
PLGTPDFVGKIQGMLTQTTREDGSTRAHKATVSTGSVHFTPKLGSVQYTTDTNNDFTGQNTKFTPVGVIQDGNHQN
EPQQWVLPNYSGRGTGHNVLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMNLDCLLPQEWVQHFYQEAAPASDVAL
RFVNPDTGRVLFECKLHKSGYVTVAHGTGPHDLVIPPNGYFRFDSWVNQFYTLAPMGNGAGRRRAL

Figure 21B

Amino acid sequence of VP1 FH02: GII.4/FarmingtonHills/2002/US_AY502023 (SEQ ID NO: 9)

MKMASNDANPSDGSTANLVPEVNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGGEFTVSPRNAPGEIL
WSAPLGPDLNPYLSHLARMYNGYAGGFEVQVILAGNAFTAGKIIFAAPVPPNFPTEGLSPSQVTMFPHIIVDVRQLEPVLIP
LPDVRNNFYHYNQSLNDPTIKLIAMLYTPLRANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFTVPILTVEEMTN
SRFPIPLEKLFTGPSGAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHIAGTHNYTMNLSQNWNNYDPTTEEIPA
PLGTPDFVGRIQGMLTQTTTRGDGSTRGHKATVSTGDVHFTPKLGSIQFNDDTNDFTGQNTKFTPVGVVQDGNQTH
QNEPQQWVLPNYSGRGTGHNVLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMNLDCLLPQEWVQHFYQEAAPASDVA
ALLRFVNPDTGRVLFECKLHKSGYVTVAHGTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAL

Figure 21C

Amino acid sequence of VP1 Hnt04: GII.4/Hunter-NSW504D/2004/AU_DQ078814 (SEQ ID NO: 10)

MKMASNDATPSDGSTANLVPEVNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGGEFTVSPRNAPGEIL
WSAPLGPDLNPYLSHLARMYNGYAGGFEVQVILAGNAFTAGKIIFAAPVPPNFPTEVLSPSQVTMFPHIIVDVRQLEPVLIP
LPDVRNNLYHYNQSDPTIRLIAMLYTPLRANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFVSPILTVEEMTN
SRFPIPLEKLFTGPSAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHIAGTQNYTMNLSQNWNNYDPTTEEIPA
PLGTPDFVGRIQGVLTQTTTRDGGSTRGHKATVSTGSVHFTPKLGSVQFSTDTSNDFETGQNTFTFPVGVVQDGSTTHQN
EPQQWVLPDYSGRDSHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMNLDCLLPQEWVQHFYQESAPASDVAL
RFVNPDTGRVLFECKLHKSGYVTVAHGTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGAGRRRAL

Figure 21D

Amino acid sequence of VP1 2006b: GII.4/Shellharbour-NSW696T/2006/AU_EF684915 (SEQ ID NO: 11)

MKMASNDANPSDGSAAANLVPEVNNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGFTVSPRNAPGEIL
WSAPLGPDLNPLYSLARMYNGYAGGFEVQVILAGNAFTAGKIIFAAVPPNFPTEGLSPSQVTMFPHIIVDVRQLEPVLIP
LPDVRNNFYHYNQSNSTIKLIAMLYTPLRANNAGEDVFTVSCRVLTRSPDFDFIFLVPPTVESRTKPFVPILTVEEMTNS
RFPIPLEKLTGPGSAFVVQPQNGRCTTDGVLGTTQLSPVNICTFRGDVTHIAGSRNYTMNLASLKWNYDPTTEEIPAPL
GTPDFVGKIQGVLTQTTKGDGSTRGHKATIYTGSAFPTPKLGSVQFSTDENDFETHQNTKFTPVGVTVQDGSTTHRNEPQ
QWVLPSSYGRNVHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQHFYQEAAPAQSDVALLRFV
NPDGTGRVLFECKLHKSGYVTVAHGTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAL

Figure 21E

Amino acid sequence of VP1 NO09: GII.4/Orange-NSW001P/2008/AU_GQ845367 (SEQ ID NO: 12)

MKMASSDANPSDGSSTANLVPEVNNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAPGGFTVSPRNAPGEIL
WSAPLGPDMNPYLSLARMYNGYAGGFEVQVILAGNAFTAGKIIFAAVPPNFPTEGLSPSQVTMFPHIIVDVRQLEPVLIP
PLPDVRNNFYHYNQSNSTIKLIAMLYTPLRANNAGDDVFTVSCRVLTRSPDFDFIFLVPPTVESRTKPFVPILTVEEMT
NSRFPIPLEKLTGPGSAFVVQPQNGRCTTDGVLGTTQLSPVNICTFRGDVTHIAGSRNYTMNLASQNWNSYDPTTEEIPA
PLGTPDFVGKIQGVLTQTTTGDGSTRGHKATVYTGSAFSPKLGRVQFATDNDNDFDANQNTKFTPVGVTVQDGNHTAHR
NEPQQWVLPSSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPAQSDVAL
LRFVNPDGTGRVLFECKLHKSGYVTVAHGTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAL

Figure 22A

Amino acid sequence of VP1 GII.12_HS206_2010_USA_AEI29586 (SEQ ID NO: 28)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNFVQAPNGFTVSPRNAPGEVLL
NLELGPENPLYLAHLARMYNGYAGGFEVQVLLAGNAFTAGKLVFAAVPPHFLENISPGQITMFPHIIVDVRTLEPVLPLP
DVRNNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRSPDFDFNYLVPPTVESRTKPFVPILTIGELTNS
RFPVPIDELYTSPNESLVVQPQNGRCALDGELQGTQLLPTAICSFGRINQKVSGENHVWNMQVTNIDGTPFDPTEDV
PAPLGTDPDFSGKLFVLSQRDHDNACRSHDAVIATNSAKFTPKLGAIQIGTWEQDDVHINQPTKFTPVGLFESEGFNQW
TLPNYSGALTINMGLAPPVAPTFPGEQILFFRSHIPLKGGVADPVIDCLLPQEWIQHLYQESAPSQTDVALIRFTNPDTGRV
LFEAKLHRSGYITVANTGSRPIVVPANGYFRFDSWVNQFYSLAPMGNGTGRRRVQ

Figure 22B

Amino acid sequence of GII.14_Saga_2008_JPN_ADE28701 native VP1 (SEQ ID NO: 46)

MKMASNDATPSDDGAAGLVPEINNEVMALEPVAGASIAAPVVGQQNIIDPWIRNNFVQAPAGEFTVSPRNSPGELLLD
LELGPELNPLYLAHLARMYNGHAGGMEVQIVLAGNAFTAGKILFAAIPPSFPYENLSPAQLTMCPHVIVDVRQLEPVLLPM
PDIRNVFYHYNQNNPKLRLVAMLYTPLRANNSGDDVFTVSCRVLTRPSPDFQFTFLVPPTVESKTKNFTLPVLRVSEMTN
SRFPVVLQDQMYTSRNIIVQPQNGRCTTDGELLGTTILQSVSICNFKGTMQAKLNEEPYQLQLTNLDGSPIDPTDDMP
APLGTPDFQAMLYGVASQRSSIDNATRAHDAQIDTAGDTFAPKIGQVRFKSSSNDFDLHDPTKFTPIGVNVDDQHPFRQ
WSLPNYGGHLALNNHLAPAVTPLFPGEQILFFRSYIPSAGGHTDGAMDCLLPQEWVEHFYQEAAPSQSDIALVRFINPDT
GRVLFEAKLHKQGFLTIAASGDHPVIMPTNGYFRFEAWVNPFFYLAPVGTGSGRRRIQ

Figure 22C

Amino acid sequence of VP1 GII.21_Sali_2011_USA_AFC89665 (SEQ ID NO: 47)

MKMASNDAAPSNDGATGLVPEINTETLPLEPVAGAAIAAPVTGQNNIIDPWIRNNFVQAPNGEFTVSPRNSPGELMNL
ELGPDLPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKILFAAVPPNFPVDMLSAQITMLPHLIVDVRTLEPIMIP
DVRNVFYHFNNQAPRMLRVAMLYTPLRSNGSGDDVFTVSCRVLTRPTDFEFTYLVPPSVESKTKPFTLPILTIGELTNSR
FPAPIDQLYTSNADVVVQPQNGRCTLGELQGTQLLTTAICSYRGMTSNPTSDYWDDHLLHLVHPNGATYDPTEDVP
APFGTQDFRGILYGMTLQNPRTSGDEAANSHGIYSTSEKFTPKLGTIGLHQQVQGDIAASNQQSKFTPVGIAVNGNTPFRQ
WELPNYSGALTNLNAPAVGPNFPGEQILFFRSNVPSVQGGQPIEIDCLIPQEWVSHFYQESAPSQSDVALVRVYNPDT
GRTIFEAKLHRQGFITIAATGSNPVVPPNGYFRFDSWVNQFYALAPMGTGNGRRRVQ

Figure 23A

Amino acid sequence of native VP2 G1.1 (SEQ ID NO: 14)

MAQAIIGAIAASTAGSALGAGIQVGGEAALQSQRYYQNLQLQENSFKHREMIGYQVEASNQLLAKNLATRYSLLRAGG
LTSADAARSVAGAPVTRIVDWNQVVRVSAPESSATTLRSGGFMSVPIPFASKQKQVQSSGISNPNYSPSSISRTTSWVESQ
NSSRFGNLSPYHAEALNTVWLTTPPGSTASSTLSSVPRGYFNTDRLPLFANNRR

Figure 23B

Nucleic acid sequence of wild-type VP2 G1.1 (SEQ ID NO: 15)

ATGGCCCAAGCCATAATTGGTGCAATTGCTGCTTCCACAGCAGGTAGTGCTCTGGGAGCGGGCATAACAGTTGGTG
GCGAAGCGGCCCTCAAAGCCAAAGGTATCAACAAAATTTGCAACTGCAAGAAAATCTTTTAAACATGACAGGGA
AATGATTGGGTATCAGGTTGAAGCTTCAAATCAATTATTGGCTAAAAATTTGGCAACTAGATATTTCACTCCTCCGTGC
TGGGGGTTTGACCAAGTGCTGATGCAGCAAGATCTGTGGCAGGAGCTCCAGTCACCCGCATTGTAGATTGGAATGGC
GTGAGAGTGTCTGCTCCCGAGTCTCTGCTACCACATTGAGATCCGGTGGCTTCATGTCAGTTCCCATACCATTTGCC
TCTAAGCAAAAACAGGTTCAATCATCTGGTATTAGTAATCCAAATTTCCCTTCATCCATTTCTCGAACCCTAGTT
GGGTCGAGTCACAAAACATCGAGATTTGGAATCTTTCTCCATACCACGCGGAGGCTCTCAATACAGTGTGGTTG
ACTCCACCCGGTTCAACAGCCTCTTCTACACTGTCTTCTGTGCCACGTGGTTATTTCAATACAGACAGGTTGCCATTAT
TCGCAAATAATAGCGCATGA

Figure 23C

Nucleic acid sequence of human codon-optimized VP2 G1.1 (SEQ ID NO: 19)

ATGGCTCAGGCCATTATTGGCGCCATCGCTGCAAGTACAGCCGGGAGTGCATTGGGGGCCGGAATACAGGTGGGC
GGGGAAGCTGCATTGCAGAGCCAGCGGTACCAGCAAAACCTGCAGTTACAGGAGAATAGCTTTAAACACGACAGG
GAGATGATTGGATATCAGGTGGAGGCCAGCAATCAGCTGCTCGCCAAAACCTGGCTACTCGATACTCATTACTGCG
CGCCGGGGGGTTGACTAGCGCCGACGCCGACGATCTGTGCGAGGCGCCCCGTGACTCGGATCGTAGACTGGAA
CGGGGTACGAGTCTCGGCTCCCGAGTCGTCTGCAACCACCCTGAGGTCGGGAGGGTTTATGTCCGTGCCCATCCCAT
TCGCTAGCAAACAGAAACAGGTCCAGAGCTCCGGAATCTCCAATCCCAATTACTCCCTAGCTCTATCTCTCGTACCA
CTTCTGGGTGAGAGTCAGAACAGCAGTAGATTTGGCAACCTGAGCCCCTACCATGCTGAAGCCCTGAACACTGTG
TGTTGACTCCACCTGGTAGCACGGCCTCTCAACCCTGAGTTCCGTGCCTCGCGGGTACTTCAATACCGACAGACTT
CCTCTGTTGCTAACAACCGCCGCTGA

FIGURE 23D

Nucleic acid sequence of human codon-optimized VP2 GII.4/ Sydney/NSW0514/2012/AU (SEQ ID NO:120)

ATGGCTGGGGCCTTTTTGCAGGTTTGGCTAGTGACGTCCTCGGGTCGGGCCTCGGAAGTCTGATCAATGCAGGAG
CTGGAGCGATTAATCAAAAAGTCGAGTTGAGAATAACCGGAACTTCAACAGGCAAGTTTCCAATTCTCAAGCAAT
TTGCAGCAGGCCTCATTTCAACACGACAAGGAAATGCTCCAGGCCAGATTGAGGCCACCAAGAACTGCAACAAG
AGATGATGAAGGTCAAACAGGCCATGCTGCTGGAGGGCGGCTTTTCGAGACCGATGCTGCGCGGGAGCCATCA
ACGCCCCAATGACAAAGGCACTCGACTGGAGTGGCACACGGTATTGGGCACCCGATGCCAGAACGACTACCTATAA
TGCCGGAAGTTTCTCCACACCTCAACCTTCTGGTGCCCTCCAGGGCGCGCAAATCTGAGGGACGCTGTGCCCGCTA
GGGGCTCCTCATCAAAGTCTTCCAATAGCTCCACTGCAACCTCGGTTTACTCAAACCAGACCATTCAACAAGATTAG
GATCAACCGCCGTGTGCGGAACATCTGTCTCTTCTTCTACAGCACGAACCAGGTCTTGGGTGAGGACCAG
AGCAGAAACCTGTCTCCGTCCATGCGCGGTGCTCACAACATTTCTTCGTGACCCCTCCTTCTCCCGATCCTCCAGCC
AAGGGACAGTGTCCACAGTGCCCAAAGAAGTGCTCGACTCTTGACAGGTGCGTTCAATACCAGACGCCAGCCTCT
CTTGCTCATATACGCAAAGGGGTGAGTCACGAGCA

Figure 23E

Amino acid sequence of VP2 GII.4/Sydney/NSW0514/2012/AU (SEQ ID NO:121)

MAGAFFAGLASDVLGSLGSLINAGAGAINQKVEFENNRKLQQASFQFSSNLQQASFQHDKEMLQAQIEATKKLQQEM
MKVKQAMLLGGFFETDAARGAINAPMTKALDWSGTRYWAPDARTTTYNAGRFTSPQPSGALPGRANLRDAVPARGS
SSKSSNSSTATSVYSNQTTSTRLGSTAVSGTSVSSFPSTARTRSWVEDQSRNLSPSMRGAHNISFVTPPSSRSSSQGTVSTV
PKEVLDSWTGAFNTRRQPLFAHIRKRGESRA

Figure 24A

Nucleic acid sequence of wild-type VP1/VP2 G1.1 (SEQ ID NO: 16)

ATGATGATGGCGTCTAAGGACGCTACATCAAGCGTGGATGGCGCTAGTGGCGCTGGTCAGTTGGTACGGAGGTTA
ATGCTTCTGACCTCTTGAATGGATCCTGTAGCAGGTTCTTCGACAGCAGTCGCGACTGCTGGACAAGTTAATCCTA
TTGATCCCTGGATAATTAATAATTTTGTGCAAGCCCCCAAGGTGAATTTACTATTTCCCAAATAATACCCCGGTG
ATGTTTTGTTTGATTTGAGTTTGGGTCCCCATCTTAATCCTTTCTTGCTCCATCTATCACAAATGTATAATGGTTGGTT
GGTAACATGAGAGTCAGGATTATGCTAGCTGGTAATGCCTTTACTGCGGGGAAGATAATAGTTTCTGCATACCCCC
TGGTTTTGGTTCACATAATCTTACTATAGCACAAGCAACTCTCTTCCACATGTGATTGCTGATGTTAGGACTCTAGAC
CCCATGAGGTGCCTTTGGAAGATGTTAGGAATGTTCTCTTTCATAATAATGATAGAAATCAACAAACCATGCGCCTT
GTGTGCATGCTGTACCCCCCTCCGCACTGGTGGTGGTACTGGTGATTCTTTGTAGTTGCAGGGCGAGTTATGAC
TTGCCCCAGTCCTGATTTTAATTTCTGTTTTAGTCCCTCCTACGGTGGAGCAGAAAACAGGCCCTTACACTCCCA
AATCTGCCATTGAGTTCTCTGTCTAACTCACGTGCCCCCTCTCCAATCAGTAGTATGGGCATTTCCCAAGACAATGTCC
AGAGTGTGCAGTTCCAAATGGTCGGTGTACTCTGGATGGCCGCTGGTTGGCACCACCCAGTTTCATTGTCACAT
GTTGCCAAGATAAGAGGGACCTCAATGGCACTGTAATCAACCTTACTGAATTGGATGGCACCCTTTACCCCTTT
GAGGGCCCTGCCCCATTGGGTTTCCAGACCTCGGTGGTTGTGATTGGCATATCAATATGACACAGTTTGGCCATTC
TAGCCAGACCCAGTATGATGTAGACACCACCCCTGACACTTTTGTCCCCATCTTGGTTCAATTCAGGCAAATGGCAT
TGGCAGTGGAATTATGTTGGTGTCTTAGCTGGATTTCCCCCATCACACCCGTCTGGCTCCCAAGTTGACCTTTG
GAAGATCCCCAATTATGGGTCAAGTATTACGGAGGCAACACATCTAGCCCCTTCTGTATACCCCCCTGGTTTCGGAG
AGGTATTGGTCTTTTTCATGTCAAAAATGCCAGGTCTGGTGCTTATAATTTGCCCTGTCTATTACCACAAGAGTACA
TTTACATCTTGCTAGTGAACAAGCCCCTACTGTAGGTGAGGCTGCCCTGCTCCACTATGTTGACCCTGATACCGGTC
GGAATCTTGGGGAATTCAAAGCATAACCTGATGGTTTCTCACTTGTGTCCCAATGGGGCTAGCTCGGGTCCACAA
CAGCTGCCGATCAATGGGGTCTTTGTCTTTGTTTCATGGGTGTCCAGATTTTATCAATTAAGCCTGTGGGAAGTCC
AGCTCGGAAGAGGTAGGCTTGGTCTGCGCCGATAATGGCCAAGCCATAATTGGTGCAATTGCTGCTTCCACAGC
AGGTAGTGCTCTGGGAGCGGGCATAACAGTTGGTGGCGAAGCGGCCCTCCAAAGCCAAAGGTATCAACAAAATTT
GCAACTGCAAGAAAATTTCTTTAAACATGACAGGGAAATGATTGGGTATCAGGTTGAAGCTTCAATCAATTATTGG
CTAAAAATTTGGCAACTAGATATTTACTCCTCCGTGCTGGGGTTTGACCAAGTCTGATGCAGCAAGATCTGTGGCA
GGAGCTCCAGTCACCCGATTGTAGATTGGAATGGCGTGAGAGTGTCTGCTCCGAGTCCTCTGCTACCACATTGAG
ATCCGGTGGCTTCATGTCAGTTCCCATACCATTTGCCTCTAAGCAAAAACAGGTTCAATCATCTGGTATTAGTAATCC
AAATTATTTCCCTTCATCCATTTCTGAACCACTAGTTGGGTGAGTCACAAAACATCGAGATTGGAAATCTTTCT
CCATACCACGCGGAGGCTCTCAATACAGTGTGGTTGACTCCACCCGTTCAACAGCCTCTTACTACTGTCTTCTGTG
CCACGTGGTTATTTCAATACAGACAGGTTGCCATTATTCGCAAATAATAGGCGATGA

Figure 24B

Nucleic acid sequence of wild-type VP1/VP2/3'UTR G1.1 (SEQ ID NO: 17)

ATGATGATGGCGTCTAAGGACGCTACATCAAGCGTGGATGGCGCTAGTGGCGCTGGTCAGTTGGTACCGGAGGTTA
ATGCTTCTGACCTCTTGAATGGATCCTGTAGCAGGTTCTTCGACAGCAGTCGCGACTGCTGGACAAGTTAATCCTA
TTGATCCCTGGATAATTAATAATTTTGTGCAAGCCCCCAAGGTGAATTTACTATTTCCCAAATAATACCCCGGTG
ATGTTTTGTTTGATTTGAGTTTGGGTCCCCATCTTAATCCTTTCTTGCTCCATCTATCACAAATGTATAATGGTTGGGT
GGTAACATGAGAGTCAGGATTATGCTAGCTGGTAATGCCTTTACTGCGGGGAAGATAATAGTTTCCTGCATACCCC
TGTTTTGGTTCACATAATCTTACTATAGCACAAGCAACTCTCTTCCACATGTGATTGCTGATGTTAGGACTCTAGAC
CCATTGAGGTGCCTTGAAGATGTTAGGAATGTTCTTTTATAATAATGATAGAAATCAACAAACCATGCGCCTT
GTGTGCATGCTGTACACCCCTCCGCACTGGTGGTGGTACTGGTGATTCTTTGTAGTTGCAGGGCGAGTTATGAC
TTGCCCCAGTCCTGATTTAATTTCTGTTTTAGTCCCTCCTACGGTGGAGCAGAAAACAGGCCCTTCACACTCCCA
AATCTGCCATTGAGTTCTGTCTAACTCACGTGCCCTCTCCAATCAGTAGTATGGGCATTTCCCAGACAATGTCC
AGAGTGTGCAGTTCAAAATGGTCGGTGTACTCTGGATGGCCGCTGGTTGGCACCACCCAGTTTCATTGTACAT
GTTGCCAAGATAAGAGGGACCTCCAATGGCACTGTAATCAACCTTACTGAATTGGATGGCACACCCCTTTCACCTTTT
GAGGGCCCTGCCCCATTGGGTTTCCAGACCTCGGTGGTGTGATTGGCATATCAATATGACACAGTTTGGCCATTC
TAGCCAGACCCAGTATGATGTAGACACCACCTGACACTTTTGTCCCATCTTGTTCAATTCAGGCAAATGGCAT
TGGCAGTGGTAATTATGTTGGTGTCTTAGCTGGATTCCCCCATCACACCCGTCTGGCTCCCAAGTTGACCTTTG
GAAGATCCCAATTATGGGTCAAGTATTACGGAGGCAACACATCTAGCCCCTTCTGTATACCCCTGGTTTCGGAG
AGGTATTGGTCTTTTTCATGTCAAAAATGCCAGGTCTGGTGCTTATAATTTGCCCTGTCTATTACCACAAGAGTACA
TTTCACATCTTGCTAGTGAACAAGCCCTACTGTAGGTGAGGCTGCCCTGCTCCACTATGTTGACCCTGATACCGGTC
GGAATCTTGGGGAATTCAAAGCATACCCTGATGGTTTCTCACTTGTGTCCCAATGGGGCTAGCTCGGGTCCACAA
CAGCTGCCGATCAATGGGGTCTTTGTCTTTGTTTCATGGGTGTCCAGATTTTATCAATTAAGCCTGTGGGAAGTCC
AGCTCGGCAAGAGGTAGGCTTGGTCTGCGCCGATAATGGCCAAGCCATAATTGGTGCAATTGCTGCTTCCACAGC
AGGTAGTGCTCTGGGAGCGGGCATAACAGTTGGTGGCGAAGCGGCCCTCAAAGCCAAAGGTATCAACAAAATTT
GCAACTGCAAGAAAATCTTTTAAACATGACAGGGAAATGATTGGGTATCAGGTTGAAGCTTCAAATCAATTATTGG
CTAAAAATTTGGCAACTAGATATTTACTCCTCCGTGCTGGGGTTTGACCAGTGCTGATGCAGCAAGATCTGTGGCA
GGAGCTCCAGTACCCGATTGTAGATTGGAATGGCGTGAGAGTGTCTGCTCCGAGTCCTCTGCTACCACATTGAG
ATCCGGTGGCTTCATGTACAGTTCCCATACCATTTGCCTAAGCAAAAACAGGTTCAATCATCTGGTATTAGTAATCC
AAATTATTTCCCTTCATCCATTTCTGAACCACTAGTTGGGTGAGTCACAAAACATCGAGATTTGGAAATCTTTCT
CCATACCACGCGGAGGCTCTCAATACAGTGTGGTTGACTCCACCGGTTCAACAGCCTCTTACACTGTCTTCTGTG
CCACGTGGTTATTTCAATACAGACAGGTTGCCATTATTCGCAATAATAGGCGATGATGTTGTAATATGAAATGTGG
GCATCATATTCATTAATTAGGTTAATTAGGTTAATTTGATGTT

Figure 24C

Nucleic acid sequence of human codon-optimized VP1/VP2 G1.1 (SEQ ID NO: 20)

ATGATGATGGCTAGTAAAGATGCGACCTCTCTGTGGATGGTGCCTCAGGGGAGGACAACCTCGTACCCGAGGTAA
ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
AATTGATCCGTGGATTATCAACAATTTCTGCCAGGCACCCAGGGCGAGTTCACAATTTACCAAAACAATACACCGG
GCGATGTGCTATTGATCTTTCTTGGGTCTCACCTTAACCCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGTGGCAAGATCATCGTCAGTTGTATTCT
CTCCCGGATTGGATCTCATAATCTGACCATTGCTCAAGCGACTCTCTTTCCCATGTATCGCCGACGTTAGGACCCCT
GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTTCACAACAACGACAGAAACCAGCAGACGATG
AGACTTGCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
TGATGACATGCCCCCTCCCCGACTTCAACTTTCTTTTCTGGTCCCACCAACCGTTGAGCAGAAGACGCGGCCCTTTA
CACTGCCCAATCTCCCGCTTTCAAGTCTGAGTAATTCACGGGCCCCATTGCCGATCTCTCAATGGGAATCTCCCCCG
ACAACGTCCAGTCTGTCCAATTCAAAAATGGGAGATGCACACTGGACGGTCGCCTGGTGGGAACAACCTCCGGTGTCT
CCTCTCATATGTGCGCAAAATCCGCGGCACATCAAATGGTACCGTAATCAATCTGACAGAAGTTGATGGCAGGCCCTT
CCATCCCTTTGAAGGACAGCCCTATTGGATTTCTGATCTGGGAGGTTGCGACTGGCACATAAACATGACACAGT
TTGGCCACTCCAGCCAGACACAGTATGATGTCGATACAACCCAGATACCTTCGTGCCACACCTGGGATCTATTCAA
GCTAACGGTATTGGATCCGGCAACTACGTGGGAGTCTTATCTTGGATCTCACCACCATCCCACCCCTCAGGATCCGAG
GTTGACTTGTGGAAGATACCGAATTATGGATCCTCGATCACTGAAGCCACGCACCTCGCACCTTCCGTCTACCCACCA
GGTTTTGGAGAAGTCTTGGTGTTCATGAGCAAAATGCCCGGCCCTGGAGCCTACAATCTCCCTTGCTACTCCCT
CAAGAGTATATTAGTCACCTCGCATCTGAGCAGGCCCGACCGTTGGCGAGGCAGCCCTGCTGCATTATGTGGATCC
GGACACCGGCAGGAACCTGGGTGAGTTCAAAGCTTATCCTGACGGTTTTCTAACATGTGTACCAAATGGCGCTTCCA
GCGGCCCTCAACAGCTCCCAATCAATGGCGTGTTCTTTTTGTCAGCTGGGTAAAGCCGCTTCTACCAGCTGAAGCCC
GTGGGGACAGCTTCTTCTGCCCGCGGACGCCTCGGTCTCGGAGATAATGGCTCAGGCCATTATTGGCGCCATCGCT
GCAAGTACAGCCGGGAGTGCATTGGGGGCCGGAATACAGGTGGGCGGGGAAGCTGCATTGCAGAGCCAGCGGTA
CCAGCAAAACCTGCAGTTACAGGAGAATAGCTTTAAACACGACAGGGAGATGATTGGATATCAGGTGGAGGCCAG
CAATCAGCTGCTCGCAAAAACCTGGCTACTCGATACTCATTACTGCGCGCCGGGGGGTTGACTAGCGCCGACGCCG
CACGATCTGTGCGAGGCGCCCCGTGACTCGGATCGTAGACTGGAACGGGTACGAGTCTCGGCTCCCGAGTCGTC
TGCAACCACCTGAGGTGGGAGGGTTTATGTCCGTGCCATCCATTCTGCTAGCAAAACAGAAACAGGTCCAGAGCT
CCGGAATCTCCAATCCAATTACTCCCTAGCTCTATCTCTGTACCACTTCTGGGTGAGAGTCAGAACAGCAGTA
GATTGGCAACCTGAGCCCTACCATGCTGAAGCCCTGAACACTGTGTGGTTGACTCCACCTGGTAGCACGGCCTCC
TCAACCCTGAGTTCGTGCTCGCGGTACTTCAATACCGACAGACTTCTCTGTTGCTAACAACCGCCGCTGA

Figure 24D

Nucleic acid sequence of human codon-optimized VP1/VP2/3'UTR G1.1 (SEQ ID NO: 21)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGCAGGACAACCTCGTACCCGAGGTAA
ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
AATTGATCCGTGGATTATCAACAATTTCTGCCAGGCACCCAGGGCGAGTTCACAATTTACCAAACAATACACCGG
GCGATGTGCTATTCGATCTTTCCTTGGGTCCTCACCTTAACCCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTC
CTCCCGGATTTGGATCTCATAATCTGACCATTGCTCAAGCGACTCTCTTCCCATGTCTCGCCGACGTTAGGACCTT
GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTTCACAACAACGACAGAAACCAGCAGACGATG
AGACTTGCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
TGATGACATGCCCCCTCCCCGACTTCAACTTCTTTTTCTGGTCCCACCAACCCTTGAGCAGAAGACGCGGCCCTTTA
CACTGCCCAATCTCCCGCTTTCAAGTCTGAGTAATTCACGGGCCCCATTGCCGATCTCCTCAATGGGAATCTCCCCCG
ACAACGTCCAGTCTGTCCAATTCCAAAATGGGAGATGCACACTGGACGGTCGCCTGGTGGGAACAACCTCCGGTGT
CCTCTCACATGTCGCCAAAATCCGCGGCACATCAAATGGTACCGTAATCAATCTGACAGAAGTTGATGGCAGCCCTT
CCATCCCTTTGAAGGACAGCCCTATTGGATTCTCTGATCTGGGAGGTTGCGACTGGCACATAAACATGACACAGT
TTGGCCACTCCAGCCAGACACAGTATGATGTCGATACAACCCAGATACCTTCGTGCCACACCTGGGATCTATTCAA
GCTAACGGTATTGGATCCGGCAACTACGTGGGAGTCTTATCTTGGATCTCACCACCATCCCACCCCTCAGGATCCAG
GTTGACTTGTGGAAGATACCGAATTATGGATCCTCGATCACTGAAGCCACGCACCTCGCACCTCCGTCTACCCACCA
GGTTTTGGAGAAGTCTTGGTGTTTTTCATGAGCAAAATGCCCGGCCCTGGAGCCTACAATCTCCCTTGCCTACTCCCT
CAAGAGTATATTAGTACCTCGCATCTGAGCAGGCCCGACCGTTGGCGAGGCAGCCCTGCTGCATTATGTGGATCC
GGACACCGGCAGGAACCTGGGTGAGTTCAAAGCTTATCCTGACGGTTTTCTAACATGTGTACCAAATGGCGCTTCCA
GCGGCCCTCAACAGCTCCCAATCAATGGCGTGTTCGTTTTTGTACAGCTGGGTAAAGCCGCTTCTACCAGCTGAAGCCC
GTGGGGACAGCTTCTTCTGCCCGCGGACGCCTCGGTCTGCGGAGATAATGGCTCAGGCCATTATTGGCGCCATCGCT
GCAAGTACAGCCGGGAGTGCATTGGGGGCCGAATACAGGTGGGCGGGGAAGCTGCATTGCAGAGCCAGCGGTA
CCAGCAAAACCTGCAGTTACAGGAGAATAGCTTTAAACACGACAGGGAGATGATTGGATATCAGGTGGAGGCCAG
CAATCAGCTGCTCGCAAAAACCTGGCTACTCGATACTCATTACTGCGCGCCGGGGGTTGACTAGCGCCGACGCCG
CACGATCTGTGCGAGGCGCCCCGTGACTCGGATCGTAGACTGGAACGGGTACGAGTCTCGGCTCCCGAGTCGTC
TGCAACCACCTGAGGTGGGAGGGTTTATGTCCGTGCCATCCCATTCTGCTAGCAAACAGAAACAGGTCCAGAGCT
CCGGAATCTCCAATCCCAATTAATCCCTAGCTCTATCTCTGTACCACTTCTGGGTGAGAGTCAGAACAGCAGTA
GATTTGGCAACCTGAGCCCTACCATGCTGAAGCCCTGAACACTGTGTGGTTGACTCCACCTGGTAGCACGGCCTCC
TCAACCCTGAGTTCGCTGCCTGCGGGTACTTCAATACCGACAGACTTCCTCTGTTGCTAACAACCGCCGCTGATGT
TGTAATATGAAATGTGGGCATCATATTCATTTAATTAGGTTTAATTAGGTTTAATTTGATGTT

Figure 25A

Amino acid sequence of S(Gl.1)+P(Gl.2) fusion VP1 (SEQ ID NO: 22)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFBVQAPQGEFTISPNNTF
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMRVRIMLAGNAFTAGKIIVSCIPPGFGSHNLIAQATLFPHVIADVRTLD
 PIEVPLEDVNRVLFHNNDNRNQQTMLVCMLYTPLRTGGGTGDSFVAGRVMTCPSPDFNLFVLPPTVEQKTRAFVTP
 NIPLQTLNSRFPSLIQGMILSPDASQVVFQNGRCLIDGQLLGTTPATSGQLFRVRGKINQGARTLNLTEVDGKPFMAF
 DSPAPVGFPDFGKCDWHMRISKTPNNTSSGDPMRSDVQTDVQGFVPHLGSIQFDEVFNHPTGDYIGTIEWISQSTPP
 GTDINLWEIPDYGSSLSQAANLAPPVFPFGFGEALVYFSAFPGPNRNSAPNDVPCLLPQEYVTHFVSEQAPTMGDAALL
 HYVDPDTNRNLGEFKLYPGGYLTCVPNGVVGAGPQQLPLNGVFLFVSWVSRYQLKPVGTASTARGRLGVRR*

Figure 25B

Nucleic acid sequence of human codon optimized S(Gl.1)+P(Gl.2) fusion VP1 (SEQ ID NO: 57)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCGTCAGGGGCAGGACAACCTCGTACCCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGCGAGTTCACAATTCACCAACAATACACCGG
 GCGATGTGCTATTCGATCTTTCCTTGGGTCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTG
 CTCCCGGATTGGATCTCATAATCTGACCATTGCTCAAGCGACTCTCTTCCCATGTATCGCCGACGTTAGGACCTT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACAGCAGACGATG
 AGACTTGTCTGTATGCTCTATACCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTCTTTTTCTGGTCCCACCAACCGTTGAGCAAAAAACAAGAGCATTCA
 CAGTGCCCAACATTCCACTGCAGACTTTAAGCAATTCAGGTTTCCAGCTTGATCCAGGGTATGATCCTTCTCCCG
 ACGCCTCCCAAGTTGTGCAGTTCAGAATGGGAGATGTCTTATCGACGGTCAGCTTCTGGGAACAACCCCTGCCACC
 TCCGGGCAACTCTCCGGGTGAGAGGCAAAATCAATCAGGGCGCCAGAACTGAATCTGACAGAAAGTGGACGGG
 AAACCTTTATGGCGTTGATAGCCCCGCGCCGTTGGATTCCCTGACTTCGGCAAGTGTGATTGGCACATGCGCAT
 CAGTAAGACTCCCAACAACATTCATCTGGAGACCCATGAGGAGCGTGGATGTCCAGACCGACGTGCAGGGCTTC
 GTGCCGCACTTGGGATCTATCCAGTTCGATGAGGTGTTCAATCACCTACTGGCGACTACATAGGCACAATTGAGTG
 GATAAGTCAACCATCTACACCTCCAGGGACCGACATAAACCTGTGGGAAATTCCTGATTACGGGTGATCCCTGAGTC
 AAGTGCCTAATCTTGCACCCCTGTCTTCCCCCGGCTTGGTGAGGCTCTTGTCTTACTTCGTCTCTGCATTTCTGG
 TCCTAACACCGCTCCGCCCTAACGATGTTCCGTGTTTGTACCCAGGAATATGTGACTCATTTCTGTTCCGAACA
 GGCACCCACCATGGGGGACGCTGCCCTGCTACACTATGTGGACCCGACACCAATAGAAACCTCGGCGAGTTCAAA
 CTCTACCCCGGGGGATACCTGACCTGTGTTCCAAATGGAGTGGGAGCAGGCCCAACAGCTGCCCTGAATGGGG
 TCTTCTGTTCTGTTCTTGGGTGTCACGCTTTTACCAGCTGAAGCCCGTTGGCACAGCTTCTACGGCACGCGGCAGGC
 TAGGGGTCCGCCGAATCTGA

Figure 26A

Amino acid sequence of S(Gl.1)+P(Gl.3) fusion VP1 (SEQ ID NO: 23)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFFVQAPQGEFTISPNNTP
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIVSCIPPGFGSHNLTIAQATLFPHVIADVRTL
 PIEVPLEDVNRNLFHNNDNRNQQTMLVCMPLYTLRTGGGTGDSFVAGRVMTCPSPDFNFLVPTVEQKTKPFSVPN
 LPLNVLSNSRVPSLIKSMMSVQDHGQMVQFQNGRVTLTGQQLGTTPTSASQLCKIRGTVYHATGGQGLNLTEIDGTPY
 HAFESPAPIGFDLGECDWHINASPANAFTDGSIIHRIDVAQDSTFAPHLGTIHYTNADYNANVGLICSLEWLSPPSGGAP
 KVNPPWAIPRYGSTLTEAAQLAPPIYPPGFGEAIVFFMSDFPIANGSDGLSVPCTIPQEFVTHFVNEQAPTRGEAALLHYVD
 PDTHRNLGFEKLYPEGFMTCVPSNGSGPQTLPIGVFTFISWVSRFYQLKPVGTTGPVRRLGIRRS*

Figure 26B

Nucleic acid sequence of human codon optimized S(Gl.1)+P(Gl.3) fusion VP1 (SEQ ID NO: 58)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCGTCAGGGGCAGGACAACCTCGTACCCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGCGAGTTCACAATTCACCAACAATACACCGG
 GCGATGTGCTATTCGATCTTCTCTGGGTCTCACCTTAACCCTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATT
 CTCCCGGATTGGATCTCATAATCTGACCATGCTCAAGCGACTCTCTTCCCATGTATCGCCGACGTTAGGACCT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACCAGCAGACGATG
 AGACTTGCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTTCTTTTTCTGGTCCCAACCGTTGAGCAGAAAAACAAGCCATTCA
 GCGTGCCAAACCTGCCCTTAACGTGCTGTGCAATTCGAGTGCCTTCCCTTATTAAGTCCATGATGGTATCTCAGG
 ATCACGGTCAAATGGTGCAGTTTCAGAACGGCCGAGTGACGTTAGACGGGCAGCTGCAGGGCACAACCCCAACCA
 GTGCCAGTCAGCTGTGTAAGATCAGAGGCACCGTCTACCACGCAACTGGCGGACAGGGGCTGAATCTTACTGAGAT
 CGATGGTACCCCTACCATGCATTCGAGTCACCTGCACCTATTGGATTTCGATCTTGGGGAGTGTGATTGGCATAT
 CAATGCTTCACCTGCCAACGCTTTCACAGACGGGTCTATTATTCATCGCATTGACGTAGCACAGGATAGCACATTTGC
 CCCGCACCTGGGTACCATCCACTATACGAACGCAGATTACAACGCAACGTGGGTCTTATCTGTAGCCTAGAGTGGC
 TATCTCCGCAAGCGGTGGGGCCCCTAAAGTTAACCCATGGGCTATTCTCGGTACGGGTCTACGCTGACTGAGGCC
 GCTCAGCTGGCACCCCATATATCCACCAGGATTCGGGGAAGCCATTGTTTTCTTATGTCCGATTTCCGATAGCC
 AACGGTTACAGATGGCCTTAGTGTCCCTGCACGATTCCACAGGAATTTGTGACACACTTCGTAACGAGCAGGCTCC
 TACTCGGGGCGAGGCTGCCTTGTTGCATTACGTAGACCCCGATACCCATAGAAACCTGGGCGAATTCAAACCTTACC
 CTGAAGGTTTCATGACCTGCGTACCTAACTCCTCCGGCAGTGGCCCTCAAACCTTGCCGATCAACGGCGTGTTCACGT
 TTATCAGCTGGGTTTCACGGTTTTACCAACTCAAGCCCGTCGGAACAACTGGGCCAGTTCGGAGGCTCGGGATCAGA
 CGGAGCTAG

Figure 27A

Amino acid sequence of S(GI.1)+P(GII.4) fusion VP1 (SEQ ID NO: 24)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFFVQAPQGEFTISPNNTP
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIVSCIPPGFGSHNLIAQATLFPHVIADVRLD
 PIEVPLEDVRNVLFHNNDNRNQQTMLVLCMLYPLRTGGGTGDSFVAGRVMTCPSPDFNFLVPTVESRTKPFVSPV
 LTVEEMTNSRFPIPLEKFTGPSSAFVVPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDY
 DPTEEIPAPLGTDPDFVGKIQGVLTQTRTDGSTRGHKATVYTGSADFAPKLGRVQFETDTRDFEANQNTKFTPVGVIQD
 GGTTHRNEPQQWVLPYSYGRNTHNVHLAPAVPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAAPA
 QSDVALLRFVNPDTGRVLFECKLHKSGYVTVAHGTGQHLVIPPNGYFRFDSWVNQFYTLAPMNGTGRRAV*

Figure 27B

Nucleic acid sequence of human codon optimized S(GI.1)+P(GII.4) fusion VP1 (SEQ ID NO: 59)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGCAGGACAACCTGTAACCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGCGAGTTCACAATTCACCAACAATACACCGG
 GCGATGTGCTATTCGATCTTTCCTTGGGTCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTG
 CTCCCGGATTTGGATCTCATAATCTGACCATGCTCAAGCGACTCTCTTCCCATGTATCGCCGACGTTAGGACCTT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACAGCAGACGATG
 AGACTTGTCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTCTTTTTCTGGTCCCAACCGTTGAGAGCCGAACCAAGCCCTTAG
 TGTCCTCCGTACTCACAGTCGAGGAGATGACAAATAGCCGCTTCCAATCCCCCTTGAGAACTGTTACAGGACCTTC
 CTCGGCATTCGTGGTTCAGCCACAGAACGGACGCTGCACAACCTGACGGCGTGCTGCTCGGAACCAACCCAGCTTAGC
 CCTGTTAATATCTGTACGTTTAGAGGCGACGTAACCTACATAACTGGCTCACGGAACCTATACCATGAATCTGGCATCA
 CAGAATTGGAATGACTACGACCAACCGAAGAGATTCGCGACCTCTTGGAACCCCGACTTTGTGGGAAAAATACA
 GGGCGTCTGACACAAACCAACGAGATGGCTCCACACGGGGACACAAGGCAACCGTCTACACTGGCTCTGCC
 GATTTTGGCCCGAACTGGGTAGAGTGAGTTTGAAGCCGACACTGACCGGGACTTTGAAGCCAATCAGAATACTA
 AGTTCACACCTGTAGGAGTGATTGAGGACGGGGGACCACTCACCGGAACGAGCCGCAACAATGGGTCTGCCCTC
 TTATAGCGGGAGGAATACTCATAATGTGCATTTGGCTCCTGCAGTGGCTCCACGTTTCCCGGGGAACAACCTGCTCT
 TTTTTCGTTCAACCATGCCTGGATGCTCCGATATCCAATATGGATCTCGATTGCCTGCTCCACAGGAATGGGTGC
 AGTATTTTATCAAGAGGCCGACCAAGCCCAATCCGACGTCGCACTTCTGCGGTTCTGTAATCCAGACACAGGCCGC
 GTGTTGTTTGAAGTGCATTCACAAATCAGGATACGTTACAGTGGCTCATACTGGACAGCATGACCTGGTGATCCC
 ACCCAACGGATATTTAGGTTGACTCCTGGGTGAATCAGTTTATACATTAGCCCCCATGGGGAATGGGACTGGCA
 GACGAGGGCTGTCTGA

Figure 28A

Amino acid sequence of S(GI.1)+P(GII.6) fusion VP1 (SEQ ID NO: 25)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFBVQAPQGEFTISPNNT
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIVSCIPPGFGSHNLIAQATLFPHVIADVRTLD
 PIEVPLEDVRNVLFHNNDNRNQQTMLVCMLYTPLRTGGGTGDSFVAGRVMTCPSPDFNLFVLPPTVESKTKPFLPIL
 TLGELSNSRFPAPIDMLYTDPNNEGIVVQPQNGRCTLDTLQGTTLVPTQICAFRGTLIGQTSRSPDSTDSAPRRRDHPLH
 VQLKNLDGTQYDPTDEVPAVLGAIDFKGTVFGVASQRDVSGQQVQVATRAHEVHINTTDPRTYTPKLGSLMYSESDDFVT
 GQPVRFPIGMDNDWHQWELPDYPGHLTLNMNLAPAVAPAFPERILFFRSIVPSAGGYGSGQIDCLIPQEWVQHFY
 QEAAPSQSAVALIRYVNPDTGRNIFEAKLHREGFITVANSNNPIVPPNGYFRFEAWVNQFYTLTPMGTGQGRRRDQ*

Figure 28B

Nucleic acid sequence of human codon optimized S(GI.1)+P(GII.6) fusion VP1 (SEQ ID NO: 63)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGCAGGACAACCTCGTACCCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGCGAGTTCACAATTCACCAACAATACACCGG
 GCGATGTGCTATTCGATCTTCTGGTCTCACCTTAACCTTTTCTACTCCATCTCTACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATT
 CTCCCGATTGGATCTCATAATCTGACCATGCTCAAGCGACTCTTTTCCCATGTATCGCCGACGTTAGGACCTT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACAGCAGACGATG
 AGACTTGTCTGTATGCTCTATACCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTTCTTTTCTGGTCCCAACCGTTGAGAGCAAGACAAAACCTTCA
 GCCTCCAATCTTAACACTCGGGGAGCTGTCTAATTCACGCTTCCCCGCACCTATTGATATGCTGTATACTGACCCCA
 ACGAGGGGATAGTGGTGCAGCCCCAAATGGACGGTGTACTCTCGACGGCACGCTCCAGGGCACAACCAACTGG
 TGCCAACCCAGATTTGTGATTGAGGGGCACTTTGATTGGGCAGACATCGAGATCTCCAGATTCTACTGATTCCGCG
 CCAAGGAGGAGGGACCACTCCACGTTCAAGTAAAAAACCTGGACGGAACCCAGTACGACCTACAGACGAGG
 TCCCCGCTGTCTCGGAGCCATCGACTTAAAGGAAGTGTATTTGGAGTGGCATCCCAAGGGATGTCTCGGGGCA
 GCAGGTGGGAGCTACGAGAGCACATGAAGTCCACATTAACACCACAGACCAAGATATACCCAAAACTAGGGTCA
 ATTTAATGTATTGGAATCAGACGATTTGTACAGGTGAGCCGTGCGGTTTACCCGATCGGAATGGGGGACAA
 CGATTGGCACCAGTGGGAATTGCCGATTACCTGGACACCTCACCTTGAATATGAATCTGGCCCCAGCCGTGCGGC
 CCGCCTTCCCCGGTGAGCGGATCTCTTTTGAAGCATAGTGCCTCCGAGGTGGGTATGGATCAGGGCAGATT
 GATTGCCTGATCCCCAAGAATGGGTACAGCATTTCTACCAGGAAGCAGCCCTAGCCAGTCCGAGTAGCACTGAT
 CAGATATGTTAATCCTGATACGGGAAGGAACATCTTGAAGCAAACTGCACCGTGAGGGCTTCATTACCGTCGCCA
 ACAGTGGAATAACCTATTGTGGTGCCTCCTAATGGATACTTCAGGTTTGAGGCATGGGTGAATCAGTTTATACTC
 TGACTCCCATGGGACAGGCCAGGGGCGACGCCGGGATCAGTGA

Figure 29A

Amino acid sequence of S(GI.1)+P(GII.13) fusion VP1 (SEQ ID NO: 26)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFBVQAPQGEFTISPNNTP
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIIVSCIPPFGSHNLIAQATLFPHVIADVRTLD
 PIEVPLEDVRNVLFHNNDNRNQQTMLVCMPLYTLRTGGGTGDSFVAGRVMTCPSPDFNFLVLPPTVESKTKPFTLPIL
 TISELTNSRFPISIEQLYTAPNENNVVQCQNGRCTLGELQGTQQLSSAVCSYRGRTVANSNGDNWDQNVLQLTYPGAS
 YDPTDEVPAPLGTQDFSGILYGVLTQDNVRENTGEAKNAKGVYISTTSKFTPKIGSIGLHSITEDVRPNQQSRFTPVGVA
 QNENTPFQQWVLPYAGALALNTNLAPAVAPTFPGEQLLFFRSRVPVQGLQGQDAFIDCLLPQEWVNHFYQEAAPSQ
 ADVALIRYVNPDTGRTLFEAKLHRSGFITVSHTGAYPLVPPNGHFRFDSWVNQFYSLAPMGTGNGRRRVQ*

Figure 29B

Nucleic acid sequence of human codon optimized S(GI.1)+P(GII.13) fusion VP1 (SEQ ID NO: 64)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGAGGACAACCTGTAACCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGGAGTTCACAATTCACCAACAATACACCGG
 GCGATGTGCTATTCGATCTTTCCTTGGGTCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTG
 CTCCCGGATTTGGATCTCATAATCTGACCATGCTCAAGCGACTCTCTTCCCATGTATCGCCGACGTTAGGACCTT
 GGACCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACAGCAGACGATG
 AGACTTGTCTGTATGCTCTATACCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTTCTTTTCTGGTCCCAACCGTTGAGAGCAAGACTAAACCTTTAC
 TCTTCCATTCTGACTATATCCGAGCTTACCAACTCCCGGTTCCCATCTCAATCGAGCAACTGTACTGCAACCAAC
 GAGAACAACGTAGTCCAGTGCCAGAACGGGAGATGTACCCTGGACGGGGAGCTCAAGGGACACGCAACTGTTA
 AGTTCAGCCGTTTGCAGTTACAGAGGCAGGACTGTGGCGAACTCTGGTGATAACTGGGATCAAAATGTGTTGCAGC
 TGAATTACCATCCGGCGCAAGCTACGATCCAACAGATGAGGTGCCAGCGCCCTTGGCACACAGGATTTCTCAGGA
 ATTCTATACGGGGTGCTTACTCAGGATAATGTGCGAGAAAATACTGGCGAGGCCAAGAATGCTAAAGGAGTGTATA
 TAAGCAGACAAGCGGTAAGTTTACCCCCAAAATTGGCAGTATTGGGCTCCACAGCATTACTGAGGACGTCCGCCCA
 AACCAGCAGTCTCGTTTCACTCCCGTGGGGGTGGCACAGAACGAGAACACACCTTTCCAGCAGTGGGTCTTGCCCCA
 TTATGCAGGTGCTTTGGCGCTCAATACAAATCTGGCACCCGCGTAGCGCCGACATTTCTGGGGAGCAATTGCTGT
 TCTTTAGAAGCCGCTGCCGTGTGTTCAAGGCTTGACAGGGCCAGGACGCGTTTATTGCTCTTGCCCCAGGAA
 TGGGTCAACCACTTTTATCAGGAGGCAGCGCCCTCTCAAGCAGATGTGGCCCTGATAAGATATGTGAATCCCGACAC
 AGGACGGACTTTGTTTGAAGCAAACTCCACCGGTCAAGATTCTTACTGTGAGTCACACAGGAGCCTATCCCTTG
 TGGTTCCACCTAATGGCCACTTCAGGTTCACTCTGGGTCAATCAGTTTATTGCTGGCACCAATGGGTACCGGGA
 ATGGTCGCCGTCGGGTGCAATGA

Figure 30A

Amino acid sequence of S(GI.1)+P(GII.17) fusion VP1 (SEQ ID NO: 27)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFMVQAPQGEFTISPNNT
 GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRIMLAGNAFTAGKIIVSCIPPFGSHNLIAQATLFPPIADVRLD
 PIEVPLEDVNRNLFHNNDNRNQQTMLVLCMLYPLRTGGGTGDSFVAGRVMTCPSPDFNLFVLPPTVEQKTRPFTLPN
 LPLSSLSNSRAPLPISSMGISPDNVQSVQFQNGRCTLGRLVGTQQLPSGICAFRGRVTAETDHRDKWHMQLQNLNGT
 TYDPTDDVPAPLGTDFKGVVFGVASQRNVGNDAPGSTRAHEAVISTYSPQFVFKLGSVNFNRNDNDFQLQPTKFTPVG
 INDDGDHPFRQWELPDYSGLLTLNMLNAPSVPYPPGFGEVLVFFMSKMPGPGAYNLPCLLPQEYISHLASEQAPTVEGAA
 LLHYVDPDTGRNLGEFKAYPDGFLTCVPNGASSGPQQLPINGVVFVFS

Figure 30B

Nucleic acid sequence of human codon optimized S(GI.1)+P(GII.17) fusion VP1 (SEQ ID NO: 65)

ATGATGATGGCTAGTAAAGATGCGACCTCCTCTGTGGATGGTGCCTCAGGGGAGGACAACTCGTACCCGAGGTAA
 ACGCCAGCGACCCACTTGCCATGGACCCCGTTGCCGGAAGTTCCACAGCAGTGGCCACAGCCGGTCAAGTGAATCC
 AATTGATCCGTGGATTATCAACAATTCGTCCAGGCACCCAGGGGAGTTCAACAATTCACCAAAACAATACACCGG
 GCGATGTGCTATTCGATCTTTCCTTGGGTCTCACCTTAACCTTTTCTACTCCATCTCTCACAGATGTACAATGGTTG
 GGTAGGAAACATGAGAGTCCGGATCATGCTGGCTGGCAATGCCTTTACCGCTGGCAAGATCATCGTCAGTTGTATTG
 CTCCCGGATTGGATCTCATAATCTGACCATGCTCAAGCGACTCTCTTCCCATGTATCGCCGACGTTAGGACCTT
 GGACCCCATCGAGGTGCCCTGGAGGACGTCCGGAATGTTTGTCCACAACAACGACAGAAACAGCAGACGATG
 AGACTTGCTGTATGCTCTATACCCCACTGCGGACTGGAGGCGGGACTGGAGACTCCTTCGTTGTGGCAGGAAGAG
 TGATGACATGCCCCCTCCCCGACTTCAACTTTCTTTTCTGGTCCCAACCGTTGAGTCTAAGACCAACCGTTTTC
 ACTGCCAATCTTAACCTCTCTCGAACTGACTAACAGCCGGTTTCCAGTACCCATAGATTCTCTTTTACCGCTCAAAAC
 AACGTACTCCAAGTCCAGTGCCAGAACGGCCGCTGTACGCTTGATGGTGAGTTGCAGGGGACAACAGCTACTCC
 CCAGTGGCATCTGTGCATTCCGGGGCCGCGTGACCGCTGAGACAGACCATCGTGACAAATGGCACATGCAACTCCA
 AAATTAACGGGACCACTACGACCAACCGACGACGTCCCTGCTCCGCTAGGGACTCCTGACTTTAAGGGGGTG
 GTGTTCCGAGTGGCCTCTCAGCGGAATGTTGGGAATGACGCCCCGGCTCTACCCGAGCTCACGAGGCCGTTATCTC
 AACATATAGCCCCAATTTGTGCCAAGCTCGGATCCGTTAATTTTCTAGTAACGACAACGACTTCAACTGCAACC
 AACGAAGTTTACGCCAGTGGGGATTAATGATGATGGAGACCATCTTTCCGCAATGGGAATACCAGATTATTCTG
 GGCTGCTCACCCCTCAATATGAACCTCGCCCCACCGTGGCCCTAATTTCCCGGTGAGCAGCTGCTGTTTTTTCGGA
 GCTTTGTGCCATGCACTGGCGGATATAATCAAGGCATCTGAGACTGCTTGATTCCCCAAGAGTGATACAACATTTT
 TACCAGGAAAGTGCGCCCTCCAGTCCGATGTGGCCCTGATACGGTACGTTAACCCCGATACCGGAAGAATATTATT
 CGAAGCGAAATTGCACAGATCAGGGTACATTACCGTTGCACATTCGGCGATTATCCCTGGTGGTTCCCGCCAACG
 GTTACTTTAGGTTTCGATAGTTGGGTCAACCAAGTTCTATTCACTAGCCCCAATGGGCACCGGTAACGGCAGACGCCG
 GCTCAGTAG

Figure 31A

Amino acid sequence of S(GI.1)+P(GII.12) fusion VP1 (SEQ ID NO: 71)

MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIIINNFVQAPQGEFTISPNNTP
GDVLFDSLGLPHLNPFLHLSQMYNGWVGNMVRVIMLAGNAFTAGKIIIVSCIPPFGSHNLIAQATLFPPIADVRTLD
PIEVPLEDVRNVLFHNNDNRNQQTMLVCMYLTPLRTGGGTGDSFVAGRVMTCPSPDFNLFVLPPTVESKTKPFTLPIL
TIGELTNSRFPVPIDELYTSPNESLVVQPQNGRCALDGEQGTQLLPTAICSFRGRINQKVSNGENHVWNMQVTNIDGTP
FDPTEDVPAPLGTPDFSGKLFVLSQRDHDNACRSHDAVIATNSAKFTPKLGAIQIGTWEQDDVHINQPTKFTPVGLFES
EGFNQWTLPNYSGALTLNMGLAPPVAPTFPGEQILFFRSHIPLKGGVADPVIDCLLPQEWIQHLYQESAPSQTDVALIRFT
NPDTRGVLFKALHRSYITVANTGSRPIVVPANGYFRFDSWVNQFYSLAPMGTGNGRRRVQ*

Figure 31B

Amino acid sequence of S(GI.5)+P(GII.4) fusion VP1 (SEQ ID NO: 48)

MMMASKDAPSSADGANGAGQLVPEVNNAEPLPLDPVAGASTALATAGQVNMIDPWIFNNFVQAPQGEFTISPNNTP
GDILFDLQLGPHLNPFLAHLISQMYNGWVGNMVRVILAGNAFTAGKVIICVPPGFQSRSLIAQATLFPPIADVRTLEPI
EIPLEDVRNTLYHTNDNQPTMRLLCMLYTPPLRTGGGSGGTDAFVAGRVLTCPSSDFNLFVLPPTVESRTKPFVSVPLTV
EEMTNSRFPIPLEKLTGPSSAFVQPNQGRCTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDP
TEEIPAPLGTPDFVGKIQGVLTQTTRTDGSTRGHKATVYTGSAFAPKLRVQFETDTRDFEANQNTKFTPVGVIQDGG
TTHRNEPQQWVLPYSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPQS
DVALLRFVNPDTGRVLFECKLHKSGYVTVAGTGQHDVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV*

Figure 32A

Amino acid sequence of S(GII.1)+P(GI.3) fusion VP1 (SEQ ID NO: 49)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRNMNFVQAPNGEFTVSPRNSPGEVLL
NLELGPELNPFLAHLISRMNGYAGGVEVQVLLAGNAFTAGKLVFAAIPPHFPLENLSPGQITMFPHVIIDVRTLEPVLLPLP
DVRNFFHYNQPEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSDFDFNYLVPPTVEQTKPFVSVPLNLNVLS
NSRVPSLIKSMMSQDHGQMVQFQNGRVTLDGQLQGTTPTSASQLCKIRGTVYHATGGQGLNLTEIDGTPYHAFESPA
PIGFDPDLGECDDHINASPAFAFTDGSIIHRIDVAQDSTFAPHLGTIHYTNADYNANVGLICSLEWLSPSSGGAPKVNPAI
PRYGSTLTEAAQLAPPIYPPGFGEAIVFFMSDFPIANGSDGLSVPCTIPQEFVTHFVNEQAPTRGEAALLHYVDPDTHRN
LGEFKLYPEGFMTCVPNSSSGSPQTLPIGVFTFISWVSRYQLKPVGTTGPVRRLGIRRS*

Figure 32B

Amino acid sequence of S(GII.1)+P(GII.4) fusion VP1 (SEQ ID NO: 50)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRNMNFVQAPNGEFTVSPRNSPGEVLL
NLELGPELNPFLAHLISRMNGYAGGVEVQVLLAGNAFTAGKLVFAAIPPHFPLENLSPGQITMFPHVIIDVRTLEPVLLPLP
DVRNFFHYNQPEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSDFDFNYLVPPTVESRTKPFVSVPLTVVEEMT
NSRFPIPLEKLTGPSSAFVQPNQGRCTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDPTEEIP
APLGTPDFVGKIQGVLTQTTRTDGSTRGHKATVYTGSAFAPKLRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHR
NEPQQWVLPYSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPASDVAL
LRFVNPDTGRVLFECKLHKSGYVTVAGTGQHDVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV*

Figure 32C

Amino acid sequence of S(GII.1)+P(GII.17) fusion VP1 (SEQ ID NO: 51)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRNMFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPFLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAIPPHFPLENLSPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQPEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFSLPILTSELTS
 RFPVPIDSLFTAQNNVLQVQCQNGRCTLDELQGTQLLPSGICAFGRVTAETDHRDKWHMQLQNLNGTTYDPTDDV
 PAPLGTPDFKGVVFGVASQRNVGNDAPGSTRAHEAVISTYSPQFVPKLGSVNFRSNDNDFQLQPTKFTPVGINDDGDHP
 FRQWELPDYSGLLTNMMNLAPPVAPNFPGEQLLFFRSFVPCSGGYNQGIVDCLIPQEWIQHFYQESAPSQSDVALIRYVN
 PDTGRTLFEAKLHRSGYITVAHSGDYPLVVPANGYFRFDSWVNQFYSLAPMGTGNGRRRAQ*

Figure 33A

Amino acid sequence of S(GII.12)+P(GI.1) fusion VP1 (SEQ ID NO: 29)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRNMFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENLSPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVEQKTRPFTLPNPLSSLSN
 SRAPLPISSMGISPDNVQSVQFQNGRCTLGRLVGTTPVSLSHVAKIRGTSNGTVINLTDELGTPFHPFEGPAPIGFPDLG
 GCDWHINMTQFGHSSQTQYDVTTPDTFVPHLGSIQANGISGNYVGVLSWISPPSHPSGSQVDLWKIPNYGSSITEAT
 HLAPSVYPPGFGEVLVFFMSKMPGPGAYNLPCLLPQEYISHLASEQAPTVGEAALLHYVDPDTGRNLGEFKAYPDGFLTC
 VPNGASSGPQQLPINGVFVFSWVSRYQLKPVGTASSARGRLGLRR*

Figure 33B

Amino acid sequence of S(GII.12)+P(GI.2) fusion VP1 (SEQ ID NO: 30)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRNMFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENLSPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVEQKTRAFTVPNIPLQTL
 NSRFPSLIQGMILSPDASQVVFQNGRCLIDGQLLGTTPATSGQLFRVRGKINQGARTLNLTEDVGKPFMAFDSPAPVGF
 PDFGKCDWHMRISKTPNNTSSGDPMSVDVQTDVQGFVPHLGSIQFDEVFNHPTGDYIGTIEWISQPSTPPGTDINLW
 EIPDYGSSLSQAANLAPPVFPPGFGEALVYFVSAPFGPNRNSAPNDVPCLLPQEYVTHFVSEQAPTMGDAALLHYVDPDT
 NRNLGEFKLYPGGYLTCVPNGVGAGPQQLPLNGVFLFVSWVSRYQLKPVGTASTARGRLGVRRI*

Figure 33C

Amino acid sequence of S(GII.12)+P(GI.3) fusion VP1 (SEQ ID NO: 31)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRSPDFDFNYLVPPTVEQKTKPFSVPNLPLNVLS
 NSRVPSLIKSMMSQDHGQMVQFQNGRVTLDGQLQGTTPTSASQLCKIRGTVYHATGGQGLNLTIDGTPYHAFESPA
 PIGFPDLGECDDWHINASPANAFTDGSIIHRIDVAQDSTFAPHLGTHYTNADYNANVGLICSEWLSPSPSGGAPKVPNPWAI
 PRYGSTLTEAAQLAPPIYPPGFGEAIVFFMSDFPIANGSDGLSVPCTIPQEFVTHFVNEQAPTRGEAALLHYVDPDTHRNL
 GEFKLYPEGFMTCPVNSSSGSPQTLPIGVFTFISWVSRYQLKPVGTTGPVRRLGIRRS*

Figure 33D

Amino acid sequence of S(GII.12)+P(GI.5) fusion VP1 (SEQ ID NO: 32)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRSPDFDFNYLVPPTVEQKTRPFSVPNIPLQLLSN
 SRVPLIQSMVLSPDQAQNVQFQNGRCTTDGQLLGTTPVSQILKFRGKVSAGSKVINLTLDGSPFLAFAEAPAGTGF
 DLGTSDWHVEMSLNSNSQSSGNPILLRDIHPNSSEFVPHLGSVCVTAIEVAGDYTGTIQWTSQPSNVTPVPDVNFWTIP
 HYGSNLAEASQLAPVVYPPGFGEAIVYFMSPIPGPNTAHKPNLVPCLLPQEFVTHFVSEQAPSMGEAALVHYVDPDPTNR
 NLGEFKLYPEGFITCVPNGTGPQQLPLNGVVFASWVSRYQLKPVGTASSARGRLGVRR*

Figure 33E

Amino acid sequence of S(GII.12)+P(GII.1) fusion VP1 (SEQ ID NO: 33)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRSPDFDFNYLVPPTVESKTKPFTLPILTIGELSNS
 RFPVPIDELYTSPNEGVEVVQPNGRSTLDGELLGTTQLVPSNICALGRINAQVDDHHQWNLQVTNANGTSFDPTE
 PAPLGTPDFLANIYGVTSQRNPDNCRADGVLATWSPKFTPLKGSVVLGTWEESDLNLNQPTRFTPVGLYDTHGF
 WVLPNYSGRLTLNMLNAPSAPVLPFGEQILFFRSHIPLKGGTSNGAIDCLLPQEWIQHFYQESAPSPTDVALIRYTNPD
 TVLFEAKLHRQGFTIVANSGRPIVPPNGYFRFDSWVNQFYSLAPMGTGNGRRRVQ*

Figure 33F

Amino acid sequence of S(GII.12)+P(GII.2) fusion VP1 (SEQ ID NO: 34)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNFVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPYLAHLSRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRSPDFDFNYLVPPTVESKTKPFTLPILTIGELSNS
 RFPVSIDQMYTSPNEVISVQCQNGRCTLGELQGTTLQVSGICAFKGEVTAHLHDNDHLYNVITITNLNGSPFDPSEDIP
 APLGVPDFQGRVFGVISQRDKHNTPGHNEPANRAHDVVPYTYAQYTPKLGQIQIGTWQTDLLTNQPVKFTPVGLND
 TDHFNQWVVPYAGALNLTNLAPSAPVFPGERLLFFRSYIPLKGGYGTAPDCLLPQEWVQHFYQEAAPSMSEVALV
 RYINPDTEGRALFEAKLHRAGFMTVSSNTSAPVVVPANGYFRFDSWVNQFYSLAPMGTGNGRRRIQ*

Figure 33G

Amino acid sequence of S(GII.12)+P(GII.3) fusion VP1 (SEQ ID NO: 35)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNYPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFSLPILTISEMSNS
 RFPVPIDSLHTSPTEINIVVQCQNGRVTLDGELMGTTQLLPSQICAFRGTLTRSTSRASDAQDTATPRLFNYYWHIQLDNLN
 GTPYDPAEDIPAPLGTPDFRGKVFVGASQRNPDATTRAHEAKIDTTSGRFTPKLGSLEISTESGDFDQNPTRFTPVGIGV
 DHEPDFQQWALPDYAGQFTHNMNLAPAVAPNFPGEQLLFFRSQLPSSGGRSNGILDCLVPQEWVQHFYQESAPSQTQ
 VALVRYVNPDTGRVLFEAKLHKLRFMTIAKSGDSPITVPPNGYFRFESWVNPFYTLAPMGTGNRRRIQ*

Figure 33H

Amino acid sequence of S(GII.12)+P(GII.4) fusion VP1 (SEQ ID NO: 36)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNYPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESRTKPFVSVPLTVEEMT
 NSRFPIPLEKFTGPSSAFVVPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDPTTEEIP
 APLGTPDFVGKIQGVLTQTTRTDGSTRGHKATVYTGSAFAPKLGRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHR
 NEPQQWVLPSSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPAQSDVAL
 LRFVNPDTGRVLFECKLHKSQYVTVAGTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV*

Figure 33I

Amino acid sequence of S(GII.12)+P(GII.5) fusion VP1 (SEQ ID NO: 37)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNYPYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFTLPVLTGELSN
 SRFPLSIDEMVTSPNESIVVQPQNGRVTLDGELLGTTQLQACNICSIRGKVTGQVPNEQHMWNLEITNLNGTQFDPTDD
 VPAPLGVPDFAGEVFGVLSQRNRGESNPANRAHDVAVATYSKYTPKLGLVQIGTWNTNDVENQPTKFTPIGLNEVAN
 GHRFEQWTLPRYSGALTLMNLAPAVAPLFPGERLLFFRSYVPLKGGFGNPAIDCLVPQEWVQHFYQESAPSLGDVAL
 RYVNPDTGRVLFEAKLHKGGLTVSSTSTGPVVVPANGYFRFDSWVNQFYSLAPMGTGNRRRFQ*

Figure 33J

Amino acid sequence of S(GII.12)+P(GII.6) fusion VP1 (SEQ ID NO: 38)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPLYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFSLPILTLGELSNS
 RFPAPIDMLYTDPNEGIVVQPQNGRCTLDTLQGTTLVPTQICAFRGTLIGQTSRSPDSTDSAPRRRDHPLHVQLKNLD
 GTQYDPTDEVPAVLGAIDFKGTVFGVASQRDVSGQVQVATRAHEVHINTTDPRTYTPKLSILMYSESDDFVTGQPVRF
 PIGMGDNDWHQWELPDYPGHLTLNMLAPAVAPAFPGERILFFRSIVPSAGGYSGQIDCLIPQEWVQHFYQEAAPSQ
 SAVALIRYVNPDTGRNIFEAKLHREGFITVANSNGNPIVPPNGYFRFEAWVNQFYTLTPMGTGQRRRDQ*

Figure 33K

Amino acid sequence of S(GII.12)+P(GII.7) fusion VP1 (SEQ ID NO: 39)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPLYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKQFTLPILKISEMTN
 SRFPVPVEMMYTARNENQVQVQNGRVTLDGELLGTTPLAVNICKFKGEVIAKNGDVRSYRMDMEITNTDGTPIIDPTE
 DTPGPIGSPDFQGILFGVASQRNKNEQNPAATRAHEANINTGGDQYAPKLAQVKFFSESQDFEVHQPTVFTVGVAGDTS
 HPFRQWVLPRYGGHLTNTHLAPAVAPLFPGEQILFFRSQIPSSGGHELGYMDCLVPQEWVQHFYQEAATAQSEVALIR
 FINPDTGRVLFEAKLHKQGFITVAHTGDNPIVMPPNGYFRFEAWVNQFYSLAPVGTGNGRRRIQ*

Figure 33L

Amino acid sequence of S(GII.12)+P(GII.13) fusion VP1 (SEQ ID NO: 40)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVQAPNGEFTVSPRNSPGEVLL
 NLELGPELNPLYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPFHVIIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFTLPILTISELTNS
 RFPISIEQLYTAPNENNVVQCQNGRCTLDTLQGTTLSSAVCSYRGRTVANSNGDNWDQNVLQLTYPGASYDPTDEV
 PAPLGTQDFSGILYGVLTQDNVRENTGEAKNAKGVYISTTSKFTPKIGSIGLHSITEDVRPNQQSRFTPVGVQAQNTNPF
 QQWVLPYAGALANTNLAPAVAPTFPGEQLLFFRSRVPCVQGLQGQDAFIDCLLPQEWVNHFYQEAAPSQADVALIR
 YVNPDTGRTLFEAKLHRSGFITVSHGTAYPLVPPNGHFRFDSWVNQFYSLAPMGTGNGRRRVQ*

Figure 33M

Amino acid sequence of S(GII.12)+P(GII.14) fusion VP1 (SEQ ID NO: 41)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNPNYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKNFTLPVLRVSEMT
 NSRFPVLDQMYTSRNNIIVQPQNGRCTTDGELLGTTILQSVSICNFKGTMQAKLNEEPYQLQLTNLDGSPIDPTDDM
 PAPLGTPDFQAMLYGVASQRSSIDNATRAHDAQIDTAGDTFAPKIGQVRFKSSNDFDLHDPTKFTPIGVNVDDQHPPFR
 QWSLPNYGGHLALNNHLAPAVTPLFPGEQILFFRSYIPSAGGHTDGAMDCLLPQEWVEHFYQEAAPSQSDIALVRFINPD
 TGRVLF EAKLHKQGF LTIAASGDHPVIMPTNGYFRFEAWVNPFFYTLAPVGTGSGRRRIQ*

Figure 33N

Amino acid sequence of S(GII.12)+P(GII.17) fusion VP1 (SEQ ID NO: 42)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNPNYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFSLPILTLSELTNS
 RFPVPIDSLFTAQNNVLQVQCQNGRCTLDGELQGTTLQPSGICAFGRVTAETDHRDKWHMQLQNLNGTTYDPTDDV
 PAPLGTPDFKGVVFGVASQRNVGNDAPGSTRAHEAVISTYSPQFVPKLGSVNFRSNDNDFQLQPTKFTPVGINDDGDHP
 FRQWELPDYSGLLTNLNMNLAPPVAPNFPGEQLFFRSFVPCSGGYNQGIVDCLIPQEWIQHFYQESAPSQSDVALIRYVN
 PDTGRTLFEAKLHRSGYITVAHSGDYPLVVPANGYFRFDSWVNQFYSLAPMGTGNGRRRAQ*

Figure 33O

Amino acid sequence of S(GII.12)+P(GII.21) fusion VP1 (SEQ ID NO: 43)

MKMASNDAAPSNDGAAGLVPEVNNETMALEPVAGASIAAPLTGQNNVIDPWIRLNQVAPNGEFTVSPRNSPGEVLL
 NLELGPELNPNYLAHLRMYNGYAGGVEVQVLLAGNAFTAGKLVFAAVPPHFPLENISPGQITMFPHVIIDVRTLEPVLLPLP
 DVRNFFHYNQNEPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPSPDFDFNYLVPPTVESKTKPFTLPILTIGELTNS
 RFPAPIDQLYTSPNADVVPQNGRCTLDGELQGTTLQTTAICSYRGMTSNPTSDYWDDHLLHLVHPNGATYDPTEDV
 PAPFGTQDFRGILYGMTQNPRTSGDEAANSHGIYSSTSEKFTPKLGTIGLHQVQGDIASNQSKFTPVGIAVNGNTPFR
 QWELPNYSGALTNLNLAPAVGPNFPGEQILFFRSNVPSVQGGQPIEIDCLIPQEWVSHFYQESAPSQSDVALVRYVNP
 TGRITFEAKLHRQGFIITAAATGSNPVVPPNGYFRFDSWVNQFYALAPMGTGNGRRRVQ*

Figure 34A

Amino acid sequence of S(GII.14)+P(GII.4) fusion VP1 (SEQ ID NO: 52)

MKMASNDATPSDDGAAGLVPEINNEVMALEPVAGASIAAPVVGQQNIIDPWIRNNFVQAPAGEFTVSPRNSPGELLLD
LELGPELNPLYLAHLARMYNGHAGGMEVQIVLAGNAFTAGKILFAAIPPSFPYENLSPAQLTMCPHVIVDVRQLEPVLLPM
PDIRNVFYHYNQNNSPKRLVAMLYTPLRANNSGDDVFTVSCRVLTRPSPDFQFTFLVPPTVESRTKPFSPVPLTVEEMTN
SRFPIPLEKLFTGPSSAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDPTEEPAP
LGTPDFVGKIQGVLTQTRTDGSTRGHKATVYTGSAADFAPKLGRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHRNE
PQQWVLPSSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAAPAQSDVALLR
FVNPD TGRVLFECKLHKSGYVTVAH TGQHD LVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV*

Figure 34B

Amino acid sequence of S(GII.21)+P(GII.4) fusion VP1 (SEQ ID NO: 53)

MKMASNDAAPSNDGATGLVPEINTETLPLEPVAGAAIAAPVTGQNNIIDPWIRNNFVQAPNGEFTVSPRNSPGEILMNL
ELGPDNLNPLYLAHLARMYNGYAGGVEVQVLLAGNAFTAGKILFAAVPPNFPVDMLSPAQITMLPHLIVDVRTLEPIMIPLP
DVRNVFYHFNNQPAPRMRLVAMLYTPLRSNGSGDDVFTVSCRVLTRPTDFEFTYLVPPSVESRTKPFSPVPLTVEEMTN
SRFPIPLEKLFTGPSSAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYTMNLASQNWNDYDPTEEPAP
LGTPDFVGKIQGVLTQTRTDGSTRGHKATVYTGSAADFAPKLGRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHRNE
PQQWVLPSSYGRNTHNVHLAPAVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAAPAQSDVALLR
FVNPD TGRVLFECKLHKSGYVTVAH TGQHD LVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV*

Figure 35

Sequence identifier	Primer name	Nucleic acid sequence (5' to 3')
SEQ ID NO: 111	IF-GI3Li08VP1.c	TCGTGCTTCGGCACCAGTACAATGATGGCTTCCAAGGATGCTCCCA
SEQ ID NO: 98	IF-GI3Li08VP1.r	ACTAAAGAAAAATAGGCCTCTAGCTCCGTCTGATCCCGAGCCTCCGAACT
SEQ ID NO: 112	IF-GI4Syd12VP1.c	TCGTGCTTCGGCACCAGTACAATGAAAAATGGCCTCGAGTGACGCTAACCC
SEQ ID NO: 101	IF-GI4Syd12VP1.r	ACTAAAGAAAAATAGGCCTTCAGACAGCCCTGCGTCTGCCAGTCCCAATT
SEQ ID NO: 113	IF-GI6Oh112VP1.c	TCGTGCTTCGGCACCAGTACAATGAAGATGGCAAGCAACGACGACGCTC
SEQ ID NO: 104	IF-GI6Oh112VP1.r	ACTAAAGAAAAATAGGCCTTCACTGATCCCGGCGTCGCCCTGTCTCCCAT
SEQ ID NO: 114	IF-GI13VA10VP1.c	TCGTGCTTCGGCACCAGTACAATGAAAAATGGCTTCTAATGATGCCGCGCCAGCAATGA
SEQ ID NO: 107	IF-GI13VA10VP1.r	ACTAAAGAAAAATAGGCCTTCATTGCACCCGACGGCGACCAATCCCGGTACCCA
SEQ ID NO: 115	IF-GI17Kaw14VP1.c	TCGTGCTTCGGCACCAGTACAATGAAAAATGGCATCTAACGACGACGCCCTC
SEQ ID NO: 110	IF-GI17Kaw14VP1.r	ACTAAAGAAAAATAGGCCTCTACTGAGCCCGGCGTCTGCCGTTACCGGTGCCCATTTG
SEQ ID NO: 96	GI3Li+GI1VP1.r	GAATGGCTTTGTTTCTGCTCAACGGTTGGTGGGACAGAAAAAGAAAGTTGAAGT
SEQ ID NO: 97	GI1VP1+GI3Li.c	TCCACCAACCGTTGAGCAGAAAAACAAAGCCATTGAGCGTGCCAAACC
SEQ ID NO: 99	GI4Syd+GI1VP1.r	AAGGGCTGGTTCGGCTCTCAACGGTTGGTGGGACCAAGAAAAAGAAAGT
SEQ ID NO: 100	GI1VP1+GI4Syd.c	TCCACCAACCGTTGAGAGCCGAACCAAGCCCTTTAGTGTCCTCCGTACT

Figure 35 continued

SEQ ID NO: 102	GI16Ohi+GI1VP1.r	AAGGGTTTTGTCTTGTCTCTCAACGGTTGGTGGGACCAGAAAAAGAAAGT
SEQ ID NO: 103	GI1VP1+GI16Ohi.c	TCCCACCAACCGTTGAGAGCAAGACAAAACCCCTTCAGCCTCCCAATCTTA
SEQ ID NO: 105	GI13Va+GI1VP1.r	AAGGGTTTAGTCTTGTCTCTCAACGGTTGGTGGGACCAGAAAAAGAAAGT
SEQ ID NO: 106	GI1VP1+GI13Va.c	TCCCACCAACCGTTGAGAGCAAGACTAAACCCCTTACTCTCCCATTTCTG
SEQ ID NO: 108	GI17Kaw+GI1VP1.r	AACGGTTTGGTCTTAGACTCAACGGTTGGTGGGACCAGAAAAAGAAAGTGAAGT
SEQ ID NO: 109	GI1VP1+GI17Kaw.c	TCCCACCAACCGTTGAGTCTAAGACCAAAACCGTTTTCACTGCCAATCT
SEQ ID NO: 117	IF-GI14Syd12VP2.c	TCGTGCTTCGGCACCAGTACAATGGCTGGGGCCCTTTTTGCAGGTTTGGCTAGT
SEQ ID NO: 119	IF-GI14Syd12VP2.r	ACTAAAGAAAAATAGGCCCTTCATGCTCGTGACTCACCCCTTTTGCGTATATGAGC
SEQ ID NO: 116	IF-NoV(US68)VP2(ORF3).c	TCGTGCTTCGGCACCAGTACAATGGCCCAAGCCATAATTGGTGCAATT
SEQ ID NO: 122	IF-NoV(US68)VP2(ORF3).r	ACTAAAGAAAAATAGGCCCTTCATCGCCTATTATTTGCGAATAATGGCAACCTGT
SEQ ID NO: 118	IF-NoV(US68)VP1/VP2(ORF3)NoV3'UTR.r	ACTAAAGAAAAATAGGCCCTAACATCAAAATTAACCTAATTAACCTAAT

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2018/050352

A. CLASSIFICATION OF SUBJECT MATTER

IPC: *C12N 15/82* (2006.01), *A01H 5/00* (2018.01), *A61K 39/12* (2006.01), *A61P 31/14* (2006.01), *A61P 37/04* (2006.01), *C07K 14/08* (2006.01) (more IPCs on the last page)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: *C12N 15/82* (2006.01), *A01H 5/00* (2018.01), *A61K 39/12* (2006.01), *A61P 31/14* (2006.01), *A61P 37/04* (2006.01), *C07K 14/08* (2006.01), *C07K 16/20* (2006.01), *C12N 15/40* (2006.01), *C12N 15/62* (2006.01), *C12N 15/63* (2006.01), *C12N 5/10* (2006.01), *C12N 7/01* (2006.01), *C12N 7/04* (2006.01), *C12P 21/02* (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Databases : Google, Google Patent, Google Scholar, NCBI, Questel Orbit, Canadian Patent Database, GenomeQuest

Keywords : s domain, p domain, norovirus, fusion, plant, protruding, shell, vaccine, NoV, capsid

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/017542 A1 (RICHARDSON, C. et al.) 11 February 2010 (11-02-2010) *please see paragraphs 046-049 and 56	1-89

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search
29 May 2018 (29-05-2018)

Date of mailing of the international search report
12 June 2018 (12-06-2018)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 819-953-2476

Authorized officer

Brad Temple (819) 576-2089

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2018/050352**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim Nos.: 22-27, 56-60, 77, 82, 83, 85, 86, 88 and 89
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 22-27, 56-60, 77, 82, 83, 85, 86, 88 and 89 are directed to a method for treatment of the human or animal body by surgery or therapy, which the International Searching Authority is not required to search under PCT Rule 39.1(iv). However, this Authority has carried out a search based on the alleged effect or purpose/use of the product as determined from the methods of claims.
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2018/050352

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2010017542A1	11 February 2010 (11-02-2010)	WO2010017542A1 AU2009279456A1 AU2009279456A2 AU2009279456B2 CA2733589A1 CN102177233A CN102177233B CN104911154A DK2324113T3 EP2324113A1 EP2324113A4 EP2324113B1 EP2324113B8 ES2668836T3 HK1215051A1 JP2011530295A JP5852883B2 JP2015171363A JP2017153484A KR20110053994A KR101793161B1 KR20170122848A SG2013057732A US2011195113A1 US8841120B2 US2015023995A1 US9518096B2	11 February 2010 (11-02-2010) 11 February 2010 (11-02-2010) 31 March 2011 (31-03-2011) 05 February 2015 (05-02-2015) 11 February 2010 (11-02-2010) 07 September 2011 (07-09-2011) 15 April 2015 (15-04-2015) 16 September 2015 (16-09-2015) 16 April 2018 (16-04-2018) 25 May 2011 (25-05-2011) 04 January 2012 (04-01-2012) 28 February 2018 (28-02-2018) 04 April 2018 (04-04-2018) 22 May 2018 (22-05-2018) 12 August 2016 (12-08-2016) 22 December 2011 (22-12-2011) 03 February 2016 (03-02-2016) 01 October 2015 (01-10-2015) 07 September 2017 (07-09-2017) 24 May 2011 (24-05-2011) 03 November 2017 (03-11-2017) 06 November 2017 (06-11-2017) 27 February 2015 (27-02-2015) 11 August 2011 (11-08-2011) 23 September 2014 (23-09-2014) 22 January 2015 (22-01-2015) 13 December 2016 (13-12-2016)

C07K 16/20 (2006.01), *C12N 15/40* (2006.01), *C12N 15/62* (2006.01), *C12N 15/63* (2006.01),
C12N 5/10 (2006.01), *C12N 7/01* (2006.01), *C12N 7/04* (2006.01), *C12P 21/02* (2006.01)